Role of Mitochondrial Uncoupling Protein 2 (UCP2) in Modulation of Adiposity by Sun, Xiaocun
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Doctoral Dissertations Graduate School 
8-2004 
Role of Mitochondrial Uncoupling Protein 2 (UCP2) in Modulation 
of Adiposity 
Xiaocun Sun 
University of Tennessee - Knoxville 
Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss 
 Part of the Other Life Sciences Commons 
Recommended Citation 
Sun, Xiaocun, "Role of Mitochondrial Uncoupling Protein 2 (UCP2) in Modulation of Adiposity. " PhD diss., 
University of Tennessee, 2004. 
https://trace.tennessee.edu/utk_graddiss/2244 
This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee 
Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact 
trace@utk.edu. 
To the Graduate Council: 
I am submitting herewith a dissertation written by Xiaocun Sun entitled "Role of Mitochondrial 
Uncoupling Protein 2 (UCP2) in Modulation of Adiposity." I have examined the final electronic 
copy of this dissertation for form and content and recommend that it be accepted in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Human 
Ecology. 
Michael B. Zemel, Major Professor 
We have read this dissertation and recommend its acceptance: 
Jay Whelan, Jung Han Kim, Michael McEntee 
Accepted for the Council: 
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
(Original signatures are on file with official student records.) 
To the Graduate Council: 
I am submitting herewith a dissertation written by Xiaocun Sun entitled “Role of 
Mitochondrial Uncoupling Protein 2 (UCP2) in Modulation of Adiposity”. I have 
examined the final electronic copy of this dissertation for form and content and 
recommend that it be accepted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy, with a major in Human Ecology. 
         
 
 
We have read this dissertation and 










(Original signatures are on the file with official student records) 
 
 
 Michael B. Zemel 
Major Professor 
 Jay Whelan 
 Jung Han Kim  
 Michael McEntee 
 
  Anne Mayhew 
Vice Provost and 














Presented for the 
Doctor of Philosophy Degree 

























Copyright © 2004 by Xiaocun Sun 













                To my family and friends who have motivated and  




I would like to express my sincere appreciation to my major professor Dr. 
Michael B. Zemel for his scientific guidance, encouragement, and kindness throughout 
my graduate study and completion of this dissertation. The enormous inspiration and 
confidence that he gave me makes me believe that I can continue my academic dream. I 
am grateful to my committee members Dr. Jay Whelan and Dr. Jung Han Kim and Dr. 
Michael McEntee for their constructive advice and enormous support. All of them, with 
their wisdom, experience, patience, and kindness, have been and will always be great 
mentors to me. 
I am also grateful to my fellow graduate students and staff members in the 
Department Nutrition, The University of Tennessee at Knoxville for the wonderful time 




Obesity is a disorder of energy balance in which energy intake exceeds energy 
expenditure. Methods to control obesity through limiting energy intake have had limited 
success, and it is widely recognized that energy expenditure must also be increased if 
long-term weight loss is to be achieved. Uncoupling proteins (UCPs) are a family of 
integral membrane proteins of mitochondrial inner membrane, where they uncouple the 
process of mitochondrial respiration from oxidative phosphorylation, diminishing the 
resulting production of ATP and decreasing the metabolic efficiency of the organism. 
Thus, UCPs provide new molecular targets for increasing energy expenditure. Unlike the 
other UCP family members, UCP2 is ubiquitously expressed, with the highest level in 
white adipose tissue. Stimulation of mitochondrial uncoupling in adipocytes in vitro 
demonstrates a direct inhibitory effect on lipogenesis and suppression on lipolysis via a 
calcium dependent mechanism, indicating a potential role of UCP2 in regulation of 
adiposity.  
Previous studies demonstrate that intracellular Ca2+ ([Ca2+]i ) plays a key role in 
metabolic disorders associated with obesity. [Ca2+]i can clearly be modulated by the 
calcitrophic hormone 1α, 25-dihydroxyvitamin D3 (1α, 25-(OH)2-D3), which appears to 
have both genomic and non-genomic action in adipocytes. 1α, 25-(OH)2-D3 modulates 
adipocyte Ca2+ signaling directly, resulting in an increased lipogenesis and decreased 
lipolysis. In addition, 1α, 25-(OH)2-D3 plays a genomic role in regulating adipocyte 
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UCP2 expression levels, indicating that the regulation of UCP2 and the resulting 
increased core temperature may contribute to increased rates of energy dissipation. 
Accordingly, the suppression of 1α, 25-(OH)2-D3 by increasing dietary calcium 
attenuates adiposity by decreasing triglyceride accumulation in the adipocytes: increasing 
dietary calcium results in a net reduction in fat mass in the absence of caloric restriction, 
a marked augmentation of body weight and fat loss during energy restriction, and an 
inhibition of weight and fat regain after food restriction in mice.  
Although these anti-obesity effects of dietary calcium are due, in part, to 
enhanced metabolic rate and thermogenic processes, it is also possible that a loss of 
adipocytes would result in a deficit cells for lipid esterification as the body recovers. 
Physiological doses of 1α, 25-(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1 
adipocytes, and the suppression of 1α, 25-(OH)2-D3 in vivo by increasing dietary calcium 
stimulates adipocyte apoptosis in refeeding following energy restriction in aP2 transgenic 
mice, indicating that the stimulation of adipocyte apoptosis contributes to adiposity 
reduction after high calcium diet administration. UCP2 plays a direct role in modulating 
adipocyte apoptosis by inducing mitochondrial potential collapse and inhibiting ATP 
production. Overexpression of UCP2 in adipocyte stimulates apoptosis while inhibition 
of mitochondrial uncoupling either by chemical inhibitor GDP or by siRNA duplexes 
suppresses adipocyte apoptosis. Accordingly, suppression of UCP2 by physiologically 
low doses of 1α, 25-(OH)2-D3, which can be induced by low dietary calcium, decreases 
apoptosis. Although 1α, 25-(OH)2-D3 causes dose-dependent stimulation on [Ca2+]i levels, 
low doses of 1α, 25-(OH)2-D3 decrease mitochondrial calcium accumulation while a high 
 vi
dose of 1α, 25-(OH)2-D3 induces markedly greater increase in [Ca2+]i and stimulates 
calcium storage in mitochondria. Bay K 8644, which is a Ca 2+ ionophore and can mimic 
the stimulatory effect of 1α, 25-(OH)2-D3 on [Ca2+]i without exerting effects on UCP2, 
causes a dose-dependent increases in apoptosis and mitochondrial calcium accumulation, 
indicating that stimulation of pharmaceutical high dose 1α, 25-(OH)2-D3 on apoptosis is a 
calcium-dependent effect. 
In summary, present data support the concept that dietary calcium exerts anti-
obesity effects in aP2 transgenic mice under conditions of varying nutrient status. In 
addition, this study extended our observation that dietary calcium not only regulates 
adipocyte size by decreasing lipid accumulation, but also modulates adipocyte number by 
stimulating apoptotic death. These anti-obesity effects of dietary calcium are attributable 
to the up-regulation of UCP2, which stimulates energy expenditure, fat utilization and 
adipocyte apoptosis in white adipose tissue. Accordingly, these data indicate an important 
role of increasing dietary calcium in prevention and management of obesity.  
 vii
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Figure 5-11 Schematic illustration of effects and mechanisms of 1α, 25-
(OH)2-D3 on adipocyte apoptosis. Physiological low doses of 
1α, 25-(OH)2-D3 restore mitochondrial potential and ATP 
production by suppressing UCP2, thereby inhibiting apoptosis. 
By contrast, high dose of 1α, 25-(OH)2-D3 induces 
mitochondrial calcium overload and stimulates apoptosis. 
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Figure 6-1 Western blot with anti-mouse UCP2 antibody of cell lysates 
harvested 48hrs after siRNA transfection for evaluation of 
UCP2 protein reduction (upper panel).The internal control 
actin is shown in the low panel. Blot shown is representative of 
three similar experiments. 
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Figure 6-2 Mitochondrial potential in 3T3-L1 and siRNA transfected 
3T3-L1 adipocytes (UCP2 ko). Data are expressed as mean ± 
SE (n =6). Different letters above the bars indicate a 
significant difference at level of p<0.05. 
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Figure 6-3 Caspase-3 expression in 3T3-L1 and siRNA transfected 
3T3-L1 adipocytes (UCP2 ko). Data are expressed as mean ± 
SE (n =6). Different letters above the bars indicate a 
significant difference at level of p<0.05. 
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Figure 6-4 Effect of mitochondrial uncoupling inhibitor GDP on 
mitochondrial potential in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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Figure 6-5 Effect of mitochondrial uncoupling inhibitor GDP on 
caspase-3 expression in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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Figure 6-6 Effect of calcium channel ionophore Bay K 8644 on 
intracellular calcium levels in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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Figure 6-7 Effect of mitochondrial uncoupling inhibitor GDP and 
calcium channel ionophore Bay K 8644 on mitochondrial 
potential in 3T3-L1 adipocytes. Data are expressed as mean 
± SE (n =6). Different letters above the bars indicate a 
significant difference at level of p<0.05. 
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Figure 6-8 Effect of calcium channel ionophore Bay K 8644 on 
caspase-3 expression in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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Figure 6-9 Effect of mitochondrial uncoupling inhibitor GDP and 
calcium channel ionophore Bay K 8644 on caspase-3 
expression in 3T3-L1 adipocytes. Data are expressed as mean 
± SE (n =6). Different letters above the bars indicate a 
significant difference at level of p<0.05. 
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Figure 6-10 Effect of calcium channel ionophore Bay K 8644 on 
mitochondrial calcium in 3T3-L1 adipocytes. Data are 





























The worldwide prevalence of obesity is increasing at an alarming rate, with major 
adverse consequences for human health (1-2). Obesity results from a chronic imbalance 
between energy intake and expenditure (3-4). This imbalance can result from either 
overeating or a constitutional decrease in one or several of the components of energy 
expenditure, including resting metabolic rate, diet-induced thermogenesis, or exercise-
related thermogenesis. Methods to control obesity through limiting energy intake have 
had modest success (5). In addition, metabolic rate is decreased with extreme calorie 
restriction. This decrease persists after the dieting period has ended, often leading to rapid 
weight regain (6). It is widely recognized that energy expenditure must be increased if 
long-term weight loss is to be achieved.  
Uncoupling proteins (UCPs) are a family of integral membrane proteins of 
mitochondrial inner membrane, where they uncouple the process of mitochondrial 
respiration from oxidative phosphorylation, diminishing the resulting production of ATP 
and decreasing the metabolic efficiency of the organism (7-8). Thus, UCPs provide new 
molecular targets for increasing energy expenditure. It is widely acknowledged that the 
brown adipose tissue (BAT) mitochondrial uncoupling protein (UCP1) plays a pivotal 
role in adaptive thermogenic responses (9). Two homologues of UCP1 (UCP2 and UCP3) 
have recently been identified and population-based genetic studies have linked them with 
basal metabolic rate, while in vitro studies report that both have proton transport activity 
and may thus be involved in regulation of energy homeostasis and hence obesity (10). 
The function of UCPs may not be restricted to thermoregulation and there is now 
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substantial data linking UCP expression levels to fatty acid metabolism and fatty acid 
flux into various tissues (11). One hypothesis indicates that UCP2 and UCP3 may 
function as a free fatty acid transporter and thereby increase fatty acid utilization. Unlike 
the other family members, UCP2 is ubiquitously expressed, with the highest level in 
white adipose tissue. Lipid metabolism of adipose tissue is affected by the energy status 
of fat cells (12). Previous experiments indicated the dependence of both lipogenesis and 
lipolysis on ATP levels in adipocytes (13). Thus, UCP-induced respiratory uncoupling in 
adipocytes that results in stimulation of energy dissipation and depression of ATP 
synthesis may contribute to the control of lipid metabolism. This hypothesis, however, 
requires further investigation. 
Previous studies of the agouti gene demonstrate a key role for intracellular Ca2+ 
([Ca2+]i) in metabolic disorders associated with obesity by regulating adipocyte lipid 
metabolism and triglyceride storage(14). Increased [Ca2+]i results in stimulation of 
lipogenic gene expression and lipogenesis and suppression of lipolysis, resulting in 
adipocyte lipid filling and increased adiposity. [Ca 2+]i can clearly be modulated by the 
calcitrophic hormone 1α, 25-dihydroxyvitamin D3 (1α, 25-(OH)2-D3), which appears to 
have both genomic and non-genomic action in adipocytes. 1α, 25-(OH)2-D3 modulates 
adipocyte Ca2+ signaling via a non-genomic action, resulting in increased lipogenesis and 
decreased lipolysis (15-17). In addition, 1α, 25-(OH)2-D3 plays a genomic role in 
regulating adipocyte UCP2 expression levels, indicating that the regulation of UCP2 and 
the resulting increased core temperature may contribute to increased rates of energy 
dissipation (18). Accordingly, we recently demonstrated that the increased 1α, 25-(OH)2-
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D3 produced in response to low-calcium diets stimulates adipocyte Ca2+ influx and, 
consequently, promotes adiposity. In contrast, the suppression of 1α, 25-(OH)2-D3 by 
increasing dietary calcium attenuates adiposity by decreasing triglyceride accumulation 
in the adipocytes, resulting in a net reduction in fat mass in the absence of caloric 
restriction, a marked augmentation of body weight and fat loss during energy restriction 
(15-17). However, a key problem in the management of obesity is the maintenance of 
reduced body weight and fat content following successful weight loss. How an individual 
responses to changes of energy and nutrient status from fasting to refeeding may have 
important long-term consequences with respect to the retention of body fat. Thus, the 
effects of dietary calcium on prevention of weight regain needs to be explored. 
Although the anti-obesity effects of dietary calcium are due, in part, to an 
enhanced metabolic rate and thermogenic processes, it is also possible that a loss of 
adipocytes would result in a deficit cells for lipid esterification as the body recovers from 
energy restriction. Clinically, the duration of maintaining at a lower body weight after 
dietary treatment of obese human seemed to be inversely proportional to the estimated 
number of adipocytes in adipose tissue (19-20). Thus, there seems to be some association 
with the severity of the obesity and with the cellular characteristics of adipose tissue. 
Recent data indicate that [Ca2+]i may play a key role in modulating sensitivity to the 
apoptotic stress (21). Several of the functional groups of molecules involved in apoptosis, 
including caspases and the Bcl-2 family, are [Ca2+]i responsive (22-23). Given that 
[Ca2+]i can be modulated by 1α, 25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in apoptosis 
should be explored. In addition, UCP2 has been demonstrated to function as 
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mitochondrial uncoupler of oxidative phosphorylation and thus reduce efficiency of ATP 
synthesis. Consequently, it is reasonable to propose that UCP2 may stimulate apoptosis in 
adipocytes. We have previously demonstrated that 1α, 25-(OH)2-D3 inhibits UCP2 
expression in human adipocyte via a genomic mechanism (18), further implying that 1α, 
25-(OH)2-D3 may play a role in adipocyte apoptosis. Although high doses of 1α, 25-
(OH)2-D3 have been reported to induce apoptosis in various tumor cells, the regulation of 
apoptosis by physiological doses of 1α, 25-(OH)2-D3 remains unclear. 
Accordingly, present studies expanded our previous observations by broadly 
exploring the effect of dietary calcium on lipid metabolism and energy partitioning under 
different nutritional status. I also investigated the direct effect and mechanisms of 
mitochondrial uncoupling on lipogenesis and lipolysis as well as the role of [Ca2+]i in this 
process. Finally, the effect and mechanism of 1α, 25-(OH)2-D3 and UCP2 on adipocyte 
apoptosis were investigated in both in vivo and in vitro environments. 
 
1.2 Obesity: General Aspects 
1.2.1 Prevalence of Obesity  
The prevalence of obesity in the United States has grown substantially over the 
past decade. Currently, approximately 20% of males and 25% females are considered 
obese based on a body mass index (BMI) of 30 or more. (24-28). Three percent of U.S. 
adults have a BMI of 40 or more, equivalent to approximately 100 lbs overweight (24-26). 
In 2000, approximately 44 million adults in the U.S. were overweight or obese, reflecting 
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an increase of 74 percent since 1991 (27). Overweight and obesity are significant and 
growing problems in children as well. Over the past decade or so, the proportion of 
children and adolescents who are overweight or obese in has increased significantly. 
Results from the 1999-2000 National Health and Nutrition Examination Survey 
(NHANES) (28), using measured heights and weights, indicate that an estimated 15 
percent of children and adolescents ages 6-19 years are overweight, representing a 40 
percent increase from the overweight estimates of 11 percent obtained from NHANES III 
(1988-94) (29-30). 
Overweight and obese individuals (BMI of 25 and above) are at increased risk for 
physical ailments such as type II diabetes mellitus, insulin resistance/glucose intolerance, 
heart disease and stroke, hypertension, cancer, obstructive sleep apnea, osteoarthritis, and 
psychological disorders (31-32). Using relative hazards associated with elevated BMI in 
six United States studies (Alameda Country Health Study, Framingham Heart Study, 
Tecumseh Community Health Study, American Cancer Society Cancer protection Study 
1, and Nurses Health Study,) the national distribution of adult BMI, and the estimates of 
population size and total deaths from the same period, Mokdad et al calculated that the 
annual number of deaths attributable to overweight in 2000 was over 490,000 (33). 
Although obesity was rarely listed as the cause of death, it is now more frequently noted 
as the associated comorbidity. 
Overweight and obesity and their associated health problems have substantial 
economic consequences for the U.S. health care system (34). The increasing prevalence 
of overweight and obesity is associated with both direct and indirect costs. Direct health 
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care costs refer to preventive, diagnostic, and treatment services related to overweight 
and obesity (for example, physician visits and hospital and nursing home care). Indirect 
costs refer to the value of wages lost by people unable to work because of illness or 
disability, as well as the value of future earnings lost by premature death (35). In 1995, 
the total (direct and indirect) costs attributable to obesity amounted to an estimated $99 
billion (36-37). In 2000, the total cost of obesity was estimated to be $117 billion ($61 
billion direct and $56 billion indirect) (36-37). Most of the cost associated with obesity is 
due to type 2 diabetes, coronary heart disease, and hypertension (36-37). 
1.2.2 Pathology of Obesity  
1.2.2.1 Genetics of Obesity  
Obesity is determined by genetic and environmental factors acting through the 
physiological mediators of energy intake and energy expenditure. It is likely that genes 
involved in weight gain increase the susceptibility of an individual to the development of 
obesity when exposed to environmental conditions that favor a positive energy balance 
(38).  
Adoption, twin and family studies have shown that human obesity has a genetic 
component (39-41). Body weight, however, is the archetypal polygenic trait, a 
quantitative phenotype that usually fails to display a Mendelian pattern of inheritance 
because it is influenced by many different loci, and this complex etiology makes the 
search for obesity genes especially challenging (42). Until recently, the analysis of 
candidate genes (known genes identified a priori on the basis of their effects in animal 
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models or suspected physiological involvement in a particular disorder) was the primary 
strategy used in the search for potential obesity genes (43-44). The ninth annual human 
obesity gene map identifies more than 70 specific gene variants thought to cause a person 
to become obese (45), including leptin gene and its receptor, pro-opiomelanocortine 
(POMC), prohormone convertase 1 (PC1), mutations in the melanocortin receptor 4, and 
more recently, lpin1. Genome scanning is an alternative but complex approach by 
conducting linkage analysis using a series of anonymous polymorphisms over the entire 
genome (46). This approach offers the potential of identifying genes previously 
unsuspected of having an influence on the phenotype of interest. To date, the results of 
two genome scans for obesity-related phenotypes have been reported, one in Mexican 
Americans (47), and the other in Indians (48), but no obvious candidate genes have been 
mapped to either chromosomal region. Results from reported genome-wide linkage 
studies suggest that serum leptin levels are significant linked to chromosome 2p21 (49-51) 
and this region of human chromosome 2 includes the POMC gene (52), in which loss-of-
function mutations have been demonstrated as rare Mendelian causes of obesity in 
humans. Other than the locus on 2p there are no other loci which have been highlighted 
in more than one of the genome wide scans reported to date. 
 
1.2.2.2 Endocrine Disorders of Obesity  
Obesity is associated with multiple alterations in the endocrine system, including 
abnormal circulating blood hormone concentrations, which can be due to changes in the 
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pattern of their secretion and/or metabolism, altered hormone transport and/or action at 
the level of target tissue. The following discussion focuses on cortisol, insulin and growth 
hormone. 
a. Cortisol  
Patients with Cushing's syndrome display a number of clinical features that 
resemble those seen in patients with the metabolic syndrome (syndrome X) (53), 
including abdominal obesity, insulin resistance, impaired glucose homeostasis, 
hypertension, and lipid abnormalities. These similarities led to the hypothesis that a 
dysregulation of the hypothalamic-pituitary adrenal (HPA) axis could potentially be a 
cause for abdominal obesity and its different metabolic consequences. Adipose tissue is 
involved in the metabolism of cortisol. The enzyme 11 beta-hydroxysteroid 
dehydrogenase-1 (11β-HSD-1), which converts cortisone to cortisol, is expressed in 
adipose tissue (54). It appears that in obesity more cortisol is derived from cortisone due 
to the increased activity of this enzyme, which could simply be due to increased fat mass 
(54). Urine studies in obesity also show an increase in the ratio of tetrahydrocortisol to 
tetrahydrocortisone indicating a relative increase in the pathways leading to cortisol 
formation (through the action of 11β-HSD-1) (55). Although the serum concentration of 
cortisol and the 24 hour urine free cortisol excretion are essentially normal or slightly 
elevated in obesity,, it is possible that there is an increase in the local production of 
cortisol in the fat tissue and this in turn could lead to increased local action of cortisol 
with the subsequent metabolic consequences known to occur in obesity. The cortisol 
response to a variety of stimuli such as corticotropin releasing hormone (CRH), or meal 
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ingestion is increased in obesity (56). An increase in cortisol response to ACTH has also 
been seen in obese men and obese premenopausal women, but not in obese 
postmenopausal women (57), indicating a possible role for estrogens in that response. A 
decrease in the mineralocorticoid receptor response to circulating corticosteroids was 
suggested by Jessop et al as an explanation for the decreased HPA axis to glucocorticoid 
feedback in obesity (58). 
b. Insulin  
Obesity is strongly associated with insulin resistance and is a risk factor for type 2 
diabetes (59). Visceral abdominal fat is inversely correlated with insulin sensitivity, and 
visceral hepatic glucose production and reduced peripheral glucose uptake are commonly 
seen in abdominal obesity (60-61). Insulin levels are elevated in obese individuals and a 
high correlation exists between insulin secretion and BMI (62). The hyperinsulinemia 
seen in obese subjects is mainly due to increased insulin secretion. In some patients, 
decreased insulin clearance can also contribute to the elevated insulin levels. When 
impaired glucose tolerance develops, the insulin secretory dynamics are altered with a 
progressive decrease in the ability of the pancreas to maintain normal glucose 
homeostasis, initially in response to glucose load, and ultimately in the basal state. 
The exact mechanism(s) by which obesity contributes to the development of 
insulin resistance is the subject of extensive research. In human insulin resistance itself 
and hyperinsulinemia can precede the development of obesity (63). Substances 
originating in the adipose tissue and capable of exerting distant or local actions may 
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explain the link between obesity and insulin resistance. Free fatty acids (FFA) are 
released in excess by abdominal fat (64-66). Increased concentrations of FFA cause 
insulin resistance and decreased glucose uptake by impairing insulin mediated glucose 
transport. Impairment at the level of the insulin receptor and insulin receptor substrate-1 
(IRS-1) are likely reasons for the impaired insulin mediated glucose uptake (67). Tumor 
necrosis factor-alpha (TNF-α) is another potential link between obesity and insulin 
resistance (68-69). TNF-α has been shown to alter basal and glucose stimulated insulin 
secretion and to produce insulin resistance in isolated cell lines (70-71). Similar 
conclusions can be drawn in regard to leptin. Leptin in vitro is capable of inhibiting 
insulin release but its role in the pathogenesis of insulin resistance in humans has not 
been confirmed (72). Resistin, a peptide isolated from the mouse, is produced by the 
adipose tissue and its expression is decreased by peroxisome proliferator-activated 
receptor gamma (PPARγ) agonists (73-74). Serum levels of resistin are elevated in obese 
mice and immunoneutralization of this peptide improves insulin sensitivity in the mouse. 
mRNA levels of resistin in freshly isolated human adipocytes are very low but the role of 
resistin in human obesity and insulin resistance is unclear at this point. Ghrelin, a potent 
growth hormone secretagogue, is produced mainly by the stomach. Administration of 
ghrelin results in increased growth formone (GH) release, hyperglycemia, and decrease 
insulin concentrations (75). Tschöp et al, found a negative correlation of circulating 
ghrelin levels with insulin, leptin levels, and percent body fat (76). Thus, Ghrelin is yet 
another peptide which may turn out to have a role in the pathogenesis of insulin 
resistance accompanying obesity. 
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c. Growth Hormone 
Obesity is typically accompanied by a decrease in GH levels and increase in 
growth hormone binding protein (GHBP) levels (77-78). An inverse relation exists 
between GH levels and percent fat mass. Another major determinant of GH level is age; 
GH levels fall with increasing age and recombinant human growth hormone, rhGH, has 
been studied as a supplement to counteract the effects of aging on body composition (79). 
The reduction in GH levels in obesity is believed to result from decreased pituitary 
release of the hormone. In animal models of genetic obesity there is a decrease in the 
number of somatotroph cells in the pituitary gland. GH responses to a variety of stimuli, 
including GHRH, arginine, and GHRPs (growth hormone releasing peptides) have been 
shown to be reduced in obesity (80). Similarly it has been found that GHBP levels are 
increased in obesity, suggesting a negative feedback mechanism on GH secretion. Other 
possible mechanisms included in the altered GH response in obesity are FFA and leptin, 
both of which are increased in obesity (81-82). Lee et al, showed that reduction in free 
fatty acids concentrations in obese subjects through use of Acipimox leads to increased 
GH response to GH-releasing hormone. In animals, leptin has an inhibitory role on GH 
secretion from the pituitary gland through its effects on GHRH and neuropeptid Y (NPY) 
at the hypothalamus level. 
Most of GH promoting effects are mediated by insulin- like growth factor-1 (IGF-
1). GH also has effects independent of IGF-1. Serum IGF-1 concentration represents the 
most accurate reflection of growth hormone biologic activity (83). In spite of the reduced 
GH levels seen in obesity, IGF-1 levels do not appear to be significantly different 
 12
between obese and non obese subjects (84). Individuals with visceral obesity, even in the 
absence of total body obesity, may, on the other hand, have lower IGF-1 levels than 
comparable individuals with no abdominal obesity. The serum concentration of unbound 
or free IGF-1 is increased in obese subjects (85). Similarly it has been found that GHBP 
levels are increased in obesity. This suggests that lower levels of GH are accompanied by 
increased peripheral sensitivity to GH accounting for the normal IGF-1 levels. Insulin 
could result in increased peripheral sensitivity to GH, reduced IGFBP-1 levels and 
increased (to within normal range) IGF-1 in spite of decreased GH secretion by the 
somatotroph (86). High free IGF-1 levels in this case exert a negative feedback 
mechanism on GH secretion. This hypothesis supports a peripheral rather than a central 
mechanism by which GH release is decreased in obesity. 
1.2.3 Dietary Management of Obesity  
Obesity results from the accumulation of excessive calories as body fat. 
Accordingly, the goal for dietary management of obesity is to reduce calorie intake from 
diet. In addition, once the obese individual has lost body fat, this healthier weight must be 
maintained. Thus the energy deficit phase must be followed by a weight maintenance 
phase. Paradoxically, the slimmer individual's energy needs are lower to stay in energy 
balance than they were prior to weight reduction (87-89). The primary reason for this is 
that some loss of lean as well as fat tissue inevitably occurs on reducing diets. Thus 
metabolically active tissue is reduced and resting metabolism is decreased. Also, it takes 
less effort to move the lighter body, and the energy cost of physical activity is thus 
reduced. The implications are that a slight decrease in energy intake from prior levels and 
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an increase in energy output will be necessary during weight maintenance. Thus there is a 
need for continued attention to these factors on the part of the physician and patient. All 
too often the weight maintenance phase is neglected or ignored, and weight is regained 
over the long term. Although the macronutrient composition of the diet does not appear 
to play a major role in overall weight loss, there is much interest in the macronutrient 
composition of reducing diets, as discussed in the next section (90). 
1.2.3.1 Dietary Fat  
Balanced deficit weight reduction diets that are moderate to low in fat (20-30% 
calories) are so called because maintain a reasonable balance between macronutrients 
similar to that recommended in the Food Group Pyramid and the Dietary Guidelines for 
Americans (91). The introduction of low-fat diets (<30% fat calories) for the prevention 
and treatment of obesity was based on the link established between dietary fat and body 
fatness. Observational and mechanistic studies show that because fat possesses a lower 
satiating power than carbohydrate and protein, a diet rich in fat can increase energy 
intake (92-93). The propensity to gain weight is enhanced in susceptible persons, 
particularly sedentary people who have a genetic predisposition to obesity. On the other 
hand, empirical evidence from dietary intervention trial shows that increase in 
carbohydrate: fat ratio achieved by low fat intervention is effective in producing 
spontaneous weight loss (94). Meta-analyses of weight change occurring on ad libitum 
low-fat diets in intervention trials consistently demonstrate a highly significant weight 
loss of in normal-weight and overweight subjects (95). Very low fat diets (<10% fat 
calories) such as the Pritikin diet (96) and the Ornish diet (97), are advocated not only for 
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weight reduction but also for improving cardiovascular risk profiles. The Ornish diet, 
which is very low in fat (13% of calories) and saturated fat, very high in carbohydrate 
(81% of calories) and very high in fiber (38 gm) with a program that includes 
nonsmoking, exercise and behavior modification was shown to reduce some 
cardiovascular risk factors in a limited long term study. However, whether the percentage 
of dietary fat in diet plays an important role in the rising prevalence of overweight and its 
treatment has been repeatedly debated in recent years. Willett has argued that there is no 
evidence that energy density has an important role on long-term weight control and thus 
that the importance of fat-restriction in dietary treatment is unproven (98).  
Even on reducing diets, needs for small amounts (e.g. 3-6 gm) of essential fatty 
acid (linoleic or arachidonic acid) are present, and some fat is also necessary as a carrier 
for the fat-soluble vitamins (99). Therefore the diet should not be devoid of fat. However, 
because fat is calorically dense, it is usually decreased to increase bulk and reduce energy. 
High fat reducing diets (55-65%) are usually also low or very low in carbohydrate 
(<200 gm carbohydrate per day) (100). There is some evidence that free-living 
overweight people who self-select high fat low carbohydrate diets which they eat ad 
libitum consume fewer calories and lose weight. Also overweight people who consume 
such diets under experimental conditions lose weight. When high fat low carbohydrate 
reducing diets are fed they also tend to cause ketosis. They may also result in decreased 
blood lipids, decreased blood glucose and insulin and decreased blood pressure, but only 
if weight is lost. Over the short term (a few days or a week) high fat, low carbohydrate, 
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ketogenic diets cause a greater loss of body water than body fat, but water balance is 
restored when carbohydrate levels increase or when the diet ends (101). 
1.2.3.2. Dietary Carbohydrate  
Carbohydrate needs are at least 50 gm per day. At least 100 gm carbohydrate, and 
preferably 55% or more of total energy intake should be provided for diets that are over 
800 kcal per day (91). On reducing diets under experimental conditions with equicaloric 
reducing diets, both diets very high in sugars and diets very high in complex 
carbohydrates as starch have similar effects in bringing about weight loss (102). However, 
from the practical standpoint, since many products that are high in sugar are also high in 
fat and calories, sugars are usually limited on reducing diets. 
Low-carbohydrate diets (<100mg carbohydrate) may be accompanied by greater 
weight loss than other diets and this concept is supported by recent evidence. A recent 
comparison of a low carbohydrate diet with a low fat diet in patients with severe obesity 
found that patients on the low carbohydrate diet lost more weight than patients on a 
calorie-restricted, fat-restricted diet, and had greater improvement in insulin sensitivity 
and triglyceride levels (103). A second study also found a similarly greater weight loss 
using a low carbohydrate diet without adverse effects on lipids, glucose, or insulin (104). 
Both diets are associated with reduced caloric consumption. Futhermore, Foster et al 
compared a low-carbohydrate, high-protein, high-fat diet with a low-calorie, high-
carbohydrate, low-fat (conventional) diet in a recent clinical trial and they demonstrated 
that the low-carbohydrate diet produced a greater weight loss than did the conventional 
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diet for the first six months (105). In addition, the low-carbohydrate diet was associated 
with a greater improvement in some risk factors for coronary heart disease. However, 
these studies were conducted in a relatively short period of time and longer and larger 
studies are required to determine the long-term safety and efficiency of low carbohydrate 
diets. 
Notably, the effect of low carbohydrate diets in promoting weight loss may be 
partially attributable to the loss of water. Glycogen is hydrated with 2 to 3 grams of water 
per gram of glycogen, while fat stores contain only 0.5 grams of water per gram of fat. 
Thus, high fat, low-carbohydrate diets deplete muscle and liver glycogen stores rapidly 
and facilitate rapid weight (water) loss (101). Also, some low carbohydrate diets are 
ketogenic and may lead to excessive protein breakdown to maintain blood glucose levels 
unless protein intakes are increased. When the body must rely on degradation of protein's 
carbon skeletons to preserve blood glucose levels (via gluconeogenesis), the catabolism 
of the protein is accompanied by loss of water. For every gram of protein (or glycogen) 
that is broken down, 3 grams of water are released, causing rapid weight loss but also a 
state of relative dehydration. This rapid weight loss may contribute to the popularity of 
very low carbohydrate diets. Furthermore, initial weight loss on low carbohydrate diets 
may be enhanced by an exaggerated diuresis related to decreased postprandial serum 
insulin levels. Insulin promotes water retention through its antinatriuretic effects. Some 
behavioral impact also contributes to the effect of weight loss. When individuals commit 
themselves to a weight-loss program, they change usual patterns of eating and commit 
themselves to paying attention to what they eat and avoiding unplanned eating episodes, 
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and thereby decrease energy intake. Furthermore, although such diets produce rapid 
weight loss due to polyuria in the short run, refeeding carbohydrates causes water 
retention and weight gain (101). The effect low carbohydrate diets on blood cholesterol 
remains controversial. A study conducted by LaRosa and colleagues examined the effect 
of lipid changes after following the Atkins low-carbohydrate, high-fat diet for four weeks 
(106). Despite a weight loss, total cholesterol insignificantly increased. Significant 
changes in LDL cholesterol triglycerides, free fatty acids and uric acid were seen. 
However, some evidence exhibited an opposite effect (107-108), with low carbohydrate 
diets decreasing blood cholesterol. 
The glycemic index (GI) is a dietary concept, originally developed for the therapy 
of diabetes, which has recently become popular in weight management. The GI is a 
property that describes the blood glucose response resulting from consumption of a 
defined amount of carbohydrate (usually 50 grams) from a given food, relative to the 
same amount of carbohydrate from a control food (usually white bread) (109). The basic 
premise is that more moderate blood glucose and metabolic responses will sustain satiety 
and energy balance to a greater extent than would larger metabolic shifts over the course 
of the day (110). Physiological studies demonstrate that consumption of high GI meals 
induce a sequence of hormonal changes that limit availability of metabolic fuels in the 
postprandial period and cause overeating. Short-term feeding studies consistently show 
less satiety or greater voluntary energy intake after consumption of high compared to low 
GI meals (111). However, it is still unclear if the glycemic index offers sustained 
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advantages to patients in planning menus and in learning to control food intake compared 
to other weight reduction methods. 
1.2.3.3. Dietary Protein 
The Recommended Dietary Allowance for protein is 0.8 gm/kg/day, but most 
Americans eat approximately 15% of their total caloric intake from protein, or about 1.2 
gm/kg per day (91). Protein requirements do not decline and may actually rise on 
hypocaloric diets, and especially on low carbohydrate diets, when protein needs sharply 
increase above the levels needed for energy balance. When energy intakes are insufficient, 
some amino acids are used to maintain blood glucose levels and others must be used for 
energy, so overall protein requirements increase (112). High protein reducing diets are 
those that provide more than 1.6 gm/kg/ideal body weight per day. Self-prescribed high 
protein reducing diets varying in their composition from about 28-65% of energy, 
providing 71-162 gm of protein per day, are currently popular as a strategy for losing 
weight. They are usually quite low in their carbohydrate content (113). High protein diets 
have been demonstrated to induce successful weight loss and other beneficial effects 
(114-115).  
There is emerging evidence that additional metabolic roles for some amino acids 
require plasma intracellular levels above minimum needs for protein synthesis. Branched 
chain amino acids (leucine, isoleucine, and valine), or BCAA's, are a group of essential 
amino acids that play important roles in protein synthesis and energy production. In 
humans, about 15-25% of total protein intake is BCAA's, and dairy products are 
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particularly high in them (116). BCAA's make up 35-40% of the essential amino acids in 
body protein and 14% of the total amino acids in skeletal muscle (117). One of the most 
important BCAA's is leucine and estimates of dietary requirements for leucine range 
from 1-12 g daily (118). Leucine stimulates skeletal muscle protein synthesis through 
multiple independent mechanisms, including increasing insulin secretion as well as 
stimulating mammalian target of rapamycin (mTOR) pathways (119-120). However, the 
potential to participate in these additional metabolic processes of leucine is limited by its 
availability and the first priority being provided to new protein synthesis (121). 
Accordingly, only diets that provide BCAAs in general, and leucine specifically, at levels 
that exceed requirements for protein synthesis can fully support the intracellular leucine 
concentrations required to support additional signaling pathways (122-124). 
Consequently, the abundance of leucine in diet is of particular interest because it plays a 
distinct role in protein metabolism and plays a pivotal role in the translation initiation of 
protein synthesis. 
However, whether a high protein diet is a safe approach for obesity management 
is questionable. Many of these diets advocate very high intakes of protein from meat and 
other foods that are also often high in saturated fat, cholesterol and sodium while they are 
low in dietary fiber, potassium, calcium, and magnesium, increasing cardiovascular risk 
(125). The purine content of meat, poultry, seafood, egg, seeds and nuts is high and 
increases uric acid levels and risk of gout in susceptible persons. The effect of dietary 
protein on calcium absorption remains controversial. Some studies demonstrate that high 
protein load may increase urinary calcium loss if it is not buffered (126-127) while 
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clinical trial conducted by Heaney suggests that dietary protein exerts no effect on 
calcium absorption (128). 
1.2.3.4 Dietary Calories  
Low calorie diets of 1000-1200 calories for women and 1200-1600 calories per 
day for men are currently recommended by the National Institutes of Health for weight 
loss in most individuals (129). The rationale is that on such regimens a deficit of 
approximately 500-1000 Calories per day will be created, which should result in slow, 
progressive weight loss of 1-2 pounds per week. The dietary composition is similar in 
macronutrients to that of the National Heart, Lung and Blood Institute's (NHLBI) Step 1 
diet to decrease risks of high blood cholesterol and blood pressure. The National Institute 
of Health's Obesity Initiative recently sponsored an evidence-based review of low calorie 
diets. It found that on the average diets such as these reduced body weight by an average 
of 8% over 3-12 months of treatment, and that the losses were accompanied by decreases 
in abdominal fat (129). 
 
1.3 Role of Intracellular Calcium in Obesity 
1.3.1 Mouse Agouti and Obesity 
Agouti originally referred to the wild-type pigmentation pattern of mouse hair, 
with a predominately black hair shaft with a subapical yellow segment (130). The mouse 
agouti gene, mapped to chromosome 2, encodes a 131 amino acid paracrine molecule that 
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is secreted from cells of the hair follicle (131-132). Agouti protein functions as a 
competitive antagonist of α-melanocyte-stimulating-hormone (α-MSH) binding to the 
melanocaortin-1 receptor (MC-1R), causing melanocytes to switch from the synthesis of 
black pigment (eumelanin) to yellow pigment (phaeomelanin), which in turn results in 
the characteristic pigmentation pattern of wild-type mice (133). However, in the absence 
of α-MSH, agouti also affects basal melanogenesis of melanoma cells in culture, 
suggesting that agouti may have an additional physiological function (134). The human 
homolog of the agouti gene is 85% identical to the mouse gene and encodes a protein of 
132 amino acids with a consensus signal peptide (135). The major difference between 
mouse and human agouti is the expression pattern. Whereas mouse agouti is only 
transiently expressed in the hair follicle during neonatal development, human agouti is 
expressed in diverse tissues; primarily adipose tissue followed by the testis, heart, liver, 
kidney, ovary, and foreskin. 
Dominant mutations in the mouse agouti gene confer a pleiotropic syndrome 
characterized by obesity, mild hyperphagia, decreased thermogenesis, hyperinsulinemia, 
peripheral insulin resistance, impaired glucose tolerance, hyperglycemia, increased 
susceptibility to cancer and yellow hair (136). Molecular analysis of six dominant agouti 
alleles (Ay, Asy, Avy, Aiapy, Ahvy and Aiy) demonstrated that mutations in promoter regions 
result in ubiquitous expression of normal agouti protein (137-140). Expressing the wild-
type agouti cDNA under the control of a ubiquitous promoter in mice resulted in the 
dominant obesity syndrome, indicating ectopic overexpression of the wild-type agouti 
gene is the cause of the obesity syndrome. 
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The actual mechanism whereby the ubiquitous expression of agouti causes yellow 
obese syndrome is not clear yet and both peripheral and central mechanism have been 
proposed.  
Ectopic expression of agouti may antagonize signal transduction cascades that are 
mediated by melanocortin receptors present in tissues other than the skin (141). Agouti 
modulation of pigmentation is mediated by MC-1R (142), which is primarily expressed 
in melanocytes, leading to the hypothesis that melanocortin receptor antagonism may be 
responsible for the metabolic effects of agouti in yellow obese syndrome. Four other 
melanocortin receptors have been cloned: MC-2R is expressed in the adrenal cortex and 
adipose tissue (143); MC-3R is expressed in the hypothalamus and limbic systems in the 
brain (143), and in the placenta and gut; MC-4R is expressed throughout the brain (144), 
and MC-5R is ubiquitously expressed (145). To test the hypothesis that agouti protein 
may antagonize these other melanocortin receptors, the receptors were expressed in 
human embryonic kidney cells and the ability of recombinant agouti protein to 
antagonize alpha-melanocyte stimulating hormone (alpha-MSH) signaling was 
determined by assaying for adenylyl cyclase activity (133). These experiments 
demonstrated that the agouti protein is a high affinity antagonist of MC-1R, MC-2R and 
MC-4R, but not of MC-3R or MC-5R. However, only disruption of MC-4R results in an 
obesity syndrome that is markedly similar to that seen in mice with dominant agouti locus 
mutations, suggesting that chronic antagonism of MC-4R by the agouti protein may be a 
central mechanism of the agouti-induced obesity syndrome (146).  
Recent studies demonstrate that melanocortin/MC-4R signaling play a key role in 
the regulation of food intake and energy homostatsis (147). MC-4R is abundantly 
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expressed in hypothalamic paraventricular nucleus (PVN), dorsomedial nucleus and 
veentromedial nucleus, which are major hypothalamic regions involved in regulating feed 
behavior, body weight and energy homeostasis (148). The importance of the central 
melanocortin system in the regulation of energy balance is highlighted by studies in 
transgenic animals and humans with defects in this system. Mice with a targeted 
disruption of MC-4R exhibit an obesity syndrome that is remarkably similar to that seen 
in mice with dominant agouti mutations, suggesting that chronic antagonism of MC-4R 
by the agouti protein may be a central mechanism of the agouti-induced obesity 
syndrome (146). In addition, agonist of MC-4R was shown to inhibit feeding in Ay/a mice, 
whereas a melanocortin antagonist stimulated feeding (149). Furthermore, diet-induced 
obesity in mice causes a down regulation of MC-4R while food restriction up-regulates 
its expression (150). In humans, the obesity phenotype, including BMI, fat mass and 
body fat content was highly associated with restriction fragment polymorphisms of MC-
4R in the Quebec family study (151). In addition, mutations in MC-4R gene have been 
identified in severely obese human subjects (152). These recent experiments strongly 
support a role for neural melanocortin receptor(s) in regulating nutrient intake and energy 
balance; 
Although agouti is not normally expressed in the central nervous system, the 
melanocortin system may modulate energy homeostasis through the actions of two other 
endogenous antagonist agouti related protein (AGRP) and α-MSH, POMC cleavage 
product (153). POMC is expressed at only two locations in the brain: the arcuate nucleus 
of the hypothalamus (ARC) and the nucleus of the tractus solitarius (NTS) of the 
brainstem. AGRP has been identified primarily in the arcuate nucleus of the 
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hypothalamus of the rat and primate with neuronal projections to the paraventricular 
hypothalamic nucleus (154). AGRP exhibits high degree of homology to agouti, with the 
highest degree of identity in the cysteine-rich carboxyl terminus (155). The AGRP 
protein was demonstrated pharmacologically to competitively antagonize the MC-3R and 
MC-4R brain melanocortin receptors, and when ectopically expressed or Central Nervous 
System administration, resulted in an obese phenotype (156-157). AGRP is co-localized 
in NPY containing neurons, and when administered centrally to NPY-/- knockout mice, 
results in increased food intake (158). α-MSH is the endogenous ligand for MC-4R. 
Previous studies demonstrate that MC-4R agonists or antagonists suppressed or 
stimulated food intake, respectively. It has been shown that the blockade of MC-4R due 
to the ectopic expression of agouti protein or the overexpression of AGRP induces 
hyperphagia and obesity. The MC-4R and POMC knockout mice also express an obese 
phenotype (159). Thus, the importance of the melanocortin system in the regulation of 
feeding behavior and body weight is generally accepted. 
Agouti also appears to exert significant peripheral effects by targeting ion 
channels, thereby causing an increase in intracellular free calcium ([Ca2+]i) in multiple 
peripheral tissues, particularly in adipose tissue and pancreatic β cells (160-161).  
Agouti protein contains a cysteine-rich carboxyl terminus, with the number and 
spacing of cysteine residues are extremely similar to those of toxins from snails (ω-
conotoxins) and spiders (plectoxins) that are known to function by targeting ion channels 
(162-163). This cysteine-rich terminus appears to have functional activity equivalent to 
the full-length agouti. Analysis of the three-dimensional structure formed by the C-
terminus of the agouti protein also showed a high similarity to those toxins (164). 
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Furthermore, recombinant agouti protein stimulates a significant increase in [Ca2+]i 
influx in skeletal muscle myocytes and adipocytes and this effect was not mediated by 
antagonizing MC-R, indicating a direct targeting of Ca2+ channel (160). 
1.3.2 Intracellular Calcium and Obesity Related Metabolic Disorder  
Agouti protein appears to stimulate lipogenesis in adipocytes (165). The mRNA 
levels of fatty acid synthase (FAS) and stearoyl-CoA desaturase (SCD), two key enzymes 
in de novo fatty acid synthesis and desaturation respectively, were dramatically increased 
in obese (Avy) mice relative to lean (a/a) controls. Treatment of adipocytes with 
recombinant agouti protein in vitro increased FAS and SCD expression and activity. 
Strong correlation between the degree of agouti expression and both [Ca2+]i levels and 
body weight have been demonstrated in mice, indicating that agouti may modulate 
adiposity via a [Ca2+.]i dependent mechanism (166). Humans also have an agouti gene, 
and the mouse and human agouti proteins are 87% identical over the cysteine rich C-
terminus, suggesting that agouti may be functionally similar in both species. Unlike the 
mouse, however, the human agouti gene is normally expressed primarily in adipose tissue. 
The presence of human agouti in adipose tissue is intriguing in light of the fact that 
recombinant murine agouti protein not only causes an increase in [Ca2+]i in cultured 
adipocytes, but also increases fatty acid synthase expression and activity, and stimulates 
the accumulation of triglycerides in a [Ca2+]i-dependent manner. Claycombe et al. 
reported that FAS promoter contains an agouti response element that also responds to 
KCl, a membrane depolarization agent (167). Furthermore, calcium channel inhibition 
results in significant decreases in adipose tissue mass and adipocyte lipogenesis in obese 
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transgenic mice that express the agouti gene in a ubiquitous manner (168). Moreover, the 
human adipocyte agouti is up-regulated during differentiation (169). In addition, agouti 
expression is highly correlated with FAS expression and activity in human adipose tissue 
which stimulates Ca2+ influx (167). These results indicate that the agouti protein may 
regulate fatty acid metabolism by acting directly on adipose tissue.  
Agouti protein also plays a role in regulation of lipolysis via a Ca2+ dependent 
mechanism (170-171). Recombinant agouti protein inhibits both basal and agonist 
stimulated lipolysis in human adipocytes. Increasing Ca2+ influx through either voltage- 
or receptor-operated Ca2+ channels also inhibits lipolysis and this effect is blocked by 
Ca2+ channel antagonists, indicating that this anti-lipolytic effect is mediated by calcium 
signaling. The mechanism underlying the anti-lipolytic effect of Ca2+ has recently been 
demonstrated to be mediated by increased activation of phosphodiesterase 3B, resulting 
in reduced cAMP levels and consequently, inhibition of hormone sensitive lipase activity. 
However, considerable species variability exists in the lipolytic response to 
melanocortins (172). Recent studies suggested that agouti may also inhibit lipolysis by 
antagonisting ACTH. ACTH and -MSH are potent lipolytic hormones (173). The 
adipocyte MC-2R exhibits properties similar to the adrenocortiacal ACTH receptor and 
couples to activation of adenylyl cyclase (174-175). Both ACTH and -MSH bind to 
mouse adipocytes, but only ACTH elevates cAMP and stimulates lypolysis. Therefore, 
agouti antagonism of ACTH to adipocytes may lead to an inhibition of lipolysis and/or 
stimulation of lipogenesis. 
Insulin resistance is of major pathogenic importance in several common human 
disorders, including type 2 diabetes and obesity. The human homologue of agouti is 
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expressed in both adipose tissue and pancreas, and may therefore exert important 
peripheral effects. Administration of AGRP caused significant increases in plasma insulin 
concentrations and fat pad mass, and transgenic mice expressing agouti exhibited 
hyperinsulinemia and hyperglycemia (176), indicating an interaction between insulin and 
agouti-induced obesity syndrome. Since agouti stimulates Ca2+ in several cell types and 
Ca2+ is the proximal signal for insulin release, it is possible that agouti may exert effect 
on pancreatic β-cells to modulate Ca2+ signaling and stimulates Ca2+ release. Indeed, 
agouti is expressed in pancreas and potently stimulates insulin release via a Ca2+ 
dependent mechanism (177).  
One of the potential factors that may account for or contribute to insulin 
resistance is a sustained high level of [Ca2+]i in the insulin target cells. Draznin et al 
demonstrated an optimal range of [Ca2+]i for the stimulatory effect of insulin on glucose 
transport in isolated rat adipocytes, with the levels beyond this range causing marked 
decrease in insulin sensitivity (178). Similarly, elevations of [Ca2+]i induced by 
incubation of adipocytes with depolarizing concentrations of K+ or parathyroid hormone 
resulted in diminished cellular responsiveness to insulin (179). High levels of the steady 
state [Ca2+]i have been observed in adipocytes of patients with obesity, type 2 diabetes, 
skeletal muscles of agouti rats, and hepatocytes of diabetic rats (180), and an inverse 
correlation between the whole body insulin sensitivity and the [Ca2+]i of peripheral blood 
cells has been observed in human studies (181). It has been postulated that high [Ca2+]i in 
the insulin target cells may diminish cellular responsiveness to insulin and thus contribute 
to the development of insulin resistance (182). The mechanism whereby the high levels 
of [Ca2+]i interfere with insulin action on glucose metabolism remains largely unknown. 
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Insulin-receptor binding is not affected, and receptor tyrosine kinase activity is only 
minimally affected. Recruitment of glucose transporter, glucose transporter (GLUT) 4, is 
also not influenced. Begum et al have demonstrated in isolated rat adipocytes that an 
elevation in [Ca2+]i induces inhibition of phosphoserine phosphatase activity through an 
activation of inhibitor 1 (183). Accordingly, sustained elevations in [Ca2+]i may result in 
insulin resistance by preventing dephosphorylation of insulin-sensitive target protein(s) 
within the cell. Reduction in insulin-induced dephosphorylation of glycogen synthase and 
GLUT4 supports this possibility (184-185).  
Alemzadeh et al. have reported that diazoxide, a drug that activates the ß cell 
KATP channel and subsequently reduces [Ca2+]i and inhibits insulin release, exerts an 
antiobesity effect in obese Zucker rats and hyperinsulinemic obese adults (186-187). 
Sulfonylureas such as glibenclamide are insulin secretagogues widely used to stimulate 
insulin secretion in the treatment of non-insulin-dependent diabetes mellitus. 
Sulfonylurea interact with specific, high affinity receptors (SUR) on the pancreatic beta-
cell to close ATP-sensitive K+ channels, depolarize the cell, activate Ca2+ influx through 
voltage-dependent Ca2+ channels, and trigger insulin secretion (188). SUR agonists also 
been demonstrated to exert direct effects on adipocytes. Draznin et al. reported that 
glibenclamide increased [Ca2+]i in isolated rat adipocytes by promoting Ca2+ influx 
through voltage-dependent Ca2+ channels, while this effect was blocked by a Ca2+ 
channels antagonist (182). Moreover, glibenclamide has been reported to potentate 
peripheral insulin effects in isolated adipocytes (189). Consistent with this, human 
adipocytes express SUR and exhibit a glibenclamide dose-responsive increase in [Ca2+]i 
(190). Moreover, glibenclamide exerts lipogenic and antilipolytic effects in human 
 29
adipocytes, whereas diazoxide completely blunts each of these effects. These data 
demonstrate that SUR in adipocyte regulates [Ca2+]i and thereby exerts coordinated 
control over lipogenesis and lipolysis (190). 
Agouti may also participate in the regulation of adipogenesis. Mynatt et al 
demonstrated substantial increases in PPAR-γ and signal transducer and activators of 
transcription (STATs) expression in the fat pads of the aP2-agouti mice and in cultured 
adipocytes that have been exposed to recombinant agouti protein (191-192). The major 
transcription factors involved in adipocyte gene regulation include PPARγ, proteins 
belonging to the CCAAT/enhancer-binding protein (CEBP) family, and adipocyte 
determination and differentiation dependent factor 1, also known as sterol regulatory 
element binding protein (193). Recent studies have also suggested that the STAT family 
of transcription factors may also be important in fat cells (194). A STAT family member 
shows a distinct pattern of activation by cytokines and, upon nuclear translocation, can 
regulate the transcription of particular genes in cell- or tissue-specific manners. In fat 
cells, the expression of STAT1, STAT5A, and STAT5B is highly induced during 
differentiation and correlates with lipid accumulation. Agouti-induced regulation of 
STAT1, STAT3, and PPAR-γ expression results in the regulation of various genes 
associated with the adipocyte phenotype. [Ca2+]i also plays a regulatory role in 
adipogenesis. [Ca2+]i appears to promote and accelerate preadipocyte differentiation 
program(s), thereby inducing the adipocyte phenotype in the late stage of differentiation 
(195-196). To achieve this, increasing [Ca2+]i causes a marked increase in the expression 
of PPAR-γ, and subsequently accelerates adipocyte differentiation by directly acting 
upon and eliciting late differentiation gene expression, such as aP2, steroyl-CoA 
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desaturase (SCD-1), phosphoenolpyruvate carboxykinase (PEPCK), and FAS. On the 
other hand, in late differentiation, preadipocytes become more committed to terminal 
differentiation after the expression of several critical differentiation transcriptional factors, 
such as CCAAT/enhancer binding protein beta and delta (C/EBP-ß and C/EBP-δ), 
PPARγ, and sterol regulatory element binding protein-1/adipocyte determination and 
differentiation factor-1 (SREBP-1/ADD-1). [Ca2+]i may synergize with these 
transcriptional factors to promote the differentiation program by stimulating late 
differentiation gene expression. 
1.3.3 Dietary Calcium and Obesity  
1.3.3.1 Dietary Calcium Intake and Obesity  
Human studies show an inverse association between calcium intake and body 
weight, body fat and the risk of becoming obese (197). The US Department of 
Agriculture’s Nationwide Food Consumption Survey from 1987 to 1988 showed that the 
average dietary calcium intake in the United States was far below the suggested optimal 
calcium intake, and that persons with the lowest calcium intakes tended to have the 
highest body weight (198-199). When stratified by ethnic group, the non-Hispanic black 
population, which has one of the highest prevalence of obesity in the United States, was 
also found to have a lower mean daily calcium intake than either the Hispanic white 
population or the non-Hispanic white population. Using data from the first National 
Health and Nutrition Examination Survey (NHANES I), McCarron found a statistically 
significant inverse association between calcium intake and body weight (199). More 
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recently, Zemel et al demonstrated a strong inverse association between the relative risk 
of obesity and calcium intake for participants of NHANES III (200). The relative risk of 
high body adiposity was found to be greatest in those with the lowest calcium intake and 
was progressively lower as calcium intake increased. Animal models have provided 
mechanistic insight as to how low calcium intakes could influence body fat stores. 
Studies in the 1980s in spontaneous hypertensive rats found a lower net weight gain in 
the rats fed a high-calcium diet than in the rats fed a low-calcium diet, respectively (201). 
Shortly afterward, it was observed that diets high in both dietary calcium and sodium 
induced favorable changes in the total body fat content of spontaneous hypertensive rats 
and Wistar-Kyoto rats (202). More recently, we studied transgenic mice that 
overexpression agouti gene, specifically in adipocytes under the control of the aP2 
promoter. We examined the effects of various calcium intakes on weight gain and 
acceleration of weight loss over 6 wk. Weight gain and fat-pad mass on obesity-
promoting diets were significantly reduced by high calcium diets, and high calcium also 
promoted weight loss during energy restriction (200). These data suggest that, an increase 
in dietary calcium decreases body weight gain during ad libitum and accelerates weight 
loss during energy restriction. 
1.3.3.2 Mechanism of Dietary Calcium Intake in Regulation of Obesity  
a. Dietary Calcium, 1, 25-(OH)2-D3 and Intracellular Calcium 
Dietary calcium supplementation has been reported to decrease the [Ca2+]i 
concentration in various cell types in rodents and human (203-204). Calcium supplements 
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significantly increased the cell Ca-ATPase activity and decreased intracellular Na+ 
concentration (205-206). The decrease in Na+ results in an increased driving force for 
Na+-Ca2+ and Na+-H+ exchange mechanisms, which have a central role in controlling the 
[Ca2+]i level, and consequently reduce reduced free cytosolic Ca2+ concentration(207).  
Dietary calcium reduces parathyroid secretion of parathyroid hormone (PTH) and 
renal production of 1, 25-dihydroxyvitamin D3 (1, 25-(OH)2-D3). Petrov et al demonstrate 
that oral calcium supplementation in man causes a reduction in plasma concentration of 
PTH and 1, 25-(OH)2-D3 (208). According to Basile et al, increasing dietary calcium 
intake increases urinary calcium excretion and reduces plasma 1, 25-(OH)2-D3, but total 
and ionized serum Ca2+ and plasma 25-(OH)-D3 are unchanged (209). 1, 25-(OH)2-D3 
also increases radio-labeled calcium uptake in various cell types. Accordingly, the 
decrease in [Ca2+]i observed after dietary calcium supplement could be attributable to a 
reduced cellular influx of Ca2+, resulting from suppression of circulating levels of 1, 25-
(OH)2-D3 and/or PTH. Indeed, 1, 25-(OH)2-D3 and PTH have both been shown to 
stimulate a significant and sustained increase in [Ca2+]i concentrations in primary 
cultures of adipocytes (210-211). Data from our laboratory recently demonstrated that 1α, 
25-(OH)2-D3 increased [Ca2+]i whereas the specific membrane vitamin D receptor 
antagonist 1ß-hydroxyvitamin D3 blocked vitamin D–stimulated increases in [Ca2+]i 
(212), indicating that a non-genomic actions of 1α, 25-(OH)2-D3 via a putative membrane 




b. Intracellular Calcium and Adipocyte Lipid Metabolism  
High-calcium diets attenuate adipocyte lipid accretion and weight gain during 
overconsumption of an energy-dense diet and increase lipolysis and preserve 
thermogenesis during caloric restriction, thereby markedly accelerating weight loss (15-
16). Previous studies of the agouti gene demonstrate a key role for intracellular Ca2+ in 
regulating adipocyte lipid metabolism and TG storage (213). The role of the increased 
[Ca2+]i in stimulation of lipogenesis has been explored using fatty acid synthase, a key 
enzyme of de novo lipogenesis (166-167). An agouti/Ca2+ response sequence has been 
mapped to the -435 to -415 region of the FAS promoter and this sequence is upstream of 
insulin response element. This location consistent with the observed additive effects of 
agouti and insulin on FAS gene transcription (166, 214). Increasing [Ca2+]i in adipocytes 
via either receptor- or voltage-mediated Ca2+ channel activation stimulated FAS gene and 
expression and consequently resulted in stimulation of FAS activity. In contrast, [Ca2+]i 
influx inhibition by a Ca2+ channel antagonist suppressed lipogenesis, indicating that 
[Ca2+]i stimulates lipogenesis directly. In addition to activating lipogenesis, recent data 
also indicate that increasing [Ca2+]i also contributes to increased triglyceride stores by 
inhibiting lipolysis (170) as reviewed in the previous section.  
Animal studies using aP2 transgenic mice confirmed these observations in vivo. 
We recently demonstrated that the increased calcitriol produced in response to low-
calcium diets stimulates adipocyte Ca2+ influx and, consequently, promotes adiposity by 
both inhibiting lipolysis and stimulating lipogenesis. Accordingly, suppressing calcitriol 
levels by increasing dietary calcium is an attractive target for obesity interventions (15-
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16). In support of this concept, transgenic mice expressing the agouti gene specifically in 
adipocytes (a human-like pattern) respond to low-calcium diets with accelerated weight 
gain and fat accretion, whereas high-calcium diets markedly inhibit lipogenesis, 
accelerate lipolysis, increase thermogenesis, and suppress fat accretion and weight gain in 
animals maintained at identical caloric intakes (15). Further, low-calcium diets impede 
body fat loss whereas high-calcium diets markedly accelerate fat loss in transgenic mice 
subjected to caloric restriction (16). Dairy sources of calcium exert markedly greater 
effects in attenuating weight and fat gain and accelerating fat loss. This augmented effect 
of dairy products is likely due to additional bioactive compounds in dairy that act 
synergistically with calcium to attenuate adiposity (215). These concepts are confirmed 
by both epidemiological and clinical data (216-217), which demonstrate that increasing 
dietary calcium results in significant reductions in adipose tissue mass in obese humans 
in the absence of caloric restriction and markedly accelerates the weight and body fat loss 
secondary to caloric restriction, whereas dairy products exert significantly greater effects.  
c. 1 α, 25-(OH)2-D3 and Adipocyte Energy Homeostasis  
1α, 25-(OH)2-D3 appears to play an important role in modulating adipocyte lipid 
metabolism and energy homeostasis via both genomic and non-genomic actions. 1α, 25-
(OH)2-D3 generates rapid, non-genomic signal transduction, including modulation of 
calcium channels, via a putative membrane vitamin D receptor (mVDR) in adipocytes 
and thereby participates in the regulation of lipid metabolism (17). Thus suppression of 
1α, 25-(OH)2-D3 with high dietary calcium induces reduction in body fat (15-16).  
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Although this anti-obesity effect of dietary calcium appears to be due, in part, to 
effects on lipolysis and lipogenesis, it is also possible that a loss of adipocytes would 
results in a cellular deficit lipid esterification as the body recovers from energy restriction. 
Thus, a reduced number of available adipocytes may not be able to store excess energy 
coming from rebound in food intake. Moreover, generating new cells would require extra 
energy that would contribute to a further metabolic enhancement. Recent data also 
indicate that [Ca2+]i may play a key role in modulating cell’s sensitivity to the apoptotic 
stress (21). Several of the functional groups of molecules involved in apoptosis are 
[Ca2+]i responsive. [Ca2+]i has been demonstrated to modulate the role of proteases, 
including caspase-3, caspase-9 and Ca2+-dependent endonucleases (22-23). Scorrano et al. 
also showed a key interaction occurs between Bcl-2 family protein and calcium signaling 
in the execution of apoptosis (218). Their data demonstrated a critical role of BAX and 
BAK in maintaining of homeostatic concentration of [Ca2+]i in endoplasmic endo-
reticulum (ER) and mitochondria, which control the apoptotic fate of cells responding to 
[Ca2+]i dependent stimuli. Numerous studies also showed that thapsigargin, which can 
induce sustained [Ca2+]i elevation by inhibiting sacro-endoplasmic reticulum Ca2+-
ATPase (SERCA), triggers apoptosis in various cell types (219-221). These data indicate 
a key role of [Ca2+]i in the apoptosis process. Given that [Ca2+]i can be modulated by 1α, 
25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in apoptosis should be explored. Although high 
dose of 1α, 25-(OH)2-D3 has been reported to induce apoptosis in various tumor cells 
(222-225), the regulation of apoptosis by physiological doses of 1α, 25-(OH)2-D3 remains 
unclear.  
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1α, 25-(OH)2-D3 also generates genomic actions via a nuclear receptor in a 
manner similar to the other members of steroid hormone superfamily. Recent study 
further demonstrated that 1α, 25-(OH)2-D3 exerts an inhibitory effect on basal, 
isoproterenol, and fatty acid-stimulated UCP2 expression via a genomic action (226). 
This inhibition is mediated by nVDR. The mVDR agonist  and antagonist fail to exert 
their actions to either mimic or prevent the 1α, 25-(OH)2-D3 inhibition of UCP2 
expression, whereas nVDR knockout by antisense oligonucleotide prevented the 
inhibitory effect of 1α,25-(OH)2-D3 on adipocyte UCP2 expression. UCP2 is ubiquitously 
expressed, with the highest level in white adipose tissue, and has been shown to stimulate 
mitochondria proton leak and therefore exhibit a potential role in thermogenesis, energy 
metabolism, and obesity (12). In addition, considerable progress has been made in 
elucidating a pivotal role of mitochondria playing in the coordination, initiation, and 
execution of apoptotic cell death (227). Three general mechanisms have been proposed, 
including 1) disruption of oxidative phosphorylation ATP production; 2) regulation of the 
apoptotic proteases; and 3) alteration of cellular reduction-oxidation potential. Because 
UCP2, which is highly expressed in white adipose tissue, has been demonstrated to 
function as mitochondrial uncoupler of oxidative phosphorylation, it is reasonable to 
propose that UCP2 may stimulate apoptosis in adipocytes. Accordingly, the obesity-
promoting effect of 1α, 25-(OH)2-D3 may also attributable to its suppression of UCP2 
expression. However, the effect and mechanism of 1α, 25-(OH)2-D3 and UCP2 in 
regulation of adipocytes apoptosis is not yet well understood. 
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1.4 Role of UCPs in Regulation of Obesity 
1.4.1 Thermogenesis and Obesity  
Obesity results from energy intake exceeding energy expenditure over time 
(228). The biochemical mechanisms responsible for the regulation of energy expenditure 
and the efficiency of energy utilization are poorly understood. Possible ways to increase 
energy expenditure include increasing physical activity and energy dissipation as heat by 
futile metabolic cycles. Thermogenesis in mammals, comprising obligatory 
thermogenesis and regulatory thermogenesis, is a spontaneous mechanism allowing body 
temperature of most mammals to be maintained at around 370C in cold environments 
(229-230). Obligatory thermogeneisis corresponds to resting energy expenditure and 
minimal biological work essential for life in resting conditions, in absence of food intake, 
and at thermoneutrality. Regulatory thermogenesis, also called adaptive thermogenesis, 
corresponds to extra heat induced by exposure to the cold or food intake. Regulatory 
thermogenesis can occur in muscle in the form of shivering thermogenesis, and in brown 
adipose tissue and some other tissues too as non-shivering thermogenesis, such as 
postprandial excess heat production. Rothwell et al postulated decades ago that non-
shivering thermogenesis could be utilized by the organism not only to protect against 
cold stress, but also to maintain energy homostatsis in response to caloric stress (231). It 
followed that obesity could rise from abnormalities in this mechanism of regulation and 
that pharmacological stimulation of non-shivering thermogenesis could be an effective 
mechanism for reducing obesity (228). This hypothesis is very attractive because 1) the 
production of heat is fundamental to the concepts of energy balance and the regulation of 
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body weight; 2) non-shivering thermogenesis is a physiological system dedicated to heat 
production; and 3) potential to develop agonists that are specific for non-shivering 
thermogenesis exist.  
The endocrine factors regulating basal thermogenesis are not well known, 
although that it has been shown that thyroid hormones play a major role in modulating 
resting energy expenditure (232). Such evidence comes from analysis of patients 
exhibiting hypo- or hyperthyroid activity, and is confirmed by experimental work on 
animals (233-234). The sympathetic nervous system and noradrenaline are the major 
regulators of adaptive and cold induced thermogenesis (235-236). Recent data point out 
the thermogenic effect of leptin, acting via the brain and activation of sympathetic fibers 
(237). 
1.4.2 UCP Family  
At the cellular level, thermogenesis results from loss of energy during a number 
of biochemical processes coupling endergonic and exergonic reactions, and linked in 
particular to ATP hydrolysis and ion transport (232). Uncoupling of mitochondrial 
respiration from ADP phosphorylation is a highly thermogenic mechanism existing in 
brown adipose tissue (BAT) (238). Unlike white adipose tissue, BAT is characterized by 
rich vascularization, which is responsible for its color, a network of sympathetic fibers 
around every cell and numerous mitochondria with dense cristae (239). In response to 
acute cold exposure, the sympathetic nerve-endings of BAT release noradrenaline (NA). 
This NA binds to membrane β-adrenergic receptors, stimulating lipolysis and the release 
of FFA. FFAs released in situ are used as substrates for the respiratory chain and they 
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apparently also activate thermogenesis in BAT (240). The brown adipocytes are also rich 
in the UCP1, which uncouples respiration from phosphorylation and leads to the 
dissipation of energy as heat. Although in large mammals BAT is present in neonates and 
hardly detectable in adults, the presence of large amounts of UCP has been shown in 
perirenal adipose tissue of adult human in certain conditions. During the past 10y, the 
interest of several pharmaceutical groups has focused on β3-adrenoceptor agonists, which 
mimic the action of noradrenaline and could be useful in stimulating UCP1 and 
increasing energy expenditure in obese patients (241). Unfortunately, these drugs often 
proved to have undesirable side-effects on the cardiovascular system and other tissues 
associated with agonist activity at β1 and β2- adrenoceptors, or have a poor bioactivity 
(242). In addition to catecholamines, several hormones activate UCP1 gene transcription, 
including thyroid hormones, retinoids and legends of PPARs (243-245).  
It was known for a long time that only 70% of the energy released from 
respiratory substrate oxidation was recovered as ATP and that respiring mitochondria 
release heat (246). Measurement of proton leaks in liver and muscle mitochondria 
favored a role for proton leak in the less than perfect coupling of O2 consumption to ATP 
synthesis (247). Rolfe and Brown quantified various processes composing mammalian 
resting metabolic rate (RMR). For the sum metabolism of various tissues, ~10% was 
estimated as being attributable to non-mitochondrial oxygen consumption and ~20% to 
oxygen consumption for maintaining the mitochondrial membrane potential against the 
leak of protons (246). The existence of proton leak suggested that proteins leaked to 
UCP1 might be involved (248). Despite a compelling rationale in support of a role for 
UCP1 in the regulation of body weight (249-251), this idea has been viewed as 
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questionable, because brown adipocytes are thought to be rare in adults human. Instead, 
white adipose tissue (WAT) and skeletal muscle are the two major peripheral tissues that 
regulate energy homostatsis and thermogenesis in adult mammals (252-253). However, 
newly identified uncoupling protein homologs (UCP2, UCP3, UCP4, UCP5, avUCP, 
HmUCP) have been found in various animal tissues (254-259). In particular, in both 
rodents and human, UCP2 is expressed in a variety of tissues such as WAT, BAT, 
skeletal muscle, heart, placenta, brain, stomach, kidney, lung and liver. UCP2 is 60% 
homologous to UCP1. In contrast to the ubiquitous expression of UCP2, UCP3 is 
dominantly expressed in skeletal muscles of human and rodents. The amino acid 
sequence of human UCP3 is 57% identical to human UCP1 and 73% identical to human 
UCP2. This high level of homology with UCP1 suggested a possible uncoupling activity 
of UCP2 and UCP3. Several reports provide both direct and indirect evidence of a role of 
UCP2 and UCP3 in the in vivo regulation of energy production and expenditure (260-
262). Such a role has been elucidated in vitro, where they both mediate mitochondrial 
proton leak in an identical fashion, and their overexpression leads to reduction of 
mitochondrial membrane potential (263-264). 
Genetic strategies have also clarified the functional role of UCP2 and UCP3 in 
modulation of energy metabolism. Markers encompassing the UCP2/3 locus have 
revealed significant linkage to resting energy expenditure in a French-Canadian cohort 
and in Pima Indians (265-266). A polymorphism in UCP2 exon 8 has demonstrated an 
association with body mass index (BMI) and leptin in specific populations (267-268). 
Numerous sequence variants have also identified in UCP3. Particular attention has 
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focused on a splice site mutation in UCP3 intron 6 detected in African-American subjects, 
which results in reduced fatty acid oxidation (269). 
So far two mechanisms have been proposed for the mitochondrial uncoupling 
(270). The fatty acid protonophore model of UCP-mediated H+ flux was first introduced 
by Skulachev and Garlid (271-272). In this mechanism, UCP doesn’t conduct protons but 
catalyzes flip-flop of the anionic head group of fatty acid from the matrix leaflet to the 
outer leaflet of the inner membrane. Transport of the anion is driven by the high, inside-
negative membrane potential (∆ψ). After the carboxyl head group has crossed the 
membrane, it picks up a proton, and the protonated fatty acid spontaneously and rapidly 
flip-flops back to the matrix side, where deprotonation completes the cycle. The net result 
of the cycle is delivery of protons with charge to the matrix. Thus, fatty acids behave as 
cycling protonophores by virtue of the fact that UCP permits the anionic charge to move 
across the inner membrane. The other model, however, assumes that UCP transports 
proton directly (273). Winkler and Klingenberg demonstrate that fatty acids are buffering 
cofactors that operate in conjunction with resident H+-conducting amino acids. Mutation 
of two histidine residues in UCP1 causes loss of H+ transport. This model is supported by 
the evidence that alkylsulfonates are competitive inhibitors of fatty acid induced proton 





1.4.3 UCPs and Obesity  
1.4.3.1 UCPs and Thermogenesis 
Thermogenesis appears to be a major function of UCP1, the uncoupling protein 
homolog that is restricted to BAT (251). In rodents, neonatal, or hibernating mammals, 
which have large amount of BAT associated UCP1 activity, energy substrate are used to 
generate heat, limiting ATP production. Thus transgenic mice with brown fat ablation 
have decreased metabolic rate and hypothermic and these mice are obese (274-275). In 
addition, the elevated expression of both UCP2 and UCP3 in ground squirrels during 
hibernation has been cited to advocate a role for these UCPs in mammalian nonshivering 
thermoregulation (276). 
Recent studies demonstrate that the synthesis of UCP2 and UCP3 is positively 
controlled by hormonal regulators, including thyroid hormone and leptin (277-278). 
These studies reinforce the putative role for UCP2 and UCP3 in energy expenditure and 
are in agreement with the genetic linkage of the UCP2 and UCP3 locus to resting 
metabolic rate in rodents and human (279). Early studies demonstrated T3 increases the 
transcription of UCP1 by acting at thyroid hormone response elements (TREs) in the 
enhancer located 2.3kb upstream of the promoter (280). However, in hyperthyroid 
animals, BAT becomes inactive, with reduced UCP1 expression, suggesting that T3 
induced thermogenesis in other tissues reduces the need for BAT thermogenesis (281). 
Since UCP1 shares high sequence similarities with UCP2 and UCP3, it is reasonable to 
propose that UCP2 and UCP3 have related function. Administration of T3 to rodents 
leads to increases in the expressions of UCP2 and UCP3 in heart and skeletal muscle 
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(282-283). In association with the alteration in the thyroid status, increases occur in 
UCP3 mRNA expression in skeletal muscle and in mitochondrial uncoupling activity. 
The latter result has been confirmed in vivo by a non-invasive method (nuclear magnetic 
resonance spectroscopy) in both rats and humans (284-285). In hypothyroid rats given a 
single injection of T3, a strict correlation in terms of time course has been shown among 
the induced increase in UCP3 protein levels in gastrocnemius muscle, the decrease in 
mitochondrial respiratory efficiency and the increase in the RMR of the whole animal 
(286). In that study, the maximal increase in mitochondrial UCP3 density was reached at 
65 h after the T3 injection, and the increase in RMR showed the same time course. At the 
same time point, mitochondria isolated from gastrocnemius muscle showed a 
significantly higher non-phosphorylating respiration rate, whereas the membrane 
potential showed a decrease, clearly indicating the occurrence of uncoupling. In contrast, 
chronic hypothyroidism decreases the UCP3 expression in skeletal muscle from rat. 
These data provide in vivo evidence that UCP3 has the potential to act as a molecular 
determinant in the influence of T3 over RMR. All these data support that T3-promoted 
increase in thermogenesis via mitochondrial uncoupling in skeletal muscle.  
In contrast to these observations, it has been reported that UCP3 null mice given a 
4 day course of T3 (at 100 µg/100 g body weight/day) show the same increase in RMR as 
wild-type controls, a finding that does not seem to support the involvement of UCP3 in 
the T3-induced increase in metabolic rate (287). Among the possible reasons for the 
discrepancy are the very high doses of T3 used in UCP3-knockout studies (which could 
have overstimulated other thermogenetic mechanisms) and the possible conversion of T3 
to other thermogenic iodothyronines, such as 3,5-diiodothyronine.  
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Leptin is believed to play a role in regulation of UCPs as well. Exogenous leptin, 
administered to rodents, results in reduced adipose mass, which is only in part explained 
on the basis of decreased food intake, implying an effect of the peptide to increase energy 
expenditure (288). Indeed, leptin has been demonstrated to increase core body 
temperature, stimulate sympathetic nerve activity, and increase norepinephrine turnover 
in BAT (289). Scarpace et al demonstrated that peripheral administration of leptin 
induced both oxygen consumption and UCP1 expression (290). Chronic injection of 
leptin in C57BL/6J was shown to induce UCP1 and UCP2 expression in brown and white 
adipose tissue and lead to depletion of lipid from these fat depots (291). Using an 
adenovirus expression vector to introduce leptin, Zhou et al observed similar effects in 
rats (292). Furthermore, leptin prevents the decrease in UCP1 and UCP2 expression 
caused by fasting and stimulates energy utilization in ob/ob mice by inducing UCP 
activity (293). Consistent with these observations, lactation is a natural model of chronic 
negative energy balance, and lactating rats have decreased adaptive thermogenesis, a 
significant reduction in UCP1 and UCP3 protein levels as well as low circulating leptin 
levels (294). Low circulating leptin levels during lactation could be the cause of the 
decrease in UCP1 and UCP3 expression. Indeed, leptin replacement during mid-lactation 
significantly increased UCP1 and UCP3 mRNA expression. One major difference 
between fasted and lactating rats is that circulating FFA levels are elevated during fasting 
but reduced during lactation due to the increased FFA uptake by mammary tissue. This 
difference may be a reason for the divergent effects of fasting and lactation on UCP3 
expression in skeletal muscle despite the low serum leptin levels in these conditions. The 
remarkable increase in UCP3 expression during fasting agrees with previous reports 
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(295). Skeletal muscle is the primary tissue responsible for the clearance of dietary 
glucose and lipids from circulation. During fasting, when the overall strategy is to 
conserve energy and to spare glucose for use by the brain, the fuel requirement of skeletal 
muscle is diminished, and its predominant fuel is shifted toward lipids. UCP3 is likely to 
be specifically involved in regulating the use of lipids as fuel substrates in skeletal muscle. 
This hypothesis is supported by previous evidence showing an up-regulation of UCP3 in 
skeletal muscle under conditions where the preference for fuel substrate is shifted toward 
lipids, such as in fasting and high fat feeding (295). Furthermore, mice lacking UCP3 
showed a tendency toward impairment in the starvation-induced shift in fatty acid 
metabolism (296).  
1.4.3.2 UCPs and Fatty Acid Metabolism  
The function of UCPs may not be restricted to thermoregulation and there is now 
a number of data linking UCP expression levels to fatty acid metabolism and fatty acid 
flux into various tissues. A high fat diet increased UCP2 gene expression in adipose 
tissue of mice (297). Starvation, which increases the level of circulation free fatty acids, 
markedly increases the level UCP2 expression in both white adipose tissue and skeletal 
muscle (298). In humans, the expression level of UCP2 is up-regulated during fasting in 
skeletal muscle and white adipose tissue of lean and obese subjects and shows a positive 
correlation with the percentage of body fat (299-300). Evidence of uncoupling, lower 
mitochondrial potential, and increased mitochondrial volume has recently been observed 
in rat pancreatic islets cultured for 1-2 days with palmitate (301). Similarly, long-term 
exposure to free fatty acids increases UCP2 expression in hepatocytes (302). These data 
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strongly support a regulation of UCP2 expression by fatty acids and also indicate that 
UCP2 activity could be related to fatty acid oxidation. The regulatory effect of fatty acids 
on UCP transcription may be attributable to PPARs, which can be activated upon binding 
fatty acid ligands. A PPAR response element (PPRE) has been identified in the UCP 
promoter region (303-304). In rats or lean and db/db mice, in vivo PPARγ activation can 
induce expression of UCP-1, -2, and -3 in BAT (305), and chronic-intense PPARγ 
activation may cause BAT to assume white adipose tissue-like phenotype with increased 
UCP-2 levels (305). PPARα activation in mice is sufficient to induce liver UCP-2 
expression (306). Since PPARs are also involved in the regulation of adipocyte 
differentiation and lipid oxidation, it is possible that PPARs are the key regulators that 
coordinate the activation of lipid metabolism and thermogenetic activity of adipocytes. 
Furthermore, administration of pyretic compounds such as lipopolysaccharides to mice 
induced significant increases in UCP2 expression in liver, indicating a potential role of 
UCP2 in infection and inflammation, both which are also highly thermogenetic processes 
(307). 
However, several studies also show that UCP2 expression is up-regulated in obese 
animals and humans. A higher level of UCP2 expression has been found in skeletal 
muscle of obese versus lean individuals and UCP2 expression is positively correlated 
with percentage of body fat (308). In ob/ob and db/db mice, which are well characterized 
model of obesity associated with increased body weight and decreased energy 
expenditure, up-regulation of UCP2 expression has been observed (309-310), suggesting 
that enhanced UCP2 expression in obesity could be a compensatory response. In fact, 
UCP2 appears to function as a free fatty acid transporter and thereby increases fatty acid 
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utilization (311), as previously discussed. Indeed, impairment in the oxidation but not in 
the uptake of free fatty acids by muscle has been found in obesity. An increased content 
of UCP2, on the other hand, could function as a compensatory mechanism that could 
favor the outward translocation of fatty acids. The export of the fatty acid anion thus 
permits continued rapid fatty acid oxidation in the face of an oversupply. A similar 
hypothesis has been proposed for that UCP3, suggesting that it may function as a fatty 
acid anion exporter in muscle and brown adipose tissue when fatty acids are the 
predominant fuel substrates (312).  
Early studies indicate that lipogenesis is dependent on mitochondrial ATP 
production. Therefore, mitochondrial uncoupling in adipocytes may have an inhibitory 
effect on lipogenesis by stimulating energy dissipation and depressing ATP production. 
Rognstad and Katz et al investigated the effect of chemical mitochondrial uncoupler, 2, 
4-dinitripenol, on glucose metabolism in epididymal fat from rat (313). Addition of 2, 4-
dinitripenol resulted in depressed synthesis of fatty acids and increased lactate, indicating 
that inhibition of fatty acid synthesis probably resulted from limited availability of 
intramitochondrial ATP for the carboxylation of pyruvate. In addition, ATP/ADP ratio 
has been demonstrated to affect pyruvate carboxylase activity (312). In agreement with 
this hypothesis, overexpression of UCP2 in adipocyte and induction of UCP1 and UCP3 
in adipose tissue by pharmacological treatments results in reduction of lipid accumulation 
(314). Expression of UCP1 from the adipose specific promoter in aP2-UCP1 transgenic 
mice attenuates both genetic and diet-induced obesity (315). 
Lipolysis also depends on the energy status of adipocytes (316-317). Cold 
temperature and high-calorie diets stimulate the sympathetic nervous system, leading to 
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the release of noradrenaline. The noradrenaline bound to adipocyte β3-adrenaline 
receptors stimulates hormone sensitive lipase via phosphorylation by protein kinase A. 
The receptor is not desensitized by noradrenaline, and thus delivers a sustained signal via 
Gs-protein to stimulate adenylate cyclase (AC). The AC synthesizes cAMP (cyclic AMP) 
and activates protein kinase (318). Protein kinase A also phosphorylates CREB (cAMP 
responsive element-binding protein), the trans-element for transcription of the messenger 
RNA for UCP1, UCP2 and UCP3 (319). A decrease of intracellular ATP, elicited in 
white adipocytes in vitro by uncoupling inhibitors of the mitochondrial respiratory chain, 
counteracted the stimulation of lipolysis by catecholamines. Incubation of isolated 
adipocytes with lipolytic hormones resulted in an up to a decrease of their intracellular 
ATP level and inhibition of lipolysis itself (320). More recently, ATP was shown to be 
required for translocation of hormone sensitive lipase from cytoplasm to the surface of 
lipid storage droplets and for phosphorylation of HSL and other proteins that are involved 
in lipolysis in adipocytes (321-323). 
1.4.3.3 Role of UCPs in Regulation of Insulin Secretion  
ATP levels are also essential for insulin signaling (324-325). The signal is altered 
at the level of the interaction of insulin with its receptor, as well as downstream from 
receptor. Like other cells, pancreatic β cells metabolism of glucose yields ATP through 
oxidative phosphorylation, and the generation of ATP is tightly coupled to the 
metabolism of glucose. In pancreatic β cells, an increase in ATP/ADP ratio associated 
with increased glucose metabolism promotes insulin release. The proposed mechanism 
involves closure of the KATP channel in response to the increased ratio causing membrane 
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deplorization, Ca2+ influx and insulin secretion (326). Defects in oxidative 
phosphorylation would be expected to impair insulin release. Thus, UCP2 may be a 
negative regulator of insulin secretion, in view of its high expression in this cell type and 
its potential uncoupling action, as suggested by the decrease in glucose stimulated insulin 
secretion that follows its overexpression in isolated rat pancreatic islets (327). Consistent 
with this, mice lacking UCP2 had significantly lower glucose levels and higher insulin 
secretion rates under basal conditions and intravenous glucose administration (328). In 
contrast, in ob/ob mice, a model of type II diabetes, hyperinsulinemia, hyperglycemia, 
exhibits a significant up-regulation of UCP2 (325). When mice lacking UCP2 were 
crossed with ob/ob mice, the resulting reduction of UCP2 expression in the ob/ob animals 
was associated with a marked improvement in glucose tolerance (329). These results 
suggest that the level of UCP2 gene expression in the pancreatic beta cells is an important 
determinant of the sensitivity of insulin secretion to changes in glucose.  
1.4.3.4 Role of UCPs in Regulation of Intracellular Calcium  
[Ca2+]i is a ubiquitous intracellular messenger involved in many cellular processes 
(330-331). To generate such complex Ca2+ signals, cells rely on the rapid release of the 
Ca2+ from storage as well as on the controlled Ca2+ influx from the extracellular 
compartment. Ca2+ concentration is maintained at extremely low levels by expelling Ca2+ 
ions to the exterior and by compartmentalization of Ca2+ stores. Ca2+ accumulation and 
protection of cells against Ca2+ overload has been considered a role of mitochondria. 
When exposed to an elevated local cytosolic Ca2+, mitochondria will take up Ca2+ 
through an electrogenic uniporter, and this action is driven by the mitochondrial 
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membrane potential generated by oxidative phosphorylation. This process causes a 
depolarization of mitochondrial potential, providing a mechanism that serves to couple 
energy supply and demand to cell function. For instance, increased work by the myocyte 
is inextricably linked to an increase in [Ca2+]i, which in turn signals an increased ATP 
requirement to the mitochondria (332).  
Since mitochondria play a key role in regulation of [Ca2+]i homestatsis, alteration 
of mitochondrial function may influence [Ca2+]i level. Pharmocological agents have been 
useful in identifying mitochondrial contributions to depolarization-evoked [Ca2+]i 
responses in intact cells. Proton ionophores, such as DNP, depolarize the inner 
mitochondrial membrane and reduce the electrochemical driving force for calcium uptake, 
suppressing mitochondrial calcium accumulation (333). In isolated cardiac myocytes, 
metabolic inhibition, such as ischaemia, has generally been reported to induce an initial 
increase in cytosolic Ca2+ concentration, which appears to be associated with the 
depletion of intracellular ATP (334). Artificially suppression of ATP production using 
DNP induced a biophasic increases in [Ca2+]i, with the initial increase resulting from 
calcium release from mitochondria after deporlarization and the secondary increase 
representing calcium release from SR. Although mitochondria will take up an imposed 
calcium load, when the load is intense and prolonged, it may precipitate opening of a 
large conductance pathway through the mitochondrial inner membrane known as the 
permeability transition pore (PTP). This may be a catastrophic event for the cell, leading 
to leakage of mitochondrial contents into cytosol, and possibly culminating in cell death, 
either through mitochondrial uncoupling and ATP depletion or by release of apoptosis-
inducing factors (335).  
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[Ca2+]i appears to regulate oxidative phosphorylation and various reactions of 
oxidative phosphorylation are possible targets for calcium activation. Some intra-
mitochondrial Krebs cycle enzymes such as pyruvate dehydrogenase and isocitrate 
dehydrogenase are calcium-sensitive (336). Activation of these enzymes results in a 
substantial stimulation of the substrate oxidation subsystem. In addition, calcium may 
directly stimulate the respiratory chain and activation of calcium influx also result 
activation of ATP synthase and adenine nucleotide translocase. (337-338). Previous 
studies suggest that the increase in the cycling of calcium across the mitochondrial 
membrane will result in an increase in proton leak (339). However, this effect appears not 
to be mediated by direct up-regulation of UCP2 expression since increase in [Ca2+]i has 
no effect on UCP2 expression.  
1.4.3.5 Role of UCPs in Regulation of Reactive Oxygen Species  
Reactive oxygen species (ROS) have been implicated in the pathogenesis of a 
number of clinical conditions, including atherosclerosis and chronic complications of 
diabetes mellitus (340-341). Recent data also indicate that manipulation of mitochondrial 
UCPs may be of interest for controlling the level of ROS (342). Mitochondrial production 
of ROS is modulated by mitochondrial potential, which is itself controlled by the level of 
coupling of respiration to ADP phosphorylation. BPQ (benzo[a]pyrene-1,6-quinone), 
which is a mitochondrial redox cycling agent that increases mitochondrial ROS 
production, up-regulates UCP-2 mRNAs in primary cultures of normal rat hepatocytes. 
Moreover, mild uncoupling of oxidative phosphorylation decreases mitochondrial ROS 
production. Duval et al demonstrate that murine endothelial cells (CRL 2181) pretreated 
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by antisense oligonucleotides directed against UCP-2 mRNA exhibited a significant and 
specific increase in membrane potential and intracellular ROS level compared with 
control scrambled or anti-UCP-1 and -UCP-3 antisense oligonucleotides (343). In 
agreement with this, UCP-ablated mice show more resistance to infection by Toxoplasma 
gondii, an intracellular parasite that may infect the brains of normal animal and cause 
death (344). The tentative conclusion of this study is that the macrophages in the absent 
of UCP2 have a greater capacity to produce ROS. There is also evidence of a role for 
UCP1 and UCP3 in the protection of tissues against oxidative damage by decreasing in 
the mitochondrial production of ROS (345). The superoxides themselves have been 
demonstrated to produce proton leak in mitochondria (346). Since changes in oxidative 
metabolism in cells and tissues provoke marked changes in free radical synthesis, the 
UCPs could represent important mechanism of control and limitation of these ions which 
have deleterious effects on cellular machinery.  
TNFα may play a key role in regulation of ROS production. Tumor necrosis 
factor α (TNFα) inhibits mitochondrial electron transport chain activity, increasing the 
interaction of electrons with O2 to generate superoxide anion and other mitochondrial 
ROS (347). In contrast, uncoupling proteins are known to increase mitochondrial electron 
transport chain activity, limiting electron interactions with O2 and reducing O2 formation 
during mitochondrial respiration (348). Accordingly, increases in UCP-2 might help 
mitochondria in cells to compensate for the TNF-related inhibition of electron transport 
chain activity. Indeed, in obese mice, rats, and humans, increased serum TNFα has been 
demonstrated to correlate with adiposity UCP-2 mRNA levels increase in cardiac muscle, 
fat and liver (337-338). In addition, normal rats treated with lipopolysaccharide, a potent 
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inducer of TNFα, exhibited UCP2 expression increases and this effect is inhibited by 
neutralizing anti- TNFα antisera (346). However, this adaptive mechanism may come at a 
risk. By enhancing proton conductance across the inner mitochondrial membrane, UCP-2 
partially depolarizes this membrane and decreases the efficiency of ATP synthesis. 
Inefficient mitochondrial ATP synthesis could cause energy failure and cell death if ATP 
requirements increase abruptly (349). Thus, increased UCP-2 activity could transform a 
survival advantage into a cause of cell death. 
 
1.5 Regulation of Adipocyte Cellularity 
1.5.1. Regulation of Adipocyte Size  
1.5.1.1. Lipogenesis  
The plasticity of adipose tissue mass is a function of both adipocyte size and 
number (350). An increase in adipose tissue mass can occur by hypertrophic growth. This 
increase in size occurs primarily by lipid accumulation within the cell. Lipogenesis is 
very responsive to the changes in diet (351). A diet rich in carbohydrates stimulates 
lipogenesis in both liver and adipose tissue, leading to elevated postprandial plasma 
triglyceride levels (352). Fasting reduces lipogenesis in adipose tissue, which, combined 
with an increased rate of lipolysis, leads to net loss of triglycerides from fat cells. High 
fat diets, in contrast, decreases lipogenesis by suppressing lipogenic gene expression in 
liver and adipose tissue, including that of FAS and SCD (353). It has been proposed that 
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the dietary nutrient may be translated into changes in hormonal secretion and altered 
expression levels of lipogenic genes (354).  
Insulin is probably the most important hormonal factor influencing lipogenesis. 
By increasing the uptake of glucose in the adipose cell via recruitment of glucose 
transporters to the plasma membrane, as well as activating lipogenic and glycolytic 
enzymes via covalent modification, insulin potently stimulates lipogenesis (354). Insulin 
also has long-term effects on the expression of lipogenic genes, probably via the 
transcription factor sterol regulatory element binding protein-1 (SREBP-1) (355-357). In 
addition, insulin causes SREBP-1 to induce the expression and activity of glucokinase, 
thereby increasing the concentration of a glucose metabolite that supposedly mediates the 
effects of glucose on lipogenic gene expression (358). Another endocrine/autocrine factor 
connected with triglyceride synthesis is acylation stimulating protein (ASP) which is 
produced by adipose tissue and appears to acts via an autocrine loop (359). Numerous in 
vitro studies have shown that ASP stimulates triglyceride accumulation in adipose cells 
(360-362). This is achieved by an increase in triglyceride synthesis, as well as by a 
simultaneous decrease in adipose tissue lipolysis. Leptin is may also be involved in 
lipogenesis. There is a growing consensus that leptin limits fat storage not only by 
inhibiting food intake, but also by affecting specific metabolic pathways in adipose and 
other tissues (363).  
Evidence that has been gathered over the past few years indicates that the effects 
of various nutrients and hormones on the expression of lipogenic genes are mediated by 
the SREBPs (364). Studies in transgenic mice that overexpress SREBP-2 in the liver 
suggested that SREBP-2 stimulates the expression of genes involved in cholesterol 
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metabolism, such as the LDL receptor, farnesyl pyrophosphate synthase and HMG-CoA 
reductase genes (365). Interestingly, mice that overexpress SREBP-1a or SREBP-1c in 
liver exhibit a dramatic build-up of hepatic triglycerides and elevated expression levels of 
lipogenic genes. This led to the conclusion that SREBP-1 activates genes connected with 
lipogenesis in liver. SREBP-1 probably has a somewhat different role in adipose tissue. 
In white adipose tissue of these mice, expression of genes implicated in cholesterol 
metabolism were markedly elevated, whereas the expression of genes implicated in fatty 
acid and triglyceride synthesis remained unchanged (366).  
In vitro studies have clearly established the importance of the upstream 
stimulatory factors (USFs) in the regulation of the fatty acid synthase promoter by insulin 
(367). USFs are ubiquitous bHLH-leucine zipper transcription factors that are able to 
interact as homo- and/or heterodimers with E boxes of CANNTG sequence (368). Such 
an E box is present in the promoter of FAS (367). Mutations that weaken binding of 
USF1 and USF2 to this E box abolish the insulin-dependent activation of the FAS 
promoter (369). Recent studies with mice lacking USF1 and/or USF2 have provided 
compelling evidence that USF1 and USF2 are involved in mediating the stimulatory 
effect of insulin/glucose on fatty acid synthase expression (370). Finally, glucose may 
regulate expression of lipogenic genes via a carbohydrate response transcription factor 
(ChoRF), which has yet to be cloned. Specific response elements that bind this 
transcription factor have been identified in the promoter of target genes, such as pyruvate 
kinase (371).  
An important transcription factor in adipose tissue is the nuclear hormone 
receptor PPARγ (372). Despite its name, this protein is not endogenously activated by 
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peroxisome proliferators but by fatty acids and their eicosanoid derivatives, as well as by 
drugs of the thiazolidinedione class. PPARγ is a part of the adipocyte differentiation 
program. To date, only a limited number of genes are known to be regulated by PPARγ in 
adipose tissue. These encode the adipocyte fatty acid binding protein, lipoprotein lipase, 
fatty acid transport protein (FATP), acyl-CoA synthetase, phospho-enol pyruvate 
carboxykinase and the fasting-induced adipose factor FIAF/PPARγ angiopoietin related 
gene (PGAR) (373). Based on the identities of these genes, coupled with the observation 
that PPARγ expression is stimulated by insulin and by SREBP-1 (374-375), one would 
expect PPARγ to have not only an adipogenic effect, but also a lipogenic effect. This is 
supported by clinical data, showing that patients taking synthetic PPARγ activators 
frequently gain weight (376). Furthermore, heterozygous PPARγ mutant mice exhibit 
smaller fat stores on a high fat diet (377). 
Recent studies demonstrate that increased lipogenesis combined with reduced 
oxidation is associated with lipotoxicity (378). When lipids accumulate in nonadipose 
tissues during overnutrition, fatty acids enter deleterious pathways such as ceramide 
production, which, through increased nitric oxide formation, causes apoptosis of lipid-
laden cells, such as pancreatic β-cells and cardiomyocytes (389-382). Lipotoxicity of 
pancreatic β-cells, myocardium, and skeletal muscle leads to type 2 diabetes, 
cardiomyopathy, and insulin resistance respectively (381). 
1.5.1.2. Lipolysis  
Lipolysis is the chemical decomposition and release of fat from adipose tissue 
(382). This process predominates over lipogenesis when additional energy is required. 
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The triglycerides within the adipocyte are acted upon by a multi-enzyme complex called 
hormone sensitive lipase (HSL), which hydrolyzes the triglyceride into free fatty acids 
and glycerol (383). These lipases act consecutively on triglycerides, diglycerides, and 
monoglycerides. Once triglycerides are hydrolyzed to fatty acids and glycerol, fatty acids 
enter the common free fatty acid pool where they may be re-esterified, undergo beta-
oxidation, or be released into the circulation as substrates for skeletal muscle, cardiac 
muscle, and liver. HSL is expressed in both WAT and BAT, although more is known 
about its function in WAT.  
In WAT, hydrolysis of triacylglycerols occurs through three consecutive reactions 
and is catalyzed by two enzymes: HSL catalyses the hydrolysis of triacylglycerols (TGs) 
and diacylglycerols (DGs) and the participation of monoglyceride lipase is required to 
hydrolyse monoglycerides (384). Although HSL is generally considered as the rate-
limiting enzyme in lipolysis, this concept has recently been challenged. Disruption of the 
HSL gene has shown that the overall rate of lipolysis was unaffected, suggesting that 
there is another lipase with considerable activity towards TGs in WAT (385). However, 
HSL appears to be rate-limiting for DGs, as loss of HSL in mice results in accumulation 
of diglycerides (386). Paradoxically, in HSL-knockout mice, obesity is not a consequence. 
In fact, it was seen that WAT mass decreases in most parts of the body (387). Both de 
novo free fatty acid (FFA) synthesis and triacylglycerol synthesis were reduced in HSL-
knockout mice (388). In a separate experiment, HSL overexpression in mice resulted in a 
decreased rate of lipolysis (389). Clearly, no simple relationship exists between HSL and 
the WAT mass and the involvement of other molecules is essential to explain this part of 
WAT metabolism (390). HSL is also the intracellular lipase in brown adipose tissue (391). 
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Fatty acids mobilized from BAT through the action of HSL are used in non-shivering 
thermogenesis. It has been interesting to note that HSL has been shown to retain high 
enzyme activity at low temperatures, which is probably a critical property in hibernating 
animals. 
HSL activity is regulated by lipolytic (catecholamines, ACTH) and antilipolytic 
(insulin, adenosine) hormones (392). Catecholamines (such as adrenaline and 
noradrenaline) and ACTH (adrenocorticotrophic hormone), otherwise known as 
corticotrophin, active lipolysis whereas insulin is exerts an anti-lipolytic effect. 
Adrenaline, synthesized in the adrenal gland, binds to β-adrenergic receptors. This 
binding induces conformational changes in the septa-spanning receptor, resulting in 
activation of adenylate cyclase, which in turn, the hydrolysis of ATP to form cAMP 
Cyclic AMP has various targets, one of which is protein kinase A (PKA). The two main 
targets for PKA-mediated phosphorylation in the adipocyte are HSL and perilipins, which 
result in a large increase in lipolysis. Perilipins (predominant isoform in adipocytes is 
perilipin A) coat the surface of lipids, thereby interfering with the access of HSL to the 
triglyceride substrate. PKA-mediated perilipin phosphorlyation removes the perilipin 
from the lipid surface. Hormone-sensitive lipase, which is also phosphorylated by PKA, 
can then access the TG and hydrolyse it to glycerol and FFAs. It was once thought that 
Ser 563 is the regulatory site (phosphorlyation site) (393), although further study found 
that mutation of Ser 563 didn’t abolish PKA-induced of HSL (394). Other serines (565, 
659 and 660) have since been considered to be possible activation sites. To prevent the 
accumulation of FFAs having a negative feedback inhibitory effect on HSL, compounds 
such as adipocyte lipid binding protein (ALBP) is associated with HSL as part of a 
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“lipolytic complex” (395). ALBP sequesters FFAs and thereby increases the hydrolytic 
activity of HSL. 
Insulin, the most important inhibitor of catecholamine-induced lipolysis, induces 
phosphorlyation and activation of phosphodiesterase type 3B (PDE 3B), leading to a 
decrease in the cAMP levels and therefore a decrease in the PKA activity (396-397). The 
signaling pathway leading to PDE 3B activation involves the insulin receptor, insulin 
receptor substrates, phosphatidyl-3 kinase and probably protein kinase B as well. Specific 
inhibition of PDE 3B blocks the antilipolytic effect of insulin, indicating that cAMP 
degradation is the main mechanism by which insulin antagonizes catecholamine-induced 
lipolysis. The phosphorlyation of PDE 3B is associated with the phosphorlyation of Ser-
302 in rat adipocyte, catalyzed by an insulin-stimulated protein serine kinase (PDE3IK) 
(398). A molecule called lipotransin has been proposed to be involved in docking HSL to 
the lipid droplet surface and to play a role in the arrest of lipolysis by insulin (399).  
1.5.2. Regulation of Adipocyte Number  
1.5.2.1. Adipogenesis  
In mammals, WAT formation begins before birth (401). The chronology of WAT 
appearance, however, is strictly dependent on the species as well as the adipose depot. 
White adipose tissue expansion takes place rapidly after birth as a result of increased fat 
cell size as well as an increase in fat cell number (402). Even at the adult stage, the 
potential to generate new fat cells persists (403). It has been demonstrated that fat cell 
number can increase when rats are fed a high-carbohydrate or high-fat diet (404). An 
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increase in fat cell number is also observed in severe human obesity (405). Moreover, 
early differentiation markers of adipocyte differentiation can be detected even in adipose 
tissue derived from very old mice (406). Fat cell precursors isolated from adult WAT of 
various species, including humans, can be differentiated in vitro into mature adipocytes 
(407-408). Several studies on multipotent clonal cell lines have suggested that the 
adipocyte lineage derives from an embryonic stem cell precursor with the capacity to 
differentiate into the mesodermal cell types of adipocytes (409-410). That potential to 
acquire new fat cells from fat cell precursors throughout the life span is now undisputed. 
In vitro systems have been extensively used to study adipocyte differentiation, 
leading to a dissection of the molecular and cellular events taking place during the 
transition from undifferentiated fibroblast-like preadipocytes into mature round fat cells 
(411). The committed preadipocyte maintains the capacity for growth but has to withdraw 
from the cell cycle before conversion to adipose. In preadipose cell lines as well as in 
primary preadipocytes, growth arrest but not cell confluence or cell-cell contact appears 
to be required for adipocyte differentiation. After growth arrest at confluence, 
preadipocytes must receive an appropriate combination of mitogenic and adipogenic 
signals to continue through subsequent differentiation steps. Studies on preadipose cell 
lines have shown that growth-arrested cells undergo at least one round of DNA 
replication and cell doubling. This has been proposed to lead to the clonal amplification 
of committed cells. Growth arrest and clonal expansion accompanied by complex 
changes in the pattern of gene expression (401). 
Expression of lipoprotein lipase (LPL) mRNA has often been cited as an early 
sign of adipocyte differentiation (412). Lipoprotein lipase is secreted by mature 
 61
adipocytes and plays a central role in controlling lipid accumulation (413). At least two 
families of transcription factors, C/EBP and PPARγ, are induced early during adipocyte 
differentiation (415). PPARγ is largely adipocyte specific and is expressed at low but 
detectable levels in preadipocytes (373). Its expression rapidly increases after hormonal 
induction of differentiation. The subsequent decrease of C/EBP- β and C/EBP-δ in early 
to mid stages of differentiation is concomitant with the induction of C/EBP-α mRNA 
(416). This increase in C/EBP-α expression occurs slightly before the expression of 
adipocyte-specific genes. Another transcription factor induced very early during 
adipocyte differentiation is SREBP-1c/ ADD1 (adipocyte determination and 
differentiation factor 1), a bHLH-leucine zipper protein that is involved in cholesterol 
metabolism and may also participate in adipocyte gene expression (417). During the 
terminal phase of differentiation, adipocytes in culture markedly increase de novo 
lipogenesis and acquire sensitivity to insulin (418). The activity, protein, and mRNA 
levels for enzymes involved in triacylglycerol metabolism including ATP citrate lyase, 
malic enzyme, acetyl-CoA carboxylase, SCD1, glycerol-3-phosphate acyltransferase, 
glycerol-3-phosphate dehydrogenase, FAS, and glyceraldehyde-3-phosphate 
dehydrogenase increase (407). Glucose transporters, insulin receptor number, and insulin 
sensitivity increase (407). During adipocyte differentiation, there is a loss of  β1-
adrenergic receptors and an increase in the β2- and the β3-subtypes, resulting in an 
increase in total adrenergic receptor number. In addition to increases in mRNAs for 
proteins directly related to lipid metabolism, adipocytes also synthesize other adipose 
tissue-specific products. These include aP2, an adipocyte-specific fatty acid binding 
protein (419); FAT/CD36, a putative fatty acid transporter (420); and perilipin, a lipid 
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droplet-associated protein (421). In addition, adipocytes produce a number of secreted 
products, including monobutyrin, an angiogenic agent; adipsin, a homolog of the serine 
protease complement factor D; Acrp30/AdipoQ; PAI-1; angiotensinogen II; and leptin 
(422-423).  
In mammals, adipose tissue is a multi-depot organ made of two tissue types, the 
white and brown adipose tissues, which collaborate in partitioning the energy contained 
in lipids between thermogenesis and the other metabolic functions (424). Recent data 
have stressed the plasticity of the adipose organ in adult animals (349). Indeed, under 
peculiar conditions fully differentiated, white adipocytes can transdifferentiate into brown 
adipocytes, and vice versa (425-426). The ability of the adipose organ to interconvert its 
main cytotypes in order to meet changing metabolic needs may be pertinent to the 
physiopathology of obesity and related to therapeutic strategies. 
The adipose tissue expansion that occurs during the development of obesity is 
initially characterized by fat cell hypertrophy (427-428). However, adipocytes do not 
have an unlimited capacity for expansion, and increases in fat cell number do occur. The 
development of hyperplastic adipose tissue noted in both genetic and diet-induced obesity 
is associated with the most severe forms of obesity and has the poorest prognosis for 
treatment (428-429). Understanding the mechanisms that regulate the growth of adipose 
tissue may enhance efforts to develop successful prevention and treatment strategies to 
limit accumulation of excess body fat. Chumlea et al estimated adipocyte number and 
adipocyte size in nonobese adults 20 to 50 yr of age (430). Women had greater 
percentage body fat and larger adipocytes than men in every age group except the oldest 
(45-50 yr). Adipocyte number, total body fat, and percentage body fat are each positively 
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correlated with age in both sexes. Adipocyte size is not correlated with age but is 
positively correlated with total and percent body fat in men and women irrespective of 
age. These cross-sectional data suggest that adipocyte number, rather than being stable 
during adulthood, increases with age and is associated with corresponding increases in 
total and percentage body fat. Noppa et al. demonstrated a significant relation between 
body build in childhood and prevalence and degree of obesity in adulthood in women 
(431). In addition, there was a significant relationship between the degree of obesity and 
total fat cell number when age of onset was kept constant, but not between age of onset 
and total fat cell number when degree of obesity was kept constant indicating that 
adipocyte number is attributable to obesity. Animal studies also confirmed that adipocyte 
hyperplasia is associated with obesity. Obst et al. assessed fat depot cellularity and cell 
number and lipid per cell for three fat depots in overfed dietary obesity resistant S 5B/Pl 
(S) and susceptible Osborne-Mendel (OM) rats (432). They found that both the size and 
the number of adipocytes was associated with overfeeding-induced obesity. However, 
other studies have the opposite observation. One study demonstrated that, when put obese 
woman underwent controlled 1000 kcal diets for 6-month, weight gaining patients 
showed a significantly higher mean fat cell number than while weight losing patients had 
a higher mean adipose cell weight than the weight gaining and weight stable patients 
(433).  
The processes involved in adipocyte hypertrophy are relatively well understood, 
but much less is known about adipocyte hyperplasia. The mature adipocyte has little 
capacity for cell division and the hyperplastic capacity of adipose tissue resides in a 
population of fibroblast-like adipocyte precursor cells (434). The origin of these cells and 
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the processes involved in their commitment to the adipocyte lineage is not known. 
Growth factors, in particular the bone morphogenetic proteins (BMP), are likely to be 
involved in regulating commitment to the adipocyte lineage. In vitro studies have shown 
that once committed to the adipocyte lineage, the proliferation and differentiation of 
adipocyte precursor cells is regulated by a number of different growth factors (435-436). 
A number of these growth factors are expressed in adipocyte precursor cells in vitro and 
may have an autocrine-paracrine role (437). Others, such as epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) are 
more likely to have an endocrine role (438). The precise role that each growth factor 
plays in regulating adipocyte development in vivo is poorly understood. It is likely that 
adipocyte hyperplasia occurs in a localized fashion; adipocytes are not randomly 
distributed in mammals but are organized in identifiable depots. In addition, adipose 
tissue growth appears to occur within these depots through local recruitment of 
pluripotent precursors rather than through generation of new loci. 
The hypothesis that a critical fat cell size precedes adipocyte hyperplasia is not a 
new one. Increases in mean fat cell size have been noted in mice and several strains of 
rats fed high-fat diets. Studies of adipose tissue cellularity in the genetically obese Zucker 
rat also indicated that hypertrophy develops before hyperplasia (428,439). Based on these 
observations, Faust proposed that attainment of a critical fat cell size initiated the events 
that lead to proliferation of adipocytes (440). A more recent study conducted by Brenda 
et al demonstrated that proliferative activity of conditioned medium obtained from all 
depots in obese Zucker rats was positively correlated to subsequent changes in fat cell 
number, indicating that enlarged adipocytes secrete growth factors that induce 
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preadipocyte proliferation (441). Considine et al report that mature adipocytes from both 
lean and obese subjects release a factor that stimulates the growth of preadipocyte-
enriched and dedifferentiated adipocyte-enriched cell cultures (442). They demonstrate 
that mature adipocytes from obese patients stimulate the growth of preadipocyte-enriched 
cultures to a greater extent than those from lean individuals. There is now a 
preponderance of evidence that adipose tissue is a source of growth factors such as IGF-I, 
IGF binding proteins (443), TNFα (444), angiotensin II (445), and macrophage colony-
stimulating factor (MCSF) (446) that are capable of stimulating proliferation. The relative 
importance of these autocrine/paracrine factors in the normal control of preadipocyte 
proliferation is unknown. In addition, the proliferative response of preadipocytes to the 
paracrine milieu is undoubtedly modulated by neural inputs to fat tissue and/or serum 
factors (447). Together, these multiple regulatory controls orchestrate overall and region-
specific adipose tissue cellularity responses associated with the development of 
hyperplastic obesity. 
1.5.2.2. Adipocyte Depletion  
Large increases in fat stores involve an increase in adipocyte number via the 
replication and differentiation of preadipocytes, with the resultant cell gain widely 
regarded as irreversible. A reduction in fat tissue mass generally involves the loss of 
stored lipids by lipolytic processes (448). However, there is now growing evidence that 
decreases in adipose tissue mass in humans may also result from a loss of fat cells 
through programmed cell death, especially in condition when large amounts of fat are lost 
(449). In cultured adipocytes, apoptosis may be induced by serum deprivation or 
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exposure to TNF-α and HIV protease inhibitors (450-453). Studies in rodents 
demonstrate that induced weight and fat loss such as starvation, dietary conjugated 
linoleic acid (CLA), injection of neuropeptide Y-Y5 receptor antisense oligo or 
intracerebroventricular administration of leptin results in apoptosis of fat cells (454-459). 
Prins et al reported that human adipocytes undergo apoptosis following growth factor 
deprivation or mild heat injury in vitro, thus suggesting a cellular mechanism by which 
normal adipocyte loss could occur in vivo (460). Fat cell apoptosis was demonstrated in 
patients with tumor cachexia (461) and in HIV-patients during treatment with protease 
inhibitors (462). Patients with acquired forms of lipodystrophy (Lawrence Syndrome, 
Barraquer-Simons Syndrome) show an immunologically mediated loss of fat cells 
probably by apoptosis (463). 
Up to now, general mechanisms for apoptosis induction in human adipocytes have 
not been intensively investigated. Little is known about either the physiologic regulators 
of cell death or the apoptotic sensitivity of preadipocytes versus adipocytes. Using the 
well-established immortalized murine 3T3-L1 cell line model of adipogenesis, Papineau 
et al reported that as adipogenesis ensues, these cells acquire resistance to apoptosis 
induced by growth factor deprivation (464). Expression of 2 cell survival genes, neuronal 
apoptosis inhibitor protein (NAIP) and Bcl-2, increased, consistent with the 
differentiation-dependent effect on survival (465). Others have confirmed the apoptotic 
sensitivity of 3T3-L1 preadipocytes (466-468). Although 3T3-L1 preadipocytes are a 
valuable experimental model, they do have distinctive attributes compared with human 
preadipocytes in primary culture, beyond the obvious species difference. 3T3-L1 
preadipocytes are aneuploid, as well as embryonal in origin, and such features could 
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influence cell survival pathways. Death receptors (CD95, TRAIL-R1 and R2, and TNFR1) 
are expressed in human fat cells and that apoptosis can be induced by specific ligands 
(469). In addition, inhibition of the auto-/ paracrine actions of IGF-1 dramatically 
sensitizes human adipocytes for death-ligand induced apoptosis. Qian et al demonstrated 
that injection of leptin could dramatically up-regulate the expression of PPARγ but 
decrease TNFα in young rat (470). Lower TNFα levels were probably a secondary effect 
of reduced fat mass and increased PPARγ maybe attributable to leptin induced apoptosis, 
as PPARγ is associated with apoptosis in cancer cells and in white adipose tissue from 
rodents treated with thiazolidinediones (471-472). Since PPARγ is a powerful promoter 
of preadipocyte differentiation, the minor change of the WAT weight may be the 
combined results of increased adipocyte recruitment and adipocyte apoptosis. 
Supplementing mature adipocytes in culture with leptin induced expression of 
angiopoietin-2(Ang-2), which antagonizes angiogenesis, and caused apoptosis of adipose 
tissue endothelial cells (473). The apoptotic process also is modulated by energy states. 
Mitochondrial dysfunction causes ATP depletion, ion dysregulation, mitochondrial and 
cellular swelling, activation of degradative enzymes, plasma membrane failure, and cell 
death (474). Augmentation of cellular ATP by manipulation of the glucose content in the 
cultures led to an increase in survival from death signaling. In vitro experiments indicated 
the dependence of both lipogenesis and lipolysis on ATP levels in adipocytes (475). Thus, 
respiratory uncoupling in adipocytes that results in stimulation of energy dissipation and 
depression of ATP synthesis may contribute to the control of lipid metabolism, adiposity, 
and insulin sensitivity. This notion is supported by the observation that the expression of 
UCPs in adipocytes as well as some protonophoric anion transporters reduce adiposity 
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(476-477). Consistent with this, recent studies demonstrated a negative correlation 
between expression of UCPs in adipocytes and accumulation of white fat (478). These 
data suggested that energy status may also play a role in regulation of adiposity via 
apoptosis. 
Based on the preceding literature review, the research described in this 
dissertation was designed to a) determine the role of dietary calcium and dairy on 
adipocyte metabolism and energy modulation during energy restriction and energy 
repletion; b) determine the role of mitochondrial uncoupling on adipocyte lipid 
metabolism; c) determine the role and mechanism of dietary calcium and 1, 25 (OH)2-D3 
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Interactive Effects of Calcium-Fortified Breakfast Cereal and of Milk 




We previously demonstrated a regulatory role for intracellular Ca2+([Ca2+]i) in 
adipocyte metabolism. Recently, we reported that increasing dietary calcium, by 
suppressing calcitriol-mediated increases in [Ca2+]i  attenuates adipocyte lipid accretion 
and weight gain during over-consumption and accelerates fat loss during energy 
restriction.  Notably, dairy sources of calcium exert consistently greater effects.  The 
present study was conducted to extend these observations by determining the efficacy of 
a calcium-fortified cereal, alone or with a small amount of milk, in attenuation of weight 
and fat gain in the aP2-agouti transgenic mouse.  Male mice placed on a basal low 
calcium (0.4%)/high fat (25 energy %)/high sucrose diet for six weeks exhibited ~2-fold 
increases in [Ca2+]i and both visceral and subcutaneous fat mass.  However, addition of a 
calcium-fortified breakfast cereal sufficient to increase dietary calcium to 1.2% with 
macronutrient adjustments to ensure identical carbohydrate, protein and fat levels with 
the basal diet resulted in a 41% decrease in adipocyte [Ca2+]i (p<0.001) and 25- 30% 
decreases in weight gain (p<0.03) and total fat pad mass compared to the basal diet 
(p<0.001), while food consumption was unaffected.  Interestingly, addition of sufficient 
non-fat dried milk to bring the calcium content of the Ca-fortified cereal diet to from 1.2 
to 1.3% (with macronutrient adjustment) resulted in substantially greater reductions in 
adipocyte [Ca2+]i (63%, p<0.001), weight gain (45%, p<0.002) and fat pad mass (39%, 
p<0.0001).  In a follow-up study, both the calcium-fortified cereal and cereal plus milk 
diets significantly accelerated weight and fat loss secondary to a fixed level of energy 
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restriction, with the cereal plus milk diet exerting markedly greater effects.  Thus, a 
calcium-fortified breakfast cereal is effective in reducing adiposity in this model of 
obesity, while addition of a small amount of milk significantly amplifies this effect.  
 
2.2 Introduction 
A substantial body of evidence has emerged over the last three years in support of 
an “anti-obesity” effect of dietary calcium and calcium-rich foods (1-3).  Increasing 
dietary calcium in the absence of caloric restriction appears to result in a re-partitioning 
of dietary energy from adipose tissue to lean body mass, resulting in a net reduction in fat 
mass in both mice and humans (1-2), while increasing dietary calcium intake during 
energy restriction results in a marked augmentation of body weight and fat loss in both 
mice and humans (1).  These observations are supported by epidemiological observations 
from NHANES III (2), the Quebec Family Study (4) and the CARDIA study (5).  Data 
from NHANES III demonstrate an 84% reduction in the probability of being in the 
highest quartile of body fat in those in the highest quartile versus those in the lowest 
quartile of calcium and dairy intake (2).  Similarly, data from the CARDIA study 
demonstrate a significant inverse relationship between dairy consumption and each of the 
components of the Insulin Resistance Syndrome (IRS), including obesity, during a 10-
year follow-up of young adults who were overweight (body mass index > 25 kg/m2) at 
baseline, with the odds of developing IRS 72% lower among overweight individuals in 
the highest (>35 times per week) versus the lowest (<10 times per week) category of 
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dairy consumption; the cumulative incidence of obesity was reduced from 64.8% in the 
lowest dairy consuming group to 45.1% in the highest dairy consuming group 
(p<0.001)(5). 
Interestingly, the source of dietary calcium has a substantial impact on the 
magnitude of calcium’s effect on adiposity, with dairy sources of calcium producing 50-
70% greater effects on fat loss during energy restriction in both mice and humans.  
Consistent with this observation, analysis of NHANES III demonstrates a significantly 
stronger inverse relationship between dietary calcium and adiposity when the number of 
dairy servings is included in addition to the level of calcium consumption (2). Moreover, 
the inverse relationship between dietary calcium and IRS in the CARDIA study was 
explained solely by dairy intake, whereas the inverse association between dairy 
consumption and IRS was not altered by adjustment for calcium, indicating an effect of 
dairy consumption independent of calcium intake (5). 
A compelling mechanism for the anti-obesity effect of dietary calcium was 
provided by studies of the mechanism of action of the agouti gene in regulating murine 
and human adipocyte metabolism (6-11). These studies demonstrated a key role for 
intracellular Ca2+ in the regulation of adipocyte metabolism, resulting in modulation of 
adipocyte triglyceride stores (7-10).  Since intracellular Ca2+ can clearly be regulated by 
calcitrophic hormones, including 1,25-(OH)2-D3 and parathyroid hormone, suppression 
of these hormones by increasing dietary calcium may facilitate re-partitioning of dietary 
energy from adipose tissue to lean body mass and thermogenesis.  In support of this 
concept, we have demonstrated that human adipocytes possess membrane (non-genomic) 
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vitamin D receptors which transduce a rapid intracellular Ca2+ response to 1,25-(OH)2-D3 
(12); consequently, 1,25-(OH)2-D3 treatment of human adipocytes results in coordinated 
activation of fatty acid synthase expression and activity and suppression of lipolysis,  
leading to an expansion of adipocyte lipid storage (2).  Moreover, 1,25-(OH)2-D3 acts via 
the adipocyte nuclear vitamin D receptor to inhibit the expression of uncoupling protein 2 
(UCP2) (13), while suppression of 1,25-(OH)2-D3 levels by feeding high calcium diets to 
mice results in increased adipose tissue UCP2 expression and increased thermogenesis 
(14), suggesting that high calcium diets may also affect energy partitioning by 
suppressing 1,25-(OH)2-D3-mediated inhibition of adipocyte UCP2 expression. 
Although the foregoing mechanism provides a plausible explanation for an anti-
obesity effect of dietary calcium, there is as of yet no compelling mechanism to explain 
the differential effects between dairy and non-dairy sources of calcium.  Accordingly, the 
present study was conducted to further explore the interaction between dairy and non-
dairy sources of calcium in modulating adiposity in a previous established transgenic 
mouse model of diet-induced obesity. 
 
2.3 Materials and Methods 
2.3.1 Animals and Diets 
We utilized transgenic mice which express agouti specifically in adipose tissue 
under the control of the aP2 promoter (15), similar to the human pattern of agouti 
signaling protein (ASIP) expression. These mice are not obese when fed standard rodent 
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chow, but develop mild to moderate obesity when fed high sucrose and/or high fat diets 
(16). 
Phase I 
40 Six-week-old male aP2-agouti transgenic mice from our colony were 
randomized to four groups, as follows. The basal group were placed on a modified AIN 
93-G diet with suboptimal calcium (0.4%), sucrose as the sole carbohydrate source, and 
fat increased to 25% of energy with lard; a Ca-fortified cereal diet group, using both 
sucrose and fortified cereal as carbohydrate sources, increased dietary calcium three-fold 
to 1.2%, with macronutrient adjustments to ensure identical carbohydrate, protein and fat 
levels with the basal diet; a Ca-fortified cereal plus non-fat milk diet group, in which 25% 
of the protein was replaced by skim fat dry milk and dietary calcium was increased to 
1.3%; a cereal control group utilized the same amount of a non-calcium fortified cereal as 
used in the Ca-fortified cereal group with macronutrients adjusted. Food intake and 
spillage were measured daily while body weight, core temperature and blood glucose 
were measured weekly. At the conclusion of the 6 wk feeding period, animals were killed 
by exsanguination under pentobarbitol (65mg/kg body weight) anesthesia, and blood was 
collected via cardiac puncture for glucose and insulin measurements. Fat pads 
(epididymal, perirenal, abdominal, and subscapular) and liver were dissected immediately, 
weighed, frozen in liquid nitrogen and stored at -80°C for later analysis. [Ca2+]i was 
measured immediately in abdominal adipocytes obtained as described below. Fatty acid 
synthase activity and mRNA levels were measured in abdominal fat, and lipolysis was 
measured in freshly obtained perirenal fat as described below.  
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Phase II 
This study was divided into two 6-week stages. In the first 6-week stage, 50 Six-week-old 
aP2-agouti transgenic mice were place on the basal diet described above to induce 
obesity. At the end of this stage, five representative mice were killed for measurement of 
fat pad mass, adipocyte [Ca2+]i, fatty acid synthase activity and mRNA levels, and 
lipolysis in abdominal fat. The remaining 45 diet-induced obese transgenic mice were 
assigned to five groups as follows. One group was continued ad lib on the same low-
calcium (0.4%) basal diet with no modification, while the other four groups received the 
four diets used in phase I (basal, Ca-fortified cereal, Ca-fortified cereal plus milk, cereal 
control) at 70% of the energy level of the ad lib four groups using a pair-feeding protocol. 
Diets were administered daily, and body weight, core temperature and blood glucose was 
monitored every 5 days. At the end of second stage, all mice were killed by 
exsanguinations under pentobarbitol anesthesia (65mg/kg body weight). Blood obtained 
via cardiac puncture was used for insulin and glucose measurements. Fat pads were 
collected for intracellular Ca2+, fatty acid synthase activity and mRNA levels, lipolysis as 
indicated for phase I. 
2.3.2 Core Temperature 
Core temperature was used as an indirect metabolic index to determine the effect 
of dietary calcium on thermogenesis. Temperature was measured via a thermocouple 
(Columbus Instruments, Columbus, Ohio) weekly. The probe was inserted a constant 
distance (1.8 cm) into the rectum of each mouse. After stabilization (10 s), the 
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temperature was recorded every 5 s for 30 s. All core temperature measurements were 
performed between 8:00 and 9:00 A.M. 
2.3.3 Adipocyte Intracellular Ca 2+ ([Ca 2+]i) Measurement 
Adipose tissue was first washed several times with Hank’s Balanced Salt Solution 
(HBBS), minced into small pieces, and digested with 0.8 mg/ml type I collagenase in a 
shaking water bath at 37o C for 30 min. Adipocytes were then filtered through sterile 500-
µm nylon mesh and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 1% fetal bovine serum (FBS). Cells were cultured in suspension and 
maintained in a thin layer at the top of culture media for 2 h for cell recovery. [Ca2+]i in 
isolated mouse adipocytes was measured by using a fura-2 dual wavelength fluorescence 
imaging system Prior to [Ca2+]i measurement, adipocytes were pre-incubated in serum-
free medium for 2 h and rinsed with HBSS containing the following components (in 
mmol/L): NaCl 138, CaCl2 1.8, MgSO4 0.8, NaH2PO4 0.9, NaHCO3 4, glucose 5, 
glutamine 6, Hepes 20, and bovine serum albumin 1%. Adipocytes were loaded with 
fura-2 acetoxymethyl ester (AM) (10μmol/L) in the same buffer in dark for 1 h at 37o C. 
Adipocytes were rinsed with HBSS three times To remove extracellular dye and then 
post-incubated at room temperature for an additional 30 min to permit complete 
hydrolysis of cytoplasmic fura-2 AM. A thin layer of adipocytes was plated in 35 mm 
dishes with glass coverslips (P35G-0-14-C, MatTek Corporation, Ashland, Mass.). The 
dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F fluorescence 
inverted microscope with a Cohu 4915 CCD camera. Fluorescent images were captured 
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alternatively at excitation wavelength of 340 and 380 nM with an emission wavelength of 
520 nM. [Ca2+]i was calculated by using a ratio equation. 
2.3.4 Fatty Acid Synthase (FAS) Activity Assay 
FAS activity was determined spectrophotometrically in crude cytosolic extracts of 
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L 
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L 
dithiothreitol (DTT), and 100μmol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). 
The homogenate was centrifuged at 18,500 X g for 1 h, and the infranatant was used for 
measuring oxidation rate of NADPH. The final FAS activity was normalized to DNA, 
which was measured by CyQUANT cell proliferation assay kit according to 
manufacturer’s instruction (Parkard instrument Company, Inc., Downers Grove, IL).  
2.3.5 Lipolysis Assay 
Perirenal adipose tissue was immediately dissected and incubated for 4h. Glycerol 
released into the culture medium was used to measure lipolysis, as described previously 
(17). Glycerol was measured using a one-step enzymatic fluorametric method (18). The 
final lipolysis was normalized by DNA, as described above.  
2.3.6 Northern Blot Analysis 
Total RNA from mouse abdominal adipose tissue was extracted by using CsCl2 
density centrifugation, run in 1% agarose gel, and transferred to nylon membrane (New 
England Nuclear, Boston, Mass.). The membrane was hybridized with FAS and β-actin 
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(as a loading control) cDNA probes that were radiolabeled by using a random primer 
method. Unbound probe was removed by rinsing the membrane with 2X SSC / 0.1% SDS 
for 30 min at room temperature and 0.1X SSC / 0.1% SDS for 45 min at 55 0C. Finally, 
the membrane was exposed to X-ray film (New England Nuclear) at –80 0C. 
Autoradiographs were quantitated densitometrically, and all blots were stripped and 
reprobed with ß-actin as a loading control. 
2.3.7 Statistical Analysis 
All data are presented expressed as mean + SE. Data were evaluated for statistical 
significance by one- way analysis of variance (ANOVA), and significantly different 
group means were then separated by the least significant difference (LSD) test by using 
SPSS (SPSS Inc, Chicago, IL).  
 
2.4 Results 
 We first investigated the effect of high calcium diet on attenuation of weight gain. 
There were no significant differences in food intake among the ad libitum-fed groups. 
Nonetheless, weight gain was reduced by 20% and 37% in the animals fed the Ca-
fortified cereal and fortified cereal plus milk diets, respectively, when compared to those 
fed the basal low calcium diet (P<0.015) (Figure 2-1). Consistent with this, fat pad mass 
was reduced by 24% and 41% by the calcium-fortified cereal and cereal plus milk diets, 
respectively (P<0.01) (Figure 2-2). Figure 2-3 demonstrates that the high calcium diet 
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Figure 2-1. Effects of high calcium diets on weight gain in aP2-agouti transgenic 
mice. Diet and animal administration was conducted as described in Materials and 
Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars 
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Figure 2-2. Effects of high calcium diets on fat pad weight (sum of four fat fads) in 
aP2-agouti transgenic mice. Diet and animal administration was conducted as described 
in Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters 
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Figure 2-3. Effects of high calcium diets on adipocyte [Ca2+]i in aP2-agouti 
transgenic mice. Diet and animal administration was conducted as described in Materials 
and Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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63% induced by the calcium-fortified cereal and cereal plus milk diets, respectively 
(p<0.001).  
To study the effect of the high calcium diets on acceleration of weight loss, aP2-
agouti mice were first placed on the ad lib basal low calcium / high fat / high sucrose diet 
to induce mild to moderate obesity and then randomized to the same dietary treatments 
used in Phase I, with energy restricted to 70% of an additional group maintained on the 
basal diet ad libitum using a pair-feeding protocol. Energy restriction on the low calcium 
diet resulted in a 6% body weight loss. However, greater weight reductions of 14% and 
19% were observed in the Ca-fortified cereal group and fortified cereal plus milk groups, 
respectively (p<0.05) (Figure 2-4). A similar pattern was noted for fat loss during energy 
restriction, with a 21% decrease in fat pad mass on the low calcium diet, versus a 43% 
decrease on the Ca fortified cereal diet and a 64% decrease on the fortified cereal plus 
milk diet (p<0.01) (Figure 2-5).  
Figure 2-6 shows that Ca-fortified cereal diet and fortified cereal plus non-fat 
milk diet caused 28% and 47% decreases, respectively, in FAS activity (p<0.05 vs. basal 
energy-restricted group). Similarly, the two high calcium diets caused corresponding 
decreases in adipocyte FAS mRNA, with 67% and 84% decreases on the Ca-fortified 
cereal diet and fortified cereal plus non-fat milk diet, respectively (Figure 2-7). 
Increasing dietary calcium on the energy-restricted diets caused a corresponding increase 
in lipolysis. The basal energy-restricted diet increased basal lipolysis by only 5% (NS) 
while the Ca-fortified cereal and fortified cereal plus non-fat dry milk diet stimulated 
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Figure 2-4. High calcium diets accelerate body weight loss in energy restricted aP2-
agouti transgenic mice. Diet and animal administration was conducted as described in 
Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters above 
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Figure 2-5. Effects of high calcium diets on fat pad mass (sum of four fat fads) in 
energy restricted aP2-agouti transgenic mice. Diet and animal administration was 
conducted as described in Materials and Methods. Data are expressed as mean ± SE (n 
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Figure 2-6. Effects of high calcium diets on fatty acid synthase activity in energy 
restricted aP2-agouti transgenic mice. Diet and animal administration was conducted 
as described in Materials and Methods. Data are expressed as mean ± SE (n =8). 











Figure 2-7. Effects of high calcium diets on fatty acid synthase mRNA in energy 
restricted aP2-agouti transgenic mice. Data are expressed as fatty acid synthase (FAS): 
actin ratio. Diet and animal administration was conducted as described in Materials and 
Methods. Data are expressed as mean ± SE (n =8). Different letters above the bars 












Figure 2-8. Effects of high calcium diets on basal lipolysis in energy restricted aP2-
agouti transgenic mice. Glycerol release was used to measure lipolysis, as described in 
Material and Methods. Diet and animal administration was conducted as described in 
Materialsand Methods. Data are expressed as mean ± SE (n =8). Different letters above 
the bars indicate a significant difference at level of p<0.05. 
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This apparent shift in the efficiency of energy utilization was reflected in the 
effects of the dietary treatments on core temperature. As expected, energy restriction 
significantly reduced core temperature (Figure 2-9).  However, the Ca-fortified cereal 
diet and fortified cereal plus milk diets caused significant increases in core temperature 




Consistent with our previous reports, administration of basal low calcium diet 
caused a significant increase in body weight, fat pad mass and basal adipocyte [Ca2+]i in 
aP2-agouti transgenic mice. In contrast, high-calcium diets caused a significant reduction 
in body weight, fat-pad mass, and basal adipocyte [Ca2+]i in energy-restricted aP2 mice. 
Further, administration of high-calcium diets suppressed lipogenesis and stimulated 
lipolysis and thermogenesis in energy-restricted aP2 mice. Notably, inclusion of non-fat 
dry milk in the diet markedly amplified the effect. 
We have previously shown that agouti stimulates Ca2+ influx (7, 19) and promotes 
energy storage in human adipocytes by coordinately stimulating the expression and 
activity of fatty acid synthase, a key enzyme in de novo lipogenesis and inhibiting 
lipolysis in a Ca2+-dependent fashion (7, 8, 20). Thus, adipocyte [Ca2+]i modulates energy 
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Figure 2-9. Effects of high calcium diets on core temperature in energy restricted 
aP2-agouti transgenic mice.Diet and animal administration was conducted as described 
in Materials and Methods. Data are expressed as mean ± SE (n =8). Different letters 
above the bars indicate a significant difference at level of p<0.05. 
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We have recently demonstrated that 1,25-dihydroxyvitamin D3 (1,25-(OH)2-D3) 
exerts a rapid action on human adipocytes to cause a sustained increase in [Ca2+]i and a 
corresponding marked inhibition of lipolysis and stimulation of fatty acid synthase 
expression as well as activity (1, 2, 12). Further, increased circulating level of 1, 25-
(OH)2-D3 was found in obese humans(21-25). In present study, we sought to decrease 
[Ca2+]i by utilizing an increase in dietary calcium to suppress 1, 25-(OH)2-D3 level. This 
approach has previously been demonstrated to suppress 1, 25-(OH)2-D3 levels in multiple 
studies (26-28). Accordingly, we proposed that dietary calcium suppression of 1, 25-
(OH)2-D3 would reduce adipocyte [Ca2+]i and thereby inhibit triglyceride accumulation. 
Increasing dietary calcium resulted in increased adipocyte lipolysis and suppression of 
lipogenesis, similar to our previous observations (1-3). Moreover, these data extend our 
previous observations by demonstrating that dietary calcium not only attenuates diet-
induced obesity but also accelerates weight loss and fat mass reduction secondary to 
caloric restriction in established obesity.  
It is noteworthy that dairy and elemental calcium exerted qualitatively comparable 
effects; however, quantitatively, the effects were significantly different. Calcium in the 
form of dairy exerted a markedly greater effect on lipid metabolism and corresponding 
body-weight/adipose tissue mass reduction compared with a like quantity of elemental 
calcium. The effects of the high calcium cereal were similar to those described previously 
for calcium carbonate, producing significant attenuation of diet-induced obesity and 
accelerating body weight and fat loss during caloric restriction (1). However, the increase 
in dietary calcium from 1.2% to 1.3% by adding small amount of non-fat dry milk 
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doubled the rate of fat loss. Similar results were reported from utilization of yogurt as a 
calcium source to increase dietary calcium from 0.4% to 1.2% (29).  
Thus, it is clear that dairy contains additional factors which augment the anti-
obesity effect of calcium. This is consistent with the recent report from the CARDIA 
study, in which the inverse relationship between dairy consumption and each of the 
components of the insulin resistance syndrome, including obesity, was explained solely 
by dairy intake, and was not altered by adjustment fro calcium, indicating an effect of 
dairy consumption independent of calcium intake (5). 
Although the anti-obesity effect of dairy is clearly attributable to other factor(s) in 
addition to calcium, the identity of these factors is not yet clear. Although conjugated 
linoleic acid (CLA) has been demonstrated to attenuate adiposity (30-33), these effects 
are primarily attributable to the trans-10, cis-12 isomer of CLA, while the predominant 
isomer present in dairy is cis-9, trans-11 (30). Moreover, since non-fat dry milk was the 
source of dairy used in present study, as well as in our previous studies (1,2), no 
appreciable CLA could have been present in this fat-free product. 
Alternatively, it is possible that one or more of the compounds in whey may 
contribute to the observed anti-obesity effect. Indeed, whey is a rich source of bioactive 
compounds (34) which may act independently or synergistically with calcium to 
attenuate lipogenesis, accelerate lipolysis and /or affect nutrient partitioning between 
adipose tissue and skeletal muscle. Notably, milk proteins have been reported to contain 
significant angiotensin converting enzyme (ACE) activity (35, 36). Furthermore, recent 
data demonstrated that adipocytes have an autocrine/paracrine rennin-angiotensin system 
and that adipocyte lipogenesis is regulated partially by angiotensin II (37). Indeed, 
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inhibition of the rennin-angiotensin system mildly attenuates obesity in rodents, and 
limited clinical observations support this concept in hypertensive patients treated with 
ACE inhibitors (37, 38). 
In summary, high-calcium diets exert potent effects in enhancing reduction of 
body weight and fat pad mass in both ad lib fed and energy-restricted aP2-agouti 
transgenic mice. High-calcium diets suppressed adipocyte [Ca2+]i, stimulated lipolysis, 
inhibited lipogenesis and caused a corresponding increase in core temperature. 
Consequently, dietary calcium facilitates reduction of fat tissue mass and body weight by 
modulating energy partitioning. Moreover, dairy products contain other bioactive 
components which markedly amplify this effect, although the identity of this 
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Calcium and Dairy Inhibit of Weight and Fat Regain during Ad 





We have previously demonstrated that dietary calcium suppression of calcitriol 
reduces adipocyte Ca2+, suppresses lipogenesis and increases lipid utilization during 
energy restriction.  Notably, dairy calcium sources exert markedly greater effects.  To 
determine the effects of dietary calcium and dairy on energy partitioning during 
subsequent re-feeding, we induced obesity in aP2-agouti transgenic mice with a high 
fat/high sucrose diet, then restricted energy intake on a high calcium (1.3%) diet for 6-
weeks to induce fat loss, and then provided ad libitum access to the low calcium (0.4%) 
diet or to high (1.3%) calcium diets which utilized either calcium-fortified foods or dairy 
(milk or yogurt) for 6-weeks.  Re-feeding the low calcium diet caused re-gain of all 
weight and fat, while all high calcium diets reduced weight gain by 53% (p<0.01). All 
high calcium diets stimulated adipose tissue UCP2 and skeletal muscle UCP3 expression 
and increased core temperature, but only the dairy diets elicited a marked (>10-fold, 
p<0.001) increase in skeletal muscle PPARα expression. The high calcium diet produced 
a 50% increase in lipolysis, a 63% decrease in fatty acid synthase (FAS) and prevented 
55% of the fat regain (p<0.001), while the high dairy diets stimulated lipolysis by 271%, 
decreased FAS by 81% and prevented 85% of total fat regain (p<0.01).Thus, high Ca 
diets elicit a shift in energy partitioning and reduction of weight gain during re-feeding, 





Although obesity results from chronic energy imbalance, the energy status of an 
individual influences the partitioning of ingested food energy between oxidation and 
storage (1-3). Since energy balance in humans is a dynamic state, often characterized by 
substantial fluctuations in energy intake and expenditure, individual responses to such 
changes in energy and nutrient status may have important long-term consequences with 
respect to the retention of body fat. Long-term weight maintenance following successful 
weight loss may be considered an example of such adaptation, and is clearly a greater 
challenge than successful short-term weight loss (4).  
Previous data from this laboratory demonstrate that adipocyte intracellular Ca2+ 
([Ca2+]i) plays a key role in disorders associated with obesity (5-9). Our understanding of 
the effects of [Ca2+]i derives from studies of the mechanism of action agouti, an obesity 
gene expressed in rodent and human adipocytes (5,9). We have demonstrated that 
recombinant agouti protein stimulates the expression and activity of fatty acid synthase 
(FAS)(10-11), and inhibits lipolysis in both human and murine adipocytes (12-13). We 
have also demonstrated that agouti is expressed in human pancreas, and stimulates both 
Ca2+-signaling and insulin release in human pancreatic islets, thereby contributing to 
hyperinsulinemia (14-15). This coordinated regulation of lipid metabolism by agouti 
appears to be responsible for the accumulation of triglyceride in adipose tissue. Further, 
these effects of agouti can be mimicked by stimulation of Ca2+ influx with KCl and 
blocked by [Ca2+]i channel antagonists (16-17), indicating that strategies directed at 
reducing adipocyte intracellular [Ca2+]i would also be expected to reduce triglyceride 
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accumulation in adipose tissue. Recent data from our laboratory demonstrates that 
calcitrophic hormones, such as 1, 25-(OH)2-D3, cause a significant, sustained increase in 
[Ca2+]i in primary cultured human adipocytes and a corresponding inhibition of lipolysis 
(18). Consistent with this, we also reported that suppression of 1, 25-(OH)2-D3 by feeding 
high calcium diets inhibits [Ca2+]i influx and subsequently attenuates diet-induced 
adiposity by simultaneously stimulating lipolysis and inhibiting lipogenesis (19-20), 
suggesting that dietary calcium may not only attenuate the diet-induced development of 
adiposity but also promote weight loss in established obesity. We also demonstrated that 
dairy sources of calcium exert substantially greater anti-obesity effects than calcium 
carbonate (19-20). Compared with calcium carbonate, using dairy as a calcium source 
induces a significantly greater attenuation of diet-induced obesity and acceleration of 
weight and fat loss during energy restriction in both mice and humans (9, 19-21). Thus 
dairy appears to contain additional bioactive compounds which provide an attenuation of 
adiposity beyond that food with calcium (5). 
We have now used an experimental model to further investigate the effect of 
[Ca2+]i in regulating lipid metabolism in aP2 transgenic mice under conditions of varying 
nutrient status: ad libitum, energy restriction and refeeding. The purpose of this study was 
to investigate the effect of dietary calcium content and sources in regulating lipid 




3.3 Materials and Methods 
3.3.1 Animals and Diets 
This study was divided into three phases. The first phase was designed to induce 
weight gain and fat accretion, the second phase to induce weight and fat loss, and the 
third phase to determine the role of calcium and dairy in attenuating weight and fat gain 
during re-feeding. We utilized aP2-agouti transgenic mice as a model of diet-induced 
obesity, as previously described (19, 20). These mice are useful models for diet-induced 
obesity in a genetically susceptible human population in that they are not obese on a 
standard AIN-93G diet, but develop mild to moderate obesity when fed high sucrose 
and/or high fat diets (19-20). Indeed, it is applicable that some individuals have 
manifested a much greater increase of weight fat than others, strongly suggesting the 
possibility that there is a subgroup that is genetically susceptible to obesity and a different 
subgroup that is relatively resistant. 
Phase I 
Six-week old aP2 transgenic mice were studied in a six-week obesity induction 
period on the basal low calcium/high sucrose/high fat diet, as follows.  
60 aP2-agouti transgenic mice from our colony were placed at 6 weeks of age on a 
modified AIN 93 G diet with suboptimal calcium ( calcium carbonate, 0.4%), sucrose as 
the sole carbohydrate source and providing 64% of energy, fat increased to 25% of 
energy with lard and protein(casein purified high nitrogen) provided 11% of energy. 
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Animals were studied for six weeks, during which food intake and spillage were 
measured daily and body weight, fasting blood glucose, food consumption and core 
temperature were assessed weekly. At the end of phase I, five representative animals 
were sacrificed to collect blood, fat pads, liver and muscle.  
Phase II 
At the end of the phase one, the 55 animals remaining from phase I were placed on 
a high calcium diet with energy intake limited to 70% of that found during ad libitum 
consumption. The high calcium diet used in this phase consisted of the basal diet with the 
addition of sufficient calcium-fortified cereal to bring the calcium content of the diet to 
1.3%, with the macronutrients adjustments as described previously (19, 20). Animals 
were then studied for six weeks, during which food intake and spillage were measured 
daily and body weight, fasting blood glucose, food consumption and core temperature 
were assessed weekly. At the end of phase II, five animals were sacrificed as following to 
collect blood, fat pads, liver and muscle.  
Phase III 
At the end of the phase II, the 50 animals remaining from phase II were further 
randomized into five ad libitum-fed groups, as follows: 1) basal: modified AIN 93 G diet 
with suboptimal calcium (0.4%), as described in phase I, 2) high-Ca cereal: the high-Ca-
(1.3%) cereal diet described in phase II; 3) high-Ca-cereal plus dry milk: a high 
calcium cereal plus non fat milk diet. 1.2% calcium was derived from calcium fortified 
cereal and an additional 0.1% calcium content was derived from non-fat dry milk, with 
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20% protein was replaced by non-fat dry milk 4)yogurt: a high calcium (1.3 %) diet in 
which sufficient spary-dried non-fat yogurt was added to the basal diet to increase 
calcium to 1.3%, with 100% protein was replaced by non-fat dry yogurt 5) cereal control: 
the basal diet with a calcium-free control cereal (identical to the calcium-fortified cereal 
used in diet 3, but without the calcium fortification) with a final calcium concentration of 
0.4% and macronutrients adjusted to match the other diets. 10 animals /group were 
studied for six weeks, during which food intake and spillage were measured daily and 
body weight, fasting blood glucose, food consumption and core temperature were 
assessed weekly. At the conclusion of the study, all mice were sacrificed under 
isofluorane anaesthesia and blood collected via cardiac puncture, and fat pads, soleus and 
gastrocnemius muscles were immediately excised, weighed and used for further study, as 
described below.  
This study was approved from an ethical standpoint by the Institutional Care and 
Use Committee of The University of Tennessee. 
3.3.2 Core Temperature 
Core temperature was used as an indirect metabolic index to determine the effect 
of the diets on thermogenesis. Temperature was measured via a thermocouple (Columbus 
Instruments, Columbus, Ohio) weekly. The probe was inserted a constant distance (1.8 
cm) into the rectum of each mouse. After stabilization (10s), the temperature was 
recorded every 5 s for 30 s. All core temperature measurements were performed between 
8:00 and 9:00 A.M. 
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3.3.3 Adipocyte [Ca 2+]i Measurement 
Adipose tissue was first washed several times with Hank’s Balanced Salt Solution 
(HBBS), minced into small pieces, and digested with 0.8 mg/ml type I collagenase in a 
shaking water bath at 37o C for 30 min. Adipocytes were then filtered through sterile 500-
µm nylon mesh and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 1% fetal bovine serum (FBS). Cells were cultured in suspension and 
maintained in a thin layer at the top of culture media for 2 h for cell recovery. [Ca 2+]i in 
isolated mouse adipocytes was measured by using a fura-2 dual wavelength fluorescence 
imaging system Prior to [Ca2+ ]i measurement, adipocytes were pre-incubated in serum-
free medium for 2 h and rinsed with HBSS containing the following components (in 
mmol/L): NaCl 138, CaCl2 1.8, MgSO4 0.8, NaH2PO4 0.9, NaHCO3 4, glucose 5, 
glutamine 6,Hepes 20, and bovine serum albumin 1%. Adipocytes were loaded with fura-
2 acetoxymethyl ester (AM) (10µmol/L) in the same buffer in dark for 1 h at 37o C. 
Adipocytes were rinsed with HBSS three times to remove extracellular dye and then 
post-incubated at room temperature for an additional 30 min to permit complete 
hydrolysis of cytoplasmic fura-2 AM. A thin layer of adipocytes was plated in 35 mm 
dishes with glass coverslips (P35G-0-14-C, MatTek Corporation, Ashland, Mass.). The 
dishes with dye-loaded cells were mounted on the stage of Nikon TMS-F fluorescence 
inverted microscope with a Cohu 4915 CCD camera. Fluorescent images were captured 
alternatively at excitation wavelength of 340 and 380 nm with an emission wavelength of 
520 nm. [Ca2+]i was calculated by using a ratio equation. 
 177
3.3.4 Fatty Acid Synthase (FAS) Activity Assay 
FAS activity was determined spectrophotometrically in crude cytosolic extracts of 
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L 
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L 
dithiothreitol (DTT), and 100µmol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). 
The homogenate was centrifuged at 18,500 X g for 1 h, and the infranatant was used for 
measuring oxidation rate of NADPH. The final FAS activity was normalized to DNA, 
which was measured by CyQUANT cell proliferation assay kit according to 
manufacturer’s instruction (Parkard instrument Company, Inc., Downers Grove, IL).  
3.3.5 Lipolysis Assay 
Perirenal adipose tissue was immediately dissected and incubated for 4h. Glycerol 
released into the culture medium was used to measure lipolysis, as described previously 
(4). Glycerol was measured using a one-step enzymatic fluorametric method. The final 
lipolysis was normalized by DNA, as described above.  
3.3.6 Total RNA Extraction 
Total cellular RNA isolation kit (Ambion Inc., Austin, TX) was used to extract 
total RNA from mouse abdominal adipose tissue and soleus muscle according to 




3.3.7 Quantitative Real-time PCR 
Mouse abdominal adipose tissue FAS, PPAR gamma, UCP2 mRNA, and mouse 
soleus muscle UCP3 and PPAR alpha mRNA were quantitatively measured using a 
Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000 
Core Reagent Kit (Applied Biosystems, Branchburg, NJ). The primers and probes for 
mouse genes are as follows. FAS: forward primer: 5’-CCCAGAGGCTTGTGCTGACT-
3’, reverse primer: 5’-CGAATGTGCTTGGCTTGGT-3’, probe: 5’-
CCGATCTGGAATCCGCACCGG-3’; PPAR alpha: forward primer: 5’-
CGATACTGTCCTCCTTGATGA-3’, reverse primer: 5’-
CGCGTGTGATAAAGCCATTG-3’, probe: 5’-ACGCGATCAGCATCCCGTCTTTG-3’; 
PPAR garma forward primer: 5’-GCCTATGAGCACTTCACAAGAAATT-3’, reverse 
primer: 5’-TGCGAGTGGTCTTCCATCAC-3’, probe: 5’-
TCTGCCCCACCAACTTCGGAATCAG-3’; UCP2 forward primer: 5’-
GCGTTCTGGGTACCATCCTAAC-3’, reverse primer: 5’-
GCGACCAGCCCATTGTAGA-3’, probe: 5’-
GCCTATGAGCACTTCACAAGAAATT-3’; UCP3 forward primer: 5’-
CCTCTACGACTCTGTCAAGCAGTTCTAC-3’, reverse primer: 5’-
CAGCCTGCCAGAATCCTGAT-3’, probe: 5’-CGCTGGAGTGGTCCGCTCCCT-3’.  
Pooled mouse abdominal adipose tissue total RNA was serial-diluted in the 
range of 1.5625-25 ng and used to establish a a standard curve of desired gene; total 
RNAs for unknown samples were also diluted in this range. Reactions of quantitative RT-
PCR for standards and unknown samples were also performed according to 
theinstructions of Smart Cycler System (Cepheid, Sunnyvale, CA) and TaqMan Real 
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Time PCR Core Kit (Applied Biosystems, Branchburg, NJ). The mRNA quatitation for 
each sample was further normalized using the corresponding 18s or cyclophilin 
quantitation, with 18S forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’, reverse 
primer: 5’-GATCCGAGGGCCTCACTAAAC-3’, probe: 5’-
CGCCCGTCGCTACTACCGATTGG-3’; Cyclophilin forward primer: 5’-
GGTGGAGAGCACCAAGACAGA-3’, reverse primer: 5’-
GCCGGAGTCGACAATGATG-3’, probe: 5’-AGCCGGGACAAGCCACTGAAGGAT-
3’. 
3.3.8 Carnitine Palmitoyltransferase (CPT) Assay 
Liver samples were first homogenized in 10 volumes (wt/vol) of 0.25M 
sucrose/0.2mM EDTA (PH 7.5) in a glass tissue grinder to isolate heptocyte 
mitochondria. The tissue homogenates were then centrifuged for 12minutes at 750g to 
collect the supernatant, which was further centrifuged for 12 min at 6,700g. These 
centrifugations were repeated twice and the pellet was then suspended in 4 ml of 
mitochondrial suspension buffer (70 mM sucrose, 220mM mannitol, 2mM HEPES buffer, 
1mM EDTA, PH 7.4). CPT activity was determined by measuring the initial rates of total 
CoASH formation by the DTNB reaction from palmitoyl CoA by mitochondria 
individually with l (-)-carnitine and d (+)-carnitine using a spectrophotometry method. 
Final data were normalized to cytosolic protein, which was assayed by the method of 
Bradford. 
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3.3.9 Statistical Analysis 
All data were evaluated for normality of distribution and equality of variance prior 
to statistical analysis. Variables with skewed distribution were ln-transformed. Outcomes 
are shown as means and SD and were evaluated for statistical significance by one- way 
analysis of variance (ANOVA), and significantly different group means were then 
separated by the least significant difference (LSD) test by using SPSS (SPSS Inc, 
Chicago, IL.).  
 
3.4 Results 
Body weight, weight regain and fat pad weight data are summarized in figure 1. 
Although we did not observe significant difference in food consumption among the five 
group of mice during the refeeding following energy restriction(average daily food intake 
per mice during ad libitum refeeding: basal group:3.5+0.3g/day, high-Ca cereal group: 
3.7+0.3g/day, high-Ca cereal plus dry milk: 3.8+0.3 3 g/day, yogurt group: 3.9+0.4 g/day 
and cereal control group: 3.7+0.3 g/day, p>0.05), there was a striking effect of diet on 
weight gain (p<0.05) (Figure 3-1 A) and fat pad weight (Figure 3-1 B) (p<0.04). Mice 
re-fed the low calcium diets exhibited weight gain and an increase in fat pad mass. In 
contrast, mice on the high calcium diets exhibited approximately 50% of this regain, with 
increases of body weight and fat pad mass. Further, the dairy-based high calcium diets 
were more effective in preventing fat gain, as the high dairy diets prevented 85% of the 
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Figure 3-1. Effect of dietary calcium and dairy on weight and fat mass regain in aP2 
transgenic mice. (A) body weight and (B) fat pads weight. Data are expressed as mean ± 
SEM (n=5 for phase I and phase II, n =8 for phase III). Different letters above the bars 
indicate a significant difference at level of p<0.05. 
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Figure 3-2 shows adipose tissue lipolysis, FAS expression and FAS activity. We 
found a slight decrease (20%, p<0.05) in lipolysis in mice on 70% restricted high calcium 
cereal diet compared to the high sucrose, high fat, low calcium diet fed ad libitum 
(Figure 3-2 A). Upon refeeding after energy restriction, the mice on the high calcium 
diets exhibited a significantly higher level of lipolysis than mice on the low calcium diets 
(p<0.05), and the dairy-based high calcium diets exhibited a significantly greater effect 
than the non-dairy source (p<0.001). Adipose tissue FAS activity and expression 
responded to dietary manipulations in an inverse fashion to lipolysis responses. Figure 3-
2 B show that energy restriction with high-Ca fortified cereal diet decreased FAS 
expression and activity by 99% and 91% respectively (FAS activity data not shown). 
Upon refeeding, the low calcium diets restored FAS activity and expression back to the 
basal level (cereal control diet) or higher (low calcium basal diet, p<0.03). In contrast, the 
groups on high calcium diets exhibited marked lower level of adipose FAS activity and 
expression. Furthermore, the mice re-fed the dairy-based high calcium diets exhibited a 
significantly lower level of FAS expression than those fed the non-dairy-based high 
calcium diet (p<0.001).  
Energy restriction in aP2 mice for 6 wks using high calcium diet resulted in a 
79% decrease in adipocyte [Ca2+]i (380 + 43nM vs. 79 + 10nM). Upon refeeding, the low 
calcium diets induced a 4 to 5-fold (p<0.001) increase in adipocyte [Ca2+]i, (Figure 3-3), 
while there was no significant increase on the high calcium diets, suggesting that diet-
induced dysregulation of adipocyte [Ca2+]i is associated with diet-induced adiposity in 










































































Figure 3-2. Effect of dietary calcium and dairy refeeding on lipid metabolism in aP2 
transgenic mice. (A) adipose basal lipolysis, (B) FAS expression. Data are expressed as 
mean ± SEM (n=5 for phase I and phase II, n =8 for phase III). Different letters above the 











































Figure 3-3. Effect of dietary calcium and dairy refeeding on adipocyte intracellular 
calcium in aP2 transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I 
and phase II, n =8 for phase III). Different letters above the bars indicate a significant 
difference at level of p<0.05. 
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To determine if shifts in liver fat oxidation potentially contributed to changes in 
adiposity, we also examined liver CPT activity (Figure 3-4). Upon refeeding, treatment 
of aP2-transgenic mice with the low calcium diets resulted in a slight increase in liver 
CPT activity by 44% and 56% while the high calcium diets increase CPT activity by 
150%. However, there was no significant effect of the source of calcium on liver CPT 
activity. 
The shift in energy metabolism in refeeding was also confirmed further by 
dietary-induced increase in UCP2 expression in adipose tissue (Figure 3-5) and UCP3 
(Figure 3-6) expression in skeletal muscle. Upon refeeding, the high calcium diets 
induced 8 to 19-fold increases in UCP2 expression in white adipose tissue and 30 to 34-
fold increases in UCP3 expression in solues muscle, compared with the low calcium diets 
(p<0.001). Furthermore, the dairy-based high calcium diets exerted greater effects on 
adipose tissueUCP2 expression than the non-dairy based high calcium diet, although a 
comparable difference between calcium sources was not found for skeletal muscle UCP3 
expression. 
We also found dietary-calcium induced increases in core temperature, with 
increases on refeeding the high-calcium, high-calcium plus milk and yogurt respectively 
(Figure 3-7). This increase, coupled with the lack of difference in food intake in 
refeeding, suggests a shift in efficiency of energy metabolism from energy storage to 
thermogenesis.  
This shift in energy metabolism was also evident in studies of the peroxisome 





















































Figure 3-4. Effect of dietary calcium and dairy refeeding on liver CPT activity in 
aP2 transgenic mice. Data are expressed as mean ± SE (n=5 for phase I and phase II, n 




















































Figure 3-5. Effect of dietary calcium and dairy refeeding on adipose UCP2 
expression in aP2 transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I 
and phase II, n =8 for phase III). Different letters above the bars indicate a significant 















































Figure 3-6. Effect of dietary calcium and dairy refeeding on UCP3 expression in aP2 
transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I and phase II, n =8 










































b b b a a 
Figure 3-7. Effect of dietary calcium and dairy refeeding on core temperature in aP2 
transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I and phase II, n =8 
for phase III). Different letters above the bars indicate a significant difference at level of 
p<0.05. 
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cellular lipid catabolism Refeeding with the dairy-based high calcium diets resulted in a 
marked (> 10-fold) increase in skeletal muscle PPARα compared to the low calcium 
diets (Figure 3-8, p<0.03), while the non-dairy calcium-enriched diet exerted no effect 
on PPARα expression. Figure 3-9 indicates that mice refed high calcium diets exhibited 
significant lower level of PPARγ expression, suggesting dietary calcium may also inhibit 
fat mass regain by suppressing adipogenesis. 
Serial measurements of plasma glucose and insulin demonstrate a diabetogenic 
effect of the basal high fat, high sucrose and low calcium diet, with an increase in fasting 
glucose from 121+23 to 169+16 mg/dl and a corresponding degree of compensatory 
hyperinsulinemia and hyperleptinemia. On refeeding after fasting, hyperglycemia, 
hyperleptinemia and hyperinsulinemia were observed in mice on low calcium diet but not 
in mice on high calcium diets (Table 3-1). 
 
3.5 Discussion 
It is well accepted that energy balance are core factor involved in the obesity 
epidemic, with increases in energy intake contribute to a net positive energy balance and 
progressive weight gain. However, it is also well known that obesity is a complex genetic 
trait, with multiple genes interacting to confer relative resistance or susceptibility to 
positive energy balance. Similarly, specific micro- or macronutrients, dietary patterns, or 
both may modulate the same metabolic pathways affected by these genetic factors and 














































Figure 3-8. Effect of dietary calcium and dairy refeeding on PPARα expression in 
aP2 transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I and phase II, 
n =8 for phase III). Different letters above the bars indicate a significant difference at 





Figure 3-9. Effect of dietary calcium and dairy refeeding on PPARγ expression in 
aP2 transgenic mice. Data are expressed as mean ± SEM (n=5 for phase I and phase II, 
n =8 for phase III). Different letters above the bars indicate a significant difference at 






















































Table 3-1. Effect of dietary calcium and dairy refeeding on serum insulin, leptin and glucose concentrations of aP2-agouti 
transgenic mice. 
Groups Insulin (ng/ml) Leptin (ng/ml) Glucose (mg/dl) I:G ratio(x10-6) 
I-Basal 9.12 + 3.21 13.15 + 4.18 169.42 + 16.98 0.07 + 0.19 
II-Calcium Cereal 1.20 + 0.46ab 4.38 + 3.39ab 127.93 + 18.61ab 0.01 + 0.02 ab
III-Basal  12.12 + 7.43 17.12 + 6.13 145.30 + 19.32b 0.12 + 0.38 
III-Calcium Cereal 3.28 + 0.20ab 8.77 + 0.86ab 131.00 + 15.07b 0.03 + 0.01 ab
III-Clacium Cereal+Milk  2.86 + 0.25ab 6.33 + 1.13ab 112.9 + 10.59ab 0.03 + 0.02 ab
III-Yogurt  2.20 + 0.34ab 6.40 + 2.21ab 129.8 + 17.12ab 0.02 + 0.02 ab
III-Cereal Control  4.46 + 0.84ab 14.07 + 4.46 151.4 + 20.10b 0.04 + 0.04 ab
a p<0.05 vs. III-Basal ad lib.  
b p<0.05 vs. I-Basal ad lib 
* Diet and animal administration was conducted as described in Materials and Methods. Data are expressed as mean ± SE (n =10). 
Statistical significance is as indicated in each panel. 
 
of evidence emerged in recent years which indicated that dietary calcium and dairy 
products may play a role in modulation of adiposity independent of energy restriction, 
with high dietary calcium and addition of dairy products attenuate weight and fat gain 
without energy restriction and stimulates weight and fat loss during energy restriction. 
However, the effect of dietary calcium and dairy products on prevention of fat and weight 
regain is not yet clear. 
The present study demonstrates that dietary calcium exerts marked effects in the 
regulation of weight and fat regain in aP2-agouti transgenic mice, as the high calcium 
diets inhibited weight and fat regain while the low calcium diets promoted fat and weight 
regain. Notably, dairy source of calcium appears to exert greater effects than elemental 
calcium. Although there were no significant diet related difference in energy intake 
during ad libitum refeeding following energy-restriction, the mice refed the low calcium 
diets showed a rapid, pronounced regain of weight and fat which exceeded that lost 
during energy restriction. In contrast, the mice refed the high calcium diets regained only 
50% of the weight lost during energy restriction period, suggesting that dietary calcium 
inhibits weight and fat regain by decreasing efficiency of energy utilization during 
rebound food ingestion.  
We also observed that dietary calcium levels are inversely associated with [Ca2+]i 
levels in white adipocyte tissue, with mice refed low calcium diets exhibiting high 
adipocyte [Ca2+]i while those refed high calcium exhibiting low adipocytes [Ca2+]i. 
Adipocyte [Ca2+]i has been determined to regulate human and murine adipocyte 
metabolism, as recently reviewed (5). Accordingly, manipulation of [Ca2+]i is an 
attractive and logical approach for development of therapeutic interventions in obesity. 1, 
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25-(OH)2-D3 has been previously shown to stimulate [Ca2+]i in multiple cell types, 
including vascular smooth muscle cells, pancreatic ß cells and adipocytes (15, 17, 18, 20). 
We demonstrated that 1,25-(OH)2-D3 also acts on human adipocytes to cause a rapid 
sustained increase in [Ca2+]i and a coordinated activation of FAS and inhibition of 
lipolysis (5, 18, 20). Increased 1,25-(OH)2-D3 has also been observed in obese humans, 
further suggesting that 1,25-(OH)2-D3 may exert effects in human energy metabolism(20). 
Consistent with this concept, we recently demonstrated that dietary calcium not only 
attenuates diet-induced obesity but also accelerates weight loss and fat mass reduction 
secondary to caloric restriction in established obesity in both mice (19) and human (9). In 
present study, antagonism of [Ca2+]i was again achieved through a dietary intervention by 
increasing dietary calcium. We proposed that suppression of 1, 25-(OH)2-D3 dietary 
calcium would reduce adipocyte [Ca2+]i and thereby regulates lipid metabolism in 
response to different energy status. Indeed, the present study extended our previous 
observations by demonstrating that dietary calcium not only attenuates diet-induced 
obesity and accelerates weight loss and fat mass reduction in energy restriction in 
established obesity, but also inhibit weight and fat mass regain during refeeding 
secondary to energy restriction. 
Notably, increasing dietary calcium not only modulates energy petitioning by 
inhibiting lipogenesis and stimulating lipolysis, but also stimulates UCP2 and UCP3 
expression and causes an increase in core temperature, an indirect metabolic index 
associated with thermogenesis during refeeding after energy restriction. This may further 
contribute to the observed attenuation of weight and fat pad regain during refeeding. This 
concept is supported by our previous observation that 1, 25-(OH)2-D3 inhibits UCP2 
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expression in human adipocytes, indicating that suppression of 1, 25-(OH)2-D3 by 
increasing dietary calcium may stimulate UCP2 induced thermogenesis and fat oxidation 
and thereby result in decreased energy efficiency.  
The function of UCPs is not restricted to thermoregulation, as a growing body of 
evidence links UCP expression to fatty acid metabolism and fatty acid flux in various 
tissues (23-24). Previous studies have demonstrated that free fatty acids increase UCP2 
and UCP3 expression in adipocytes, pancreatic beta cells and myocytes (25-28). These 
data strongly support a regulation of UCP2 and UCP3 expression by fatty acids and also 
indicate that UCPs activity could be related to fatty acid oxidation. In fact, UCP2 and 
UCP3 may function as free fatty acid transporter and thereby increases fatty acid 
utilization (29-30).  
The regulation of UCP transcription is attributable a group of ligand-regulated-
transcription factors such as peroxisome-peroliferation-activted factors, which can be 
activated upon binding fatty acid ligand (31). Since PPARs are also involved in the 
regulation of adipocyte differentiation and lipid oxidation (31), it is possible that PPARs 
are the key regulators which coordinate the activation of lipid metabolism and oxidation 
in adipocytes. In fact, a PPAR response element (PPRE) has been identified in the UCP 
promoter region (32-33), and PPARα activation in mice is sufficient to induce liver UCP-
2 expression (34). Consistent with this, our data showed that high calcium diets induced 
increases in UCP2 and UCP3 expression were accompanied by marked increases in 
PPARα expression during refeeding, indicating that high dietary calcium may stimulates 
UCPs via a PPARα-dependent mechanism. Consistent with the effect of dietary calcium 
on stimulating thermogenesis and energy partitioning via up-regulation of UCPs, we also 
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observed high calcium diets caused a significant increase in hepatic activity of CPT 
during refeeding, suggesting that dietary calcium may stimulate a diversion of hepatic 
fatty acid metabolism towards oxidation pathway during ad libitum refeeding. These data 
suggest that dietary calcium reduces lipid accumulation via energy repartitioning and 
dissipation, resulting in less regain of fat during ad libitum refeeding. 
We also found that refeeding high calcium diets caused a significant decrease in 
PPARγexpression in white adipose tissue. Unlike PPARα, which is highly expressed in 
liver and skeletal muscle and modulates fatty acid oxidation, PPARγis mainly restricted 
to white and brown adipose tissue and regulates adipogenesis (35). Accordingly, these 
present data suggest the possibility that dietary calcium may also inhibit adiposity by 
decreasing adipogenesis during food re-administration. 
It is also noteworthy that although dairy and elemental calcium exerted 
qualitatively comparable effects, the magnitude of these effects was significantly 
different. Although all three high calcium diets exerted similar effect on inhibition of 
body weight regain during refeeding, the inclusion of dairy resulted in significantly less 
regain of fat and weight compared to mice fed elemental calcium. Consistent with this, 
calcium derived from dairy exerted a markedly greater inhibitory effect on lipogensis and 
greater stimulatory effect of lipolysis compared with the non-dairy-calcium source. 
Previous data demonstrated that the increase in dietary calcium from 1.2% to 1.3% by 
adding small amount of non-fat dry milk doubled the rate of fat loss (unpublished data 
from this lab) and data from present study are consistent with these observations. Thus, 
utilizing a dairy source of calcium is maximizing the anti-obesity effects of calcium.  
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Additional factors in dairy responsible for this effect besides calcium have been 
recently discussed. Several investigators have reported that conjugated linoleic acid 
(CLA), a component in dairy product and meat is an effective regulator of body fat 
accumulation and retention (36). However, the dairy diet utilized in this study was from 
non-fat dry milk and fat-free yogurt, which does not contain CLA, indicating that 
additional effect cannot be attributed to CLA. Other components of dairy which may 
contribute to these anti-obesity effects include branch chain amino acids and small 
bioactive peptides. Our preliminary data in mice isolated most of the additional 
bioactivity of dairy products to the whey fraction (unpublished data), which containing 
high proportion of branch chain amino acids (BCAAs, leucine, isoleucine, and valine). 
BCAAs, especially leucine, play a specific metabolic role in regulation of energy 
metabolism and muscle protein synthesis (37-38). In skeletal muscle, leucine stimulates 
protein synthesis and inhibits protein catabolism through multiple independent 
mechanisms (39-40). Leucine stimulates protein synthesis through the mammalian target 
of rapamycin (mTOR) pathways, 70-kDa ribosomal protein S6 kinase activity, and 
enhances eIF4E-binding protein phosphorylation and the association of eukaryotic 
initiation factor eIF4E with eIF4G (41-42). Accordingly, dairy products provide 
sufficient BCAAs to be able to maintain the high concentration of intracellular leucine 
required by these signaling pathways. Milk proteins have also been reported to contain 
significant angiotensin converting enzyme (ACE) activity (43-44). Furthermore, recent 
data demonstrate that adipocytes have an autocrine/paracrine rennin-angiotensin system 
and that adipocyte lipogenesis is regulated partially by angiotensin II (45). Moreover, 
inhibition of the rein-angiotensin system mildly attenuates obesity in rodents and clinical 
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observations in hypertensive patients treated with ACE inhibitors support this concept 
(21). In addition, our recent data demonstrate that dairy-derived ACE inhibitor augments 
the anti-obesity effects of calcium in aP2 transgenic mice. 
In summary, high-calcium diets exert potent effects in weight maintenance during 
refeeding following energy-restriction in aP2-agouti transgenic mice. High-calcium diets 
suppressed adipocyte [Ca2+]i, stimulated lipolysis, inhibited lipogenesis and a 
corresponding increase in core temperature. Consequently, dietary calcium facilitates 
reduction of fat tissue mass and body weight in refeeding by modulating energy 
metabolism, which serves to reduce energy storage and increase beta-oxidation. This 
concept that calcium modulation of adiposity is consistent with the observations obtained 
epidemiologically in the NHANES III data set , Quebec Family Study; CARDIA and a 
recent clinical trial (20, 46, 47, 9). Moreover, dairy source of calcium exerts greater 
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This part is a slightly revised version of a paper by the same name published in 
the Journal of Nutritional Biochemistry in 2003 by Xiaocun Sun, Michael B. Zemel: 
Xiaocun Sun, Michael B. Zemel. Effect of mitochondrial uncoupling on adipocyte 





Previous data from this laboratory demonstrate that increased intracellular Ca2+ 
([Ca2+]i) coordinately regulates human and murine adipocyte lipid metabolism by 
stimulating lipogenesis and inhibiting lipolysis. However, recent data demonstrate 
metabolic uncoupling increase [Ca2+]i but inhibit lipogenesis by suppressing fatty acid 
synthase (FAS) activity. Accordingly, we have evaluated the interaction between 
mitochondrial uncoupling, adipocyte [Ca2+]i, and adipocyte lipid metabolism. 
Pretreatment of 3T3-L1 cells with mitochondrial uncouplers (DNP or FCCP) amplified 
the [Ca2+]i response to depolarization with KCl by 2-4 fold (p<0.001), while this increase 
was prevented by [Ca2+]i channel antagonism with lanthanum. Mitochondrial uncouplers 
caused rapid (within 4hr) dose-dependent inhibition of FAS activity (p<0.001), while 
lanthanum caused a further additive inhibition. The suppression on FAS activity induced 
by uncoupler DNP was reversed by addition of ATP. Mitochondrial uncouplers increased 
FAS expression significantly while [Ca2+]i antagonism with lanthanum decreased FAS 
expression (P<0.001). In contrast, mitochondrial uncouplers independently inhibited 
basal and isoproterenol-stimulated lipolysis (20-40%, p<0.001), while this inhibition was 
 209
fully reversed by lanthanum. Thus, mitochondrial uncoupling exerted short-term 
regulatory effects on adipocyte [Ca2+]i and lipogenic and lipolytic systems, serving to 




The discovery of novel homologues of the brown adipose tissue mitochondrial 
uncoupling protein (UCP), such as UCP2, has provoked intensive study of these 
mitochondrial proteins and the role that they may play in energy metabolism (1). Since 
lipogenesis is dependent upon mitochondrial ATP production (2), mitochondrial 
uncoupling in adipocytes may contribute to control of lipid metabolism. 
Previous data from our laboratory demonstrates that intracellular calcium ([Ca2+]i) 
plays a key role in the regulation of adipocyte energy metabolism (3). Increased [Ca2+]i 
stimulates the expression and activity of fatty acid synthase (FAS), a key enzyme in de 
novo lipogenesis, and inhibits basal and agonist-stimulated lipolysis in both human and 
murine adipocytes(4-5). However, little is known of the mitochondrial regulation of 
[Ca2+]i and lipid metabolism in adipose tissue. Accordingly, in the present study, the role 
of mitochondrial uncoupling in regulating lipolysis and lipogenesis as well as 
intracellular calcium have been examined in differentiated 3T3-L1 adipocytes. We used 
two different mitochondrial uncouplers to induce uncoupling effect on adipocytes 
mitochondria (6-7). We report that mitochondrial uncoupling increases [Ca2+]i and down-
regulates lipolysis via a calcium-dependent mechanism. In contrast, the effect of 
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mitochondrial uncoupling on fatty acid synthase is more complex, with up-regulation of 
FAS expression via a calcium-dependent mechanism, and suppression of FAS activity via 
a Ca2+-independent mechanism.  
 
4.3 Materials and Methods
4.3.1 Culture and Differentiation of 3T3-L1 Adipocytes  
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish) 
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and 
antibiotics at 37°C in 5% CO2 in air. Confluent preadipocytes were induced to 
differentiate with a standard differentiation medium consisting of DMEM-F10 (1:1, 
vol/vol) medium supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM) and 
antibiotics (1% BSA). Preadipocytes were maintained in this differentiation medium for 3 
days and subsequently cultured in adipocyte medium. Cultures were refed every 2–3 days. 
Cell viability was measured via trypan blue exclusion.
 4.3.2 Fatty Acid Synthase (FAS) Activity Assay 
Adipocytes were incubated for 4 h in the presence of 0-50 µM 2,4-dinitrophenol 
(DNP) or 0-5 µM carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (Sigma, 
St Louis, MO) with or without insulin (30nM) and with or without lanthanum(1mM) 
(Sigma, St Louis, MO) . Subsequently, the cells were returned to serum free medium 
(containing 1% BSA) for 48 hours. Fatty acid synthase activity was measured in cytosolic 
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extracts by measuring the oxidation rate of NADPH, as described previously (8-10). 
Adipocytes were then homogenized in 250 mmol/L sucrose solution containing 1 
mmol/L ethylenediamine-tetraacticacid (EDTA), 1mmol/L dithiothreitol (DTT), and 100
μ mol/L phenylmethylsulfonyl fluoride (PMSF) (pH 7.4). The homogenates were 
centrifuged at 18,500 X g for 1h and then incubated in phosphate buffer and acetyl-CoA, 
with or without ATP (10nM) (Sigma, St Louis, MO), for 15 minutes, and the infranatant 
was used for measuring oxidation of NADPH right after adding malonyl-CoA. The final 
FAS activity was normalized to nucleic acids, which was measured by CyQUANT cell 
proliferation assay kit (Parkard instrument Company, Inc., Downers Grove, IL) according 
to manufacturer’s instruction.  
4.3.3 Lipolysis Assay 
Adipocytes were incubated for 2 h in the presence of 0-50 µM DNP or 0-5 µM 
FCCP with or without insulin (30nM) and with or without lanthanum (1mM), and with or 
without isoproterenol (50nM). Glycerol released into the culture medium was determined 
as an indicator for lipolysis, using a one-step enzymatic fluorometric method (11). 
Glycerol release data was normalized for cellular nucleic acids as described above. 
4.3.4 [Ca2+]i Measurement 
[Ca2+]i in 3T3-L1 adipocytes was measured using a fura-2 dual-wavelength 
fluorescence imaging system. Preadipocytes were plated in 35-mm dishes (P35G-0-14-C, 
MatTek). Prior to [Ca2+]i measurement, cells were preincubated with or without different 
concentration 0-50 µM DNP or 0-5 µM FCCP with or with or without lanthanum(1mM) 
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for one hour. Cells were then put in serum-free medium overnight and rinsed with 
HEPES balanced salt solution (HBSS) containing the following components (in mM): 
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20 
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl 
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5% 
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then 
postincubated at room temperature for an additional 1 h for complete hydrolysis of 
cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of 
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled 
device (CCD) camera. Fluorescent images were captured alternatively at excitation 
wavelength of 340 and 380 nm with an emission wavelength of 520 nm. After 
establishment of a stable baseline, the response to 40mM KCl was determined. [Ca2+]i 
was calculated using a ratio equation as described previously(12). Each analysis 
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt 
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were 
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR) 
to create a calibration curve in solution, and cellular calibration was accomplished using 
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal 
[Ca2+]i levels respectively.  
4.3.5 Total RNA Extraction  
Total cellular RNA isolation kit (Ambion Inc., Austin, TX) was used to extract 
total RNA from 3T3-L1 cells according to manufacturer’s instruction.  
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4.3.6 Quantitative Real-time PCR 
3T3-L1 adipocyte FAS mRNA was quantitatively measured using a Smart Cycler 
Real Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000 Core Reagent 
Kit (Applied Biosystems, Branchburg, NJ). The primers for mouse FAS are as follows. 
Forward primer: 5’-CCCAGAGGCTTGTGCTGACT-3’ reverse primer: 5’-
CGAATGTGCTTGGCTTGGT-3’. Pooled 3T3-L1 adipocyte total RNA was serial-
diluted in the range of 1.5625-25 ng and used to establish a FAS standard curve; total 
RNAs for unknown samples were also diluted in this range. Reactions of quantitative RT-
PCR for standards and unknown samples were also performed according to the 
instructions of Smart Cycler System (Cepheid, Sunnyvale, CA) and TaqMan Real Time 
PCR Core Kit (Applied Biosystems, Branchburg, NJ). The FAS mRNA quantitation for 
each sample was further normalized using the corresponding 18s quantitation, with a 
forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’ and a reverse primer: 5’-
GATCCGAGGGCCTCACTAAAC-3’. 
4.3.7 Statistical Analysis 
All data are expressed as mean ± SE. Data were evaluated for statistical 
significance by one-way analysis of variance (ANOVA), and significantly different group 
means were then be separated by the least significant difference test by using SPSS 





Both mitochondrial uncouplers increased KCl-stimulated [Ca2+]i (p<0.001). 
Antagonism of calcium channels with the non-specific inhibitor lanthanum decreased 
both basal and stimulated [Ca2+]i significantly (p<0.001) and reversed the stimulation of 
[Ca2+]i induced by mitochondrial uncouplers (Figures 4-1 and 4-2).  
Mitochondrial uncoupling with DNP or FCCP significantly inhibited lipolysis 
(Figures 4-3 and 4-4). This effect was attenuated by insulin while lanthanum completely 
reversed the suppression by mitochondrial uncouplers or/and insulin. These results 
indicate that metabolic uncouplers suppress lipolysis via a calcium dependent mechanism. 
In short-term (4 hours) treatment with DNP, FAS activity was decreased significantly by 
mitochondrial uncoupling (p<0.001) (Figure 4-5). However, lanthanum was unable to 
reverse this short-term suppression, indicating that this short-term suppression of FAS 
activity by DNP was calcium-independent. Similar results were observed with a long-
term (48hours) treatment with both mitochondrial uncouplers, with lanthanum causing a 
further suppression (Figures 4-5 and 4-6). However, both mitochondrial uncouplers 
significantly increased FAS expression and this effect was reversed by lanthanum 
(Figure 4-7). Thus, metabolic uncoupling has a dual effect on FAS: to decrease activity 
via a Ca2+-independent mechanism and to increase FAS expression via a Ca2+-dependent 
mechanism. The addition of ATP reversed the DNP-induced suppression of FAS activity, 







Figure 4-1. Effect of DNP on intracellular calcium in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM, 50µM), 
DNP plus KCl (40mM) or DNP plus lanthanum(1mM). Data are expressed as mean ± SE 










Figure 4-2. Effect of FCCP on intracellular calcium in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with or without FCCP (1µM, 5µM), 
FCCP plus KCl (40mM) or FCCP plus lanthanum (1mM). Data are expressed as mean ± 








Figure 4-3. Effect of DNP on lipolysis in 3T3-L1 adipocytes. Differentiated 3T3-L1 
adipocytes were treated with or without DNP (25µM), DNP plus insulin (30nM), DNP 
plus isoproterenol (50nM) or DNP plus lanthanum (1mM). Lipolysis was determined as 
glycerol release by enzymatic fluorescence method, which was conducted as described in 
Materials and Methods.  Data are expressed as mean ± SE (n =12). Difference letters 






Figure 4-4. Effect of FCCP on lipolysis in 3T3-L1 adipocytes. Differentiated 3T3-L1 
adipocytes were treated with or without FCCP (1µM, 5µM), FCCP plus insulin (30nM), 
FCCP plus isoproterenol (50nM) or FCCP plus lanthanum (1mM). Lipolysis was 
determined as glycerol release by enzymatic fluorescence method, which was conducted 
as described in Materials and Methods.  Data are expressed as mean ± SE (n =12). 












Figure 4-5. Effect of DNP on fatty acid synthase (FAS) activity in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM), Insulin 
(30nM), Lanthanum(1mM), DNP plus insulin or DNP plus lanthanum. FAS activity was 
measured as the oxidative rate of NADPH, which was conducted as described in 
Materials and Methods.  Data are expressed as mean ± SE (n =12). Difference letters 








Figure 4-6. Effect of FCCP on fatty acid synthase (FAS) activity in 3T3-L1 
adipocytes. Differentiated 3T3-L1 adipocytes were treated with or without FCCP (1µM, 
5µM), Insulin (30nM), Lanthanum (1mM), FCCP plus insulin or FCCP plus lanthanum. 
FAS activity was measured as the oxidative rate of NADPH, which was conducted as 
described in Materials and Methods.  Data are expressed as mean ± SE (n =12). 








Figure 4-7. Effect of DNP on fatty acid synthase (FAS) expression in 3T3-L1 
adipocytes. Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM), 
Insulin (30nM), Lanthanum (1mM), DNP plus insulin or DNP plus lanthanum. FAS 
mRNA was measured by real time PCR, which was conducted as described in Materials 
and Methods.  Data are expressed as mean ± SE (n =6). Difference letters above the bars 








Figure 4-8. Effect of DNP on fatty acid synthase (FAS) activity in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with or without DNP (25µM), ATP 
(10nM), Lanthanum(1mM), DNP plus ATP, DNP plus lanthanum or Lanthanum plus 
ATP. FAS activity was measured as the oxidative rate of NADPH, which was conducted 
as described in Materials and Methods.  Data are expressed as mean ± SE (n =6). 




Several studies have reported that mitochondrial uncoupling regulates lipid 
metabolism both in vivo and in vitro (13-15). However, the mechanism mediating this 
effect remains unclear. Our previous data suggested intracellular calcium is an important 
regulator of both lipogenesis and lipolysis. Accordingly, We investigated whether there is 
an effect of mitochondrial uncoupling on intracellular calcium level and whether [Ca2+]i 
is the mediator for the regulation of lipid metabolism by mitochondrial uncoupling.
The role of the mitochondria in regulation of [Ca2+]i  homeostasis has been 
widely investigated. Several observations suggest that [Ca2+]i is regulated by 
mitochondria in an energy-linked process (16-18). In addition, experimental evidence 
indicates a positive association between mitochondrial calcium and mitochondrial ATP 
production (19-22). Our results suggest that mitochndrial uncoupling contributes to the 
control of membrane calcium channel activity in differentiated 3T3-L1 adipocytes. We 
report that mitochondrial uncouplers dose-responsively increase [Ca2+]i in adipocytes. 
This regulation of [Ca2+]i level by mitochondrial uncouplers in adipocytes appears to 
involve membrane calcium channels, as this effect can be completely blocked by non-
specific calcium channel antagonist (lanthanum). Although Makowska et al. previously 
reported that mitochondrial uncoupler depressed the rate of calcium influx in vitro (23), 
this inhibitory effect of uncoupler on intracellular calcium was observed on store-
operated calcium channel rather than voltage-gated calcium channel (VGCC). However, 
an important relevant role of VGCCs is to serve as highly regulated mechanisms to 
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deliver calcium ions into specific intracellular locales for a variety of calcium-dependent 
processes (24), Thus, the observation from present work demonstrated that mitochondrial 
uncoupler regulates VGCC by increasing the calcium influx. Additionally, Lynch et al 
have shown that calcium was released from mitochondrial as a result of DNP dissipation 
of the H+ gradient (25). Consequently, we reasoned that intracellular calcium may be a 
trigger in the effect of mitochondrial uncoupling on lipid metabolism.   
Previous studies have demonstrated that lipolysis depends on the energy status of 
adipocytes (26-27). A decrease in intracellular ATP elicited in white adipocytes in vitro 
by inhibitors of the mitochondrial respiratory chain reversed the stimulation of lipolysis 
by catecholamines (28). More recently, ATP was shown to be required for translocation 
of HSL from cytoplasm to the surface of lipid storage droplets and for phosphorylation of 
HSL and other proteins that are involved in lipolysis in adipocytes (29). Incubation of 
isolated adipocytes with lipolytic hormones resulted in up to 50% decrease of their 
intracellular ATP level and in inhibition of lipolysis itself (29). In addition, The 
intracellular ATP is also essential for insulin signaling (30-31), which is altered at the 
level of the interaction of insulin with its receptor (32).  In present study, we also showed 
that mitochondrial uncoupling inhibits lipolysis and this effect is via a calcium dependent 
mechanism. Previous data from our laboratory demonstrate that increasing [Ca2+]i 
inhibits adipocyte lipolysis. This effect is primarily mediated by activation of adipocyte 
phosphodiesterase 3B and a reduction of cAMP levels, leading to a decrease in hormone 
sensitive lipase phosphorylation and, consequently, an inhibition of lipolysis (32). In the 
present study, increased [Ca2+]i and decreased lipolysis were observed concomitantly 
with two individual mitochondrial uncouplers, while inhibition of Ca2+ influx prevented 
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the suppression of lipolysis. Therefore, [Ca2+]i appears to mediate the effect of 
mitochondrial uncouplers on lipolysis. In addition, the mitochondrial uncoupling results 
in reduced adipocytes lipolysis in response to isoproterenal or insulin, suggesting a 
reduction in adipocytes cAMP levels.  
We also found that mitochondrial uncoupling has dual effects on a key lipogenic 
system, fatty acid synthase. The suppression of FAS activity induced by short-term 
treatment with mitochondrial uncouplers indicates a non-genomic effect of mitochondrial 
uncoupling on FAS. This effect is a calcium-independent since lanthanum is unable to 
reverse the suppression. The stimulation of FAS expression was induced by long-term 
treatment with mitochondrial uncouplers and this stimulation of FAS expression can be 
fully reversed by lanthanum, indicating that a genomic effect of mitochondrial 
uncoupling on FAS expression is [Ca2+]i-dependent, consistent with our previous reports 
of [Ca2+]i regulation of FAS expression(8-9). To our surprise, FAS activity was 
suppressed by long-term treatment with mitochondrial uncouplers and addition of 
lanthanum induced a further suppression on FAS activity, which suggests that there is 
both a calcium dependent and a non-genomic, Ca2+-independent effect similar to that 
observed in the short-term treatment. This non-genomic effect of suppression on FAS 
activity by mitochondrial uncoupling may result from the shortage of the substrates (e.g. 
NADPH and ATP) secondary to reduced mitochondrial energy with mitochondrial 
uncouplers (33). For each molecule of acetate incorporated into long-chain FA, two 
molecules of NADPH are necessary in the reaction catalyzed by FA synthase. Moreover, 
mitochondrial production of ATP is required for synthesis of oxalacetate by carboxylation 
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of pyruvate and subsequent synthesis of citrate in mitochondria and for FA synthesis and 
esterification in cytoplasm (34-35). The ATP/ADP ratio has been demonstrated to affect 
pyruvate carboxylase activity directly (35-36). Although the in vitro assay system used in 
this study provides acetyl-CoA, malonyl -CoA and NADPH, it does not provide 
exogenous ATP. Therefore, reduced availability of intramitochondrial ATP and the a 
reduced ATP: ADP ratio secondary to uncoupling may be responsible for the observed 
reduction in activity (37-38). To further test this hypothesis, we found that addition of 
ATP reversed the uncoupler-induced suppression on FAS activity, indicating that 
inhibition of FA synthesis by uncouplers probably resulted from limited availability of 
intramitochondrial ATP. 
In conclusion, mitochondrial uncoupling participates in the regulation in lipid 
metabolism and [Ca2+]i. Figure 4-9 depicts a proposed scheme for the integration of this 
regulation, as follows. Mitochondrial uncoupling increases [Ca2+]i by activating 
membrane calcium channels and thereby inhibits lipolysis via a Ca2+-dependent pathway. 
Mitochondrial uncoupling has dual effects on lipogenesis: it inhibits FAS activity via a 








Figure 4-9. A proposed scheme for the integration of the regulation of lipid 
metabolism by mitochondrial uncoupling. Mitochondrial uncoupling increases [Ca2+]i 
by activating membrane calcium channels and thereby inhibits lipolysis via a Ca2+-
dependent pathway. Mitochondrial uncoupling has dual effects on lipogenesis: it inhibits 
FAS activity via a Ca2+-independent mechanism and stimulates of FAS expression via a 
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This part is a slightly revised version of a paper by the same name published in 
the FASEB Journal in 2004 by Xiaocun Sun, Michael B. Zemel: 
Xiaocun Sun, Michael B. Zemel. Role of uncoupling protein 2 (UCP2) expression 
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We previously found that 1α,25-(OH)2-D3 modulates adipocyte lipid 
metabolism via a Ca2+-dependent mechanism and inhibits adipocyte UCP2 expression, 
indicating that the anti-obesity effects of dietary calcium are mediated by suppression of 
1α, 25-(OH)2-D3 levels. However, because UCP2 reduces mitochondrial potential, we 
have evaluated the roles of UCP2, mitochondrial uncoupling and 1α, 25-(OH)2-D3 in 
adipocyte apoptosis. Overexpressing UCP2 in 3T3-L1 cells induced marked reductions in 
mitochondrial potential (∆ψ) and ATP production (p<0.01), increases in the expression of 
caspases (p<0.05) and a decrease in Bcl-2/Bax expression ratio (p<0.01). Physiological 
doses of 1α, 25-(OH)2-D3 (0.1-10 nM) restored mitochondrial ∆ψ in LI-UCP2 cells and 
protected against UCP2 overexpression-induced apoptosis (p<0.01), while a high dose 
(100 nM) stimulated apoptosis in 3T3-L1 and L1-UCP2 cells (p<0.05). 1α, 25-(OH)2-D3 
stimulated cytosolic Ca2+ dose-dependently in both 3T3-L1 and L1-UCP2 cells. However, 
physiological doses suppressed mitochondrial Ca2+ levels by ~50% while the high-dose 
increased mitochondrial Ca2+ by 25% (p<0.05); this explains stimulation of apoptosis by 
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the high dose of 1α, 25-(OH)2-D3. Using high calcium diets to suppress 1α, 25-(OH)2-D3 
stimulated adipose tissue apoptosis in aP2 transgenic mice (p<0.01), suggesting that 
increasing dietary calcium stimulates adipose apoptosis and thereby further contributes to 
an anti-obesity effect of dietary calcium. 
 
5.2 Introduction 
Previous data from this laboratory demonstrate a key role for intracellular Ca2+ 
([Ca2+]i) in the regulation of adipocyte metabolism and lipid storage(1-3). Because [Ca 
2+]i can clearly be modulated by calcitrophic hormones, including 1α, 25-
dihydroxyvitamin D3 (1α, 25-(OH)2-D3), these data provide a theoretical framework to 
explain an anti-obesity effect of high calcium diet (4). Indeed, increasing dietary calcium 
in the absence of caloric restriction appears to result in a re-partitioning of dietary energy 
from adipose tissue to lean body mass, resulting in a net reduction in fat mass in both 
mice and humans, while increasing dietary calcium intake during energy restriction 
results in a marked augmentation of body weight and fat loss in both mice and humans(4-
6). 
We have also found that high calcium diets attenuate the decreases in core 
temperature which otherwise occur with energy restriction in mice(4), and that dietary 
calcium up-regulates uncoupling protein 2(UCP2) expression in white adipose tissue(7). 
We recently extended this concept by demonstrating that 1α, 25-(OH)2-D3 directly 
suppresses UCP2 expression in isolated human adipocytes (8), indicating that the up-
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regulation of UCP2 induced by dietary calcium may result from the loss of inhibition of 
UCP2 expression by 1α, 25-(OH)2-D3. 
Recent data also indicate that [Ca 2+]i may play a key role in modulating 
sensitivity to the apoptotic stress(9-12). Several of the functional groups of molecules 
involved in apoptosis, including caspases and the Bcl-2 family, are [Ca 2+]i 
responsive(15-18). [Ca 2+]i has been demonstrated to modulate the role of proteases, 
including caspase-3, caspase-9 and Ca2+-dependent endonucleases(9,19-22). Scorrano et 
al. also showed a key interaction occurs between Bcl-2 family protein and calcium 
signaling in the execution of apoptosis (23). Their data demonstrate a critical role of 
BAX and BAK in maintaining of homeostatic concentration of [Ca2+]i in endoplasmic 
endo-reticulum(ER) and mitochondria, which control the apoptotic fate of cells 
responding to [Ca2+]i dependent stimuli. Several studies have also shown that 
thapsigargin, which can induce sustained [Ca2+]i elevation by inhibiting sacro-
endoplasmic reticulum Ca2+-ATPase(SERCA), triggers apoptosis in various cell 
types(24-26). These data indicate a key role of [Ca2+]i in the apoptosis process. Given 
that [Ca2+]i can be modulated by 1α, 25-(OH)2-D3, the role of 1α, 25-(OH)2-D3 in 
apoptosis should be explored. Although high dose of 1α, 25-(OH)2-D3 has been reported 
to induce apoptosis in various tumor cells (27-30), the regulation of apoptosis by 
physiological doses of 1α, 25-(OH)2-D3 remains unclear.  
Considerable progress has been made in elucidating a pivotal role of mitochondria 
playing in the coordination, initiation, and execution of apoptotic cell death (31-33). 
Three general mechanisms have been proposed, including 1) disruption of oxidative 
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phosphorylation ATP production; 2) regulation of the apoptotic proteases; and 3) 
alteration of cellular reduction-oxidation potential. Because UCP2, which is highly 
expressed in white adipose tissue, has been demonstrated to function as mitochondrial 
uncoupler of oxidative phosphorylation thus reduce efficiency of ATP synthesis, it is 
reasonable to propose that UCP2 may stimulate apoptosis in adipocytes. Accordingly, in 
the present study, the effect and mechanisms of mitochondrial uncoupling and 1α, 25-
(OH)2-D3 on apoptosis in adipocytes were examined. We report here that 1) 
mitochondrial uncoupling induces apoptosis in differentiated 3T3-L1 cells; 2) low-doses 
of 1α, 25-(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1 cells in a dose-dependent 
manner while high-dose of 1α, 25-(OH)2-D3 stimulates apoptosis; and 3)high calcium 
diets, which suppress 1α, 25-(OH)2-D3 levels in vivo, stimulate adipose tissue apoptosis 
in aP2 transgenic mice. 
 
5.3 Materials and Methods 
5.3.1 Culture and Differentiation of 3T3-L1 Adipocytes 
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish) 
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and 
antibiotics (adipocyte medium) at 37°C in 5% CO2 in air. Confluent preadipocytes were 
induced to differentiate with a standard differentiation medium consisting of DMEM-F10 
(1:1, vol/vol) medium supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM) 
and antibiotics (1% Penicillin-Streptomycin). Preadipocytes were maintained in this 
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differentiation medium for 3 days and subsequently cultured in adipocyte medium. 
Cultures were re-fed every 2–3 days to allow 90% cells to reach fully differentiation 
before conducting chemical treatment. Chemicals were freshly diluted in adipocyte 
medium before treatment. Cells were washed with fresh adipocyte medium, re-fed with 
medium containing the different treatments, and incubated at 37°C in 5% CO2 in air 
before analysis. Cell viability was measured via trypan blue exclusion. 
5.3.2 UCP2 Transfection 
UCP2 full-length cDNAs was amplified by RT-PCR using mRNAs isolated 
from mouse white adipose tissues. The PCR primers for this amplification are shown as 
follows: UCP2 forward, 5’-GCTAGCATGGTTGGTTTCAAG-3’, reverse, 5’-
GCTAGCTCAGAAAGGTGAATC-3’. The PCR products were then subcloned into 
pcDNA4/His expression vectors. The linearized constructs were transfected into 3T3-L1 
preadipocytes using lipofectamine plus standard protocol (Invitrogen, Carlsbad, CA). 
After 48 hrs of transfection, cells were split and cultured in selective medium containing 
400 ug/ml zeocin for the selection of resistant colonies. Cells were fed with selective 
medium every 3 days until resistant colonies could be identified. These resistant foci 
were picked, expanded, tested for expression, and frozen for future experiments. 
5.3.3 Determination of Mitochondrial Membrane Potential 
Adipocytes were incubated with adipocyte medium for 4h with or without 1α, 
25-(OH)2-D3. Mitochondrial membrane potential was analyzed fluorometrically with a 
lipophilic cationic dye JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol 
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carbocyanine iodide) using a mitochondrial potential detection kit (Biocarta, San Diego, 
CA). Mitochondrial potential was determined as the ratio of red fluorescence (excitation 
550 nm, emission 600 nm) and green fluorescence (excitation 485 nm, emission 535 nm) 
using a fluorescence microplate reader. 
5.3.4 ATP Measurement 
Adipocytes were incubated with adipocyte medium for 4h with or without 1α, 25-
(OH)2-D3. ATP levels were measured using ENLITEN® Total ATP Rapid 
Biocontamination Detection Kit (Promega, Madison, MI) according to the 
manufacturer’s instruction. Cellular ATP was extracted as described previously (34), and 
was using a microplate luminometer (Labsystem, Helsinki, Finland). The integration time 
of the luminometer was set at 1s with normal gain.  
5.3.5 Measurement of Cytosolic Ca2+([Ca2+]c) and Mitochondrial Calcium([Ca2+]m)  
[Ca2+]c in adipocytes was measured using a fura-2 dual-wavelength fluorescence 
imaging system. Cells were plated in 35-mm dishes (P35G-0-14-C, MatTek). Prior to 
[Ca2+]c measurement, cells were put in serum-free medium overnight and rinsed with 
HEPES balanced salt solution (HBSS) containing the following components (in mM): 
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20 
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl 
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5% 
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then 
post-incubated at room temperature for an additional 1h for complete hydrolysis of 
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cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of 
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled 
device (CCD) camera. Fluorescent images were captured alternatively at excitation 
wavelengths of 340 and 380 nm with an emission wavelength of 520 nm. After 
establishment of a stable baseline, the responses to 1α, 25-(OH)2-D3 was determined. 
[Ca2+]c was calculated using a ratio equation as described previously. Each analysis 
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt 
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were 
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR) 
to create a calibration curve in solution, and cellular calibration was accomplished using 
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal 
[Ca2+]c levels respectively.  
Rhod-2/AM was used for qualitative measurement of [Ca2+]m(35). Cells were 
incubated with the Ca2+ sensitive fluorescent indicator rhod-2 AM (1-1·5 µM), for at least 
1 h at 370C in 5% CO2 in humidified air. Since rhod-2 AM consists of a cationic 
rhodamine molecule, it accumulates preferentially inside the mitochondria due to their 
negative membrane potential. After loading, the cells were kept in rhod-2 AM-free 
standard solution for at least 1 h to allow conversion of the dye to its Ca2+-sensitive, free 
acid form. Images of [Ca2+]m were acquired at the wavelength of 552nm excitation and 
590nm emission using the intracellular imaging system described above. Since rhod-2 is 
not a ratiometric dye, its fluorescence intensity was not calibrated to obtain absolute 
values of [Ca2+]m. Instead, only relative values were recorded as fluorescence signal (F) 
relative to the control value (F0). After baseline calcium concentration was measured, the 
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1, 25(OH)2 D3 was immediately applied to the cells and the calcium concentration was 
measured again. 
5.3.6 Total RNA Extraction  
A total cellular RNA isolation kit (Ambion, Austin, TX) was used to extract total 
RNA from 3T3-L1 cells according to manufacturer’s instruction.  
5.3.7 Quantitative Real-time PCR 
Adipocyte caspase-1, caspase-3, Bcl-2 and Bax mRNA were quantitatively 
measured using a Smart Cycler Real Time PCR System (Cepheid, Sunnyvale, CA) with a 
TaqMan 1000 Core Reagent Kit (Applied Biosystems, Branchburg, NJ). The primers and 
probe sets were ordered from Applied Biosystems TaqMan® Assays-on-Demand™ Gene 
Expression primers and probe set collection according to manufacture’s instruction. 
Pooled 3T3-L1 adipocyte total RNA was serial-diluted in the range of 1.5625-25 ng and 
used to establish a standard curve; total RNAs for unknown samples were also diluted in 
this range. Reactions of quantitative RT-PCR for standards and unknown samples were 
also performed according to the instructions of Smart Cycler System (Cepheid, 
Sunnyvale, CA) and TaqMan Real Time PCR Core Kit (Applied Biosystems, Branchburg, 
NJ). The mRNA quantitation for each sample was further normalized using the 
corresponding 18s quantitation, with a forward primer: 5’-




5.3.8 Animals and Diets 
This study was divided into three phases. The first phase was designed to induce 
weight gain and fat accretion, the second phase studied acceleration of weight and fat lass 
on the obese animals induced by phase one, and the third phase determined attenuation of 
graining back of weight and fat. The study was conducted in the aP2 transgenic mice 
used in the studies described previously. These mice exhibit a normal pattern of leptin 
gene expression and activity as well as a pattern of agouti gene expression similar to that 
found in humans. Therefore, these mice are useful models for diet-induced obesity in a 
genetically susceptible human population in that they are not obese on a standard AIN-
93G diet, but develop mild to moderate obesity when fed high sucrose and/or high fat 
diets (4). 
Phase I 
Six-week old aP2 transgenic mice were studied in a six-week obesity induction 
period on a basal low Calcium/high sucrose/high fat diet.  
60 aP2 transgenic mice from our colony were placed at 6 weeks of age on a 
modified AIN 93 G diet with suboptimal calcium (0.4%), sucrose as the sole 
carbohydrate source, and fat increased to 25% of energy with lard. Animals were studied 
for six weeks, during which food intake and spillage were measured daily, and body 
weight and food consumption were assessed weekly. At the end of phase I, five 




At the end of the phase one, the 55 animals remaining from phase I were put into 
high calcium diet but the energy intake was limited to 70% of that found in the ad libitum 
fed during phase I. The high calcium diet used in this phase was made of the basal diet 
with the addition of sufficient calcium to bring the calcium content of the diet to 1.3%. 
Animals were maintained on this diet for six weeks, during which food intake and 
spillage were measured daily and body weight as well as food consumption were 
assessed weekly. At the end of phase II, five animals were sacrificed as following to 
collect fat pads.  
Phase III 
At the end of the phase II, the 50 animals remaining from phase II were further 
randomized into five groups, as following: 1) Basal-refed group were put on high 
sucrose/high fat/low calcium basal diet ad lib 2) High-Ca cereal-refed group were put on 
high-Ca-(1.3%)cereal diet ad lib. 3) High-Ca-cereal plus dry milk group were put on high 
calcium cereal plus non fat milk diet ad lib, in which 1.2% calcium content comes from 
fortified cereal and 0.1% calcium content comes from non fat milk; 4)Yogurt refed group 
were put on high calcium (1.3 %)-yogurt diet ad lib. 5) Cereal control refed group were 
put on low calcium (0.4%)-cereal diet ad lib. 10 animals /group were studied for six 
weeks, during which food intake and spillage were measured daily and body weight and 
food consumption were assessed weekly. At the conclusion of the study, all mice were 
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sacrificed under isofluorane anaesthesia and fat pads were immediately excised, weighed 
and snap-frozen in liquid nitrogen for subsequential assessment of gene expression. 
The animal portion of this study was approved from an ethnical standpoint by the 
University of Tennessee, Institutional Animal Care and Use Committee. 
5.3.9 Statistical Analysis  
All data are expressed as mean ± SE. Data were evaluated for statistical 
significance by one-way analysis of variance (ANOVA), and significantly different group 
means were then separated by the least significant difference test by using SPSS (SPSS 
Inc, Chicago, IL.). 
 
5.4 Results 
All apoptosis signaling pathways converge on a common pathway of cell 
destruction that is activated by a family of cysteine proteases (caspases) that cleave 
protein at aspartate residues. Accordingly, we first studied the effect of 1α, 25-(OH)2-D3 
and DNP on caspase-1 and caspase-3 expression in differentiated 3T3-L1(control) and 
UCP2 transfected 3T3-L1 cells. Figures 5-1 and 5-2 demonstrate that physiological low-
doses of 1α, 25-(OH)2-D3 (0.1nM, 1nM, 5nM and 10nM) inhibited Caspase-1 and 
caspase-3 expression respectively (p<0.05), indicating reduced apoptosis in both control 
and UCP2 transfected 3T3-L1 cells. In contrast, a high-dose of 1α, 25-(OH)2-D3(100nM) 
stimulated both caspase-1 and caspase-3 expression in both control and UCP2 transfected 

































































Figure 5-1. Caspase-1 expression in 3T3 L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA 
levels. Caspase-1 mRNA levels were measured by real-time PCR and these 
measurements were conducted as described in Materials and Methods. Data are expressed 
as mean ± SE (n =6). Different letters above the bars indicate a significant difference at 






























































Figure 5-2. Caspase-3 expression in 3T3-L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA 
levels. Caspase-1 mRNA levels were measured by real-time PCR and these 
measurements were conducted as described in Materials and Methods. Data are expressed 
as mean ± SE (n =6). Different letters above the bars indicate a significant difference at 
level of p<0.05. 
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exerted similar effects on caspases-1 and 3 expression in 3T3-L1 and UCP2 transfectd 
3T3-L1 cells, the basal expression levels of these two caspases were significantly higher 
in the DNP treated and UCP2 transfected cells in compared to control cells(p<0.05), 
suggesting that mitochondrial uncoupling stimulates apoptosis in cultured 3T3-L1 cells. 
Both Bcl-2 and Bax are apoptotic proteins belonging to Bcl-2 family. Due to their 
completely different roles in apoptotic signaling pathway, the ratio of protective Bcl-2 to 
apoptotic Bax is widely used to determine the susceptibility to apoptosis by regulating 
mitochondrial function following an apoptotic stimuli. Figure 5-3 shows the effect of 1α, 
25-(OH)2-D3 on Bcl-2/ Bax expression ratio. We found that the lower levels of 1α, 25-
(OH)2-D3 induced a dose-dependent increase in Bcl-2/Bax ratio(p<0.01), indicating a 
protective role of  lower level of 1α, 25-(OH)2-D3 against apoptosis. In contrast, the high 
dose of 1α, 25-(OH)2-D3  resulted in a significant decrease in the Bcl-2/Bax ratio in 
control and UCP2 transfected 3T3-L1 cells(p<0.01). In addition, the DNP treated and 
UCP2 transfected cells showed significantly lower ratio of Bcl-2/Bax than non-
transfected 3T3-L1 cells (p<0.02), indicating mitochondrial uncoupling induced a 
decrease in protection from apoptotic death. 
Since physiological low-dose of 1α, 25-(OH)2-D3 appears to inhibit adipocyte 
apoptosis, suppression of 1α, 25-(OH)2-D3 with high calcium diet may stimulate 
apoptosis. Accordingly, we compared caspase-1 and caspase-3 expression as well as Bcl-
2/Bax expression ratio in aP2 transgenic mice fed diets with different calcium content 
after energy restriction. As shown in the Figure 5-4, 5-5 and 5-6, we found significant 
higher increases in caspase-1 and caspase-3 expression (p<0.001), and decreases in Bcl-






















































Figure 5-3. Bcl-2/Bax expression ratio in 3T3-L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
(0.1nM, 1nM, 10nM, and 100nM) and DNP (25µM and 50µM) for 24 h for mRNA levels. 
Caspase-1 mRNA levels were measured by real-time PCR and these measurements were 
conducted as described in Materials and Methods. Data are expressed as mean ± SE (n 
































Figure 5-4. Effect of dietary calcium on caspase-1 expression white adipose tissue of 
aP2-agouti transgenic mice. Diet and animal administration was conducted as described 
in Materials and Methods. Data are expressed as mean ± SE (n =8). Difference letters 





























Figure 5-5. Effect of dietary calcium on caspase-3 expression white adipose tissue of 
aP2-agouti transgenic mice. Diet and animal administration was conducted as described 
in Materials and Methods. Data are expressed as mean ± SE (n =8). Difference letters 
































Figure 5-6. Effect of dietary calcium on Bcl-2/Bax expression in white adipose tissue 
of aP2-agouti transgenic mice. Diet and animal administration was conducted as 
described in Materials and Methods. Data are expressed as mean ± SE (n =8). Difference 
letters above the bars indicate a significant difference at level of p<0.05. 
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0.4%) (p<0.01). These data suggest that suppression 1α, 25-(OH)2-D3 physiologically in 
vivo may stimulate adipocytes apoptosis.  
Figure 5-7 shows the effect of 1α, 25-(OH)2-D3 on mitochondrial potential in 3T3 
L1 and UCP2 stably transfectd 3T3 L1 cells. We found that lower-doses of 1α, 25-(OH)2-
D3 significantly increased mitochondrial potential in all three groups of cells whereas the 
high-dose of 1α, 25-(OH)2-D3 caused mitochondrial potential collapse. Consistent with 
these data, ATP production was markedly increased in response to low-dose 1α, 25-
(OH)2-D3 treatment (p<0.01)(Figure 5-8), while the high-dose of 1α, 25-(OH)2-D3 
inhibited ATP production (p<0.05). These effects are consistent with our previous 
observation that low-dose of 1α, 25-(OH)2-D3 inhibited UCP2 expression(6). Thus, by 
inhibiting UCP2 expression, the low-dose of 1α, 25-(OH)2-D3 restored mitochondrial 
potential and increased ATP production. 
1α, 25-(OH)2-D3 also stimulated Ca2+ influx in both control and UCP2 transfected 
cells. Figure 5-9 demonstrates a dose-dependent increase in cytosolic calcium levels in 
response to 1α, 25-(OH)2-D3. Notably, the high-dose of 1α, 25-(OH)2-D3 induced a 10-
fold higher in increase in calcium influx than the lower doses. 
Figure 5-10 shows the effect of 1α, 25-(OH)2-D3 on [Ca2+]m levels in control and 
UCP2 transfected cells. Low-doses of 1α, 25-(OH)2-D3 decreased mitochondrial calcium 
in both type of cells while the high-dose of 1α, 25-(OH)2-D3 significantly stimulated 
[Ca2+]m. Since mitochondrial calcium overload might trigger apoptosis by inducing 
mitochondrial collapse and cytochrome c release, the pro-apoptotic effect of the high-
































Figure 5-7. Mitochondrial potential in 3T3-L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
(0.1nM, 1nM, 5Nm, 10nM, and 100nM) for 4h before assay. Mitochondrial potential 
were measured using fluorospectrometry as described in Materials and Methods. Data are 
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant 



































Figure 5-8. ATP production in 3T3-L1 and UCP2 transfected 3T3-L1 adipocytes. 
Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 ( 1nM, 5nM, 
10nM, and 100nM) for 4h before assay. ATP levels were measured using a microplate 
luminometer as described in Materials and Methods. Data are expressed as mean ± SE (n 
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Figure 5-9. Intracellular calcium levels in 3T3-L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
( 1nM, 5nM, 10nM, and 100nM) instantly before assay. Intercellular calcium levels were 
measured using a dual wavelength fluorescence microscope as described in Materials and 
Methods. Data are expressed as mean ± SE (n =6). Different letters above the bars 






















Figure 5-10. Mitochondrial calcium levels in 3T3-L1 and UCP2 transfected 3T3-L1 
adipocytes. Primary-cultured adipocytes were treated with or without 1α, 25-(OH)2-D3 
(1nM, 5nM, 10nM, and 100nM) instantly before assay. Mitochondrial calcium levels 
were measured using a dual wavelength fluorescence microscope as described in 
Materials and Methods. Data are expressed as mean ± SE (n =6). 
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the decreases in [Ca2+]m observed in response treatment lower doses of 1α, 25-(OH)2-D3 
indicate that, in addition to the inhibitory effect on UCP2, reducing the mitochondrial 
calcium load may contribute to the anti-apoptotic effect of low doses of 1α, 25-(OH)2-D3.  
 
5.5 Discussion 
Obesity is characterized by an increase in both adipocyte size and number. 
Adipose tissue is thus linked to the dynamic role played by adipocytes. However, the 
concept of adipocyte deletion by apoptosis as a significant contributor to adipose tissue 
loss during weight reduction is a relatively recent one. Qian et al showed that rat 
adipocytes underwent apoptosis following brain administration of leptin and thereby 
demonstrated that leptin induced weight loss was a result not only of an decrease in food 
intake and increase in energy expenditure, but also of adipocyte depletion (36). Niesler et 
al. found a depot specific susceptibility to apoptosis in human preadipocytes. Omental 
preadipocytes were more susceptible to apoptotic stimuli than were subcutaneous 
preadipocytes, indicating a possible mechanism for regulation of adipocyte tissue 
distribution (37). Several studies also demonstrated that conjugated linoleic acid (CLA) 
reduces body fat content in part by inducing adipocyte apoptosis, and that some factors, 
including PPARs (38), UCPs (39), leptin (39) and TNF-α (40), are involved in CLA 
modestly induced adipocyte apoptosis. However, data on the mechanisms and regulation 
of adiopcyte apoptosis are still limited. 
Previous data from our laboratory have demonstrated that 1α, 25-(OH)2-D3 
appears to modulates adipocyte lipid and energy metabolism via both genomic and non-
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genomic mechanisms(3,4,7,8). We have reported that 1α, 25-(OH)2-D3 plays a direct role 
in the modulation adipocyte Ca2+ signaling(8), resulting in an increased lipogenesis and 
decreased lipolysis(1,5,8). In addition, 1α, 25-(OH)2-D3 also plays a role in regulating 
human adipocyte UCP2 mRNA and protein levels, indicating that the suppression of 1α, 
25-(OH)2-D3 and the resulting up-regulation of UCP2 may contribute to increased rates 
of lipid oxidation(7). Accordingly, the suppression of 1α, 25-(OH)2-D3 by increasing 
dietary calcium attenuates adipocyte triglyceride accumulation and caused a net reduction 
in fat mass in both mice and humans in the absence of caloric restriction (4-5), a marked 
augmentation of body weight and fat loss during energy restriction in both mice and 
humans(4-5), and a reduction in the rate of weight and fat regain after food restriction in 
mice(4, 41). Although these anti-obesity effects of dietary calcium are appear to be due, 
in part, to effects on lipolysis and lipogenesis(1,4), it is also possible that a loss of 
adipocytes would results in a cellular deficit lipid esterification as the body recovers from 
energy restriction. Thus, a reduced number of available adipocytes may not be able to 
store excess energy coming from rebound in food intake. Moreover, generating new cells 
would require extra energy that would contribute to a further metabolic enhancement. 
Accordingly, present study demonstrates that lower (physiological) doses of 1α, 25-
(OH)2-D3 inhibit apoptosis in differentiated 3T3-L1 adipocytes, and the suppression of 1α, 
25-(OH)2-D3 in vivo by increasing dietary calcium stimulates adipocyte apoptosis during 
refeeding following energy restriction in aP2 transgenic mice, suggesting that the 
stimulation of adipocyte apoptosis contributes to reduced adipose tissue mass after 
administration of high calcium diets. 
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Key feature of apoptosis involves the proteolytic caspases (42) as well as 
apoptotic proteins Bcl-2 and Bax (43). Activation of Bax induces apoptosis by disturbing 
mitochondrial electron transport chain, counters the death repressor activity of Bcl-2, and 
promotes the release of cytochrome c into the cytoplasm (44-45). This, in turn, activates 
caspases that initiate execution of apoptotic death. Bcl-2, which is localized to 
mitochondria, inhibits Bax induced apoptosis, and consequently, the Bcl-2/Bax ratio can 
be used to determine the susceptibility to apoptosis. In the present study, we found that 
lower doses of 1α, 25-(OH)2-D3(0.1nm, 1nm, 5nm and 10nm) dose-dependently inhibit 
caspase-1 and caspase-3 gene expression, and increase the Bcl-2/Bax expression ratio in 
control and UCP2 transfected 3T3-L1 adipocytes, indicating an inhibition of apoptosis. 
We also found that UCP2 transfected 3T3-L1 adipocytes have higher basal level of 
caspase-1 and caspase-3 expression but a lower Bcl-2/Bax ratio than non-transfected 
3T3-L1 cells. These results are consistent with our observation that UCP2 stimulates 
apoptosis by inducing mitochondrial potential collapse and inhibiting ATP production. 
We previously demonstrated that 1α, 25-(OH)2-D3 inhibits UCP2 expression in human 
adipocytes (7). Consistent with our this observation, we have found 1α, 25-(OH)2-D3 
functionally inhibits UCP2 action by increasing mitochondrial potential and ATP 
production in both non-tranfected and UCP2 transfected 3T3-L1 cells. Thus, the 
suppression of apoptosis induced by 1α, 25-(OH)2-D3 is, in part, mediated by inhibiting 
UCP2 expression and activity. Accordingly, we proposed that the suppression of 1α, 25-
(OH)2-D3 secondary to consumption of high calcium diets may stimulate adipocytes 
apoptosis in vivo. We evaluated this concept in aP2 transgenic mice undergoing re-
feeding following energy restriction, and found a significant increases in white adipose 
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tissue apoptosis in mice re-fed high calcium diets(1.3%) compared to low calcium diets 
(0.4% Ca). These results further confirm that suppression of 1α, 25-(OH)2-D3 stimulates 
apoptosis in white adipose tissue and suggest that this effect also contribute to the anti-
obesity effect of dietary calcium. 
In contrast, very high doses of 1α, 25-(OH)2-D3, which are three to four fold 
higher than physiological levels, exert the opposite effect. We found that a high-dose of 
1α, 25-(OH)2-D3( 100nM) actually stimulated caspase-1 and caspase-3 expression and 
inhibited Bcl-2/Bax ratio, a complete reversal of the effect of lower doses of 1α, 25-
(OH)2-D3 on apoptosis. Although lower doses of 1α, 25-(OH)2-D3 caused moderate 
increases in cytosolic [Ca2+] levels in adipocytes, the high-dose of 1α, 25-(OH)2-D3 
induced an extreme elevation, and excessive intracellular calcium has been reported to be 
a pro-apoptotic factor(45-46). Ca2+ is a ubiquitous intracellular messenger involved in 
many cellular processes. To generate such complex Ca2+ signals, cells rely on the rapid 
release of the Ca2+ storage (such as ER/SR and mitochondria) as well as on the controlled 
Ca2+ influx from the extracellular medium upon stimuli, and strive to maintain the Ca2+ 
concentration at extremely low levels by expelling Ca2+ ions to the exterior and by 
compartmentalization of Ca2+ intracellular stores under physiological conditions of rest. 
Mitochondria take up Ca2+ through the uniporter on the inner membrane at the expense of 
∆ψ(48). Mitochondria are often located close to the ER, and therefore exposed to the 
Ca2+ release by the Inositol-1,4,5-trisphosphate receptor(IP3R) and ryanodine receptor 
(RyR). The high Ca2+ levels achieved at these contact sites favors Ca2+ uptake into 
mitochondria. Because of their tight coupling to ER Ca2+ store, mitochondria are highly 
susceptible to abnormalities in Ca2+ signaling (49). Recent evidence suggests that the 
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amount of Ca2+ going through mitochondria is crucial in triggering a Ca2+-dependent 
apoptosis response, probably by the opening of a sensitized state of permeability 
transition pore (PTP) (50). Scorrano et al reported that mouse embryonic fiberblasts 
deficient in Bax were protected from apoptosis because of reducing resting concentration 
of calcium in ER and decreased uptake of Ca2+ by mitochondria from the ER(23). 
Expression of SERCA, on the other hand, corrected [Ca2+]er and [Ca2+]m, thereby 
restoring apoptotic death (51). In the present study, we also monitored the mitochondrial 
Ca2+ concentration and found that low-does of 1α, 25-(OH)2-D3 decreased mitochondrial 
Ca2+ levels in a dose-dependent manner while high-dose of 1α, 25-(OH)2-D3 markedly 
stimulates the elevation of [Ca2+]m, indicating that the increase [Ca2+]m is associated with 
the induction of apoptosis by high-dose of 1α, 25-(OH)2-D3. We have previously reported 
that mitochondrial uncoupling stimulated [Ca2+]c level, which may in turn induce an 
increase in[Ca2+]m to maintain cytoplasmic calcium homeostasis. Low-doses of 1α, 25-
(OH)2-D3 induce dose-dependent depletion [Ca2+]m by inhibiting UCP2, thereby 
protecting adipocytes from apoptotic death. High-doses of 1α, 25-(OH)2-D3, on the other 
hand, increases [Ca2+]c to extreme level, which may increase both [Ca2+]m and [Ca2+]er. 
Since ER can open their Ca2+ release channel in response to elevations in [Ca2+]c and 
contribute to Ca2+ induced Ca2+ release (CICR), this may further increases [Ca2+]m and 
calcium overload in mitochondria in turn triggers apoptosis. 
In summary, the present study demonstrates dual effects of 1α, 25-(OH)2-D3 on 
apoptotic death. These are summarized in Figure 5-11 as follows: by inhibiting UCP2 























Figure 5-11. Schematic illustration of effects and mechanisms of 1α, 25-(OH)2-D3 on 
adipocyte apoptosis. Physiological low doses of 1α, 25-(OH)2-D3 restore mitochondrial 
potential and ATP production by suppressing UCP2, thereby inhibiting apoptosis. By 
contrast, high dose of 1α, 25-(OH)2-D3 induces mitochondrial calcium overload and 
stimulates apoptosis. 
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inhibit apoptosis in adipocytes, while suppression of 1α, 25-(OH)2-D3 using high calcium 
diets stimulates adipose apoptosis in mice. In contrast, a high dose of 1α, 25-(OH)2-D3 
stimulates mitochondrial calcium overload and apoptosis in adiocytes. These results 
indicate that dietary calcium not only regulates adipocytes size by decreasing lipid 
accumulation, but also modulates adipocyte number by stimulating apoptotic death. Thus, 
these results provide a new mechanism in support of the “anti-obesity” of dietary calcium. 
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We have previously shown that 1α, 25-Dihydroxyvitamin D3 (1α, 25-(OH)2-D3) 
has dual effects on apoptotic death in adipocytes: physiological doses of 1α, 25-(OH)2-D3 
inhibit adipocyte apoptotic death while suppression of 1α, 25-(OH)2-D3 using high 
calcium diets stimulates adipose apoptosis in mice; In contrast, pharmacological doses of 
1α, 25-(OH)2-D3 stimulate apoptosis. We have also demonstrated that 1α, 25-(OH)2-D3 
inhibits expression of mitochondrial uncoupling protein 2 (UCP2), which plays a key role 
in regulation of mitochondrial potential and apoptosis. We therefore hypothesized that 
low doses of 1α, 25-(OH)2-D3 inhibit adipocyte apoptotic death by inhibiting UCP2 
expression while high doses stimulate adipocyte apoptotic death via a calcium dependent 
mechanism. In the current study, Ca2+ ionophore Bay K 8644(BK8644) induced 3-4 fold 
of increases in [Ca2+]i (within the response range to physiological low doses of 1α, 25-
(OH)2-D3) and dose-dependently stimulated caspase-3 expression by 94%-260% (p<0.01). 
In contrast, GDP, a potent inhibitor of mitochondrial uncoupling, decreased [Ca2+]I, and 
increased mitochondrial potential, and suppressed caspase-3 expression in a dose 
dependent manner(47%-80%, p<0.05). To address the independent effect of 
mitochondrial uncoupling, pretreatment of 3T3-L1 cells with BK 8644 prevented GDP-
induced decreases in [Ca2+]i but preserved the effect on GDP stimulated mitochondrial 
potential. GDP suppressed caspase-3 expression by 45% (p<0.05) in BK8644 pretreated 
cells. Transfection of dsRNA specific for UCP2 mRNA into 3T3-L1 cells suppressed 
UCP2 expression by 70%, and caused a 52% increase in mitochondrial potential but a 
58% decrease in caspase-3 expression (p<0.05), indicating a direct role of mitochondrial 
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uncoupling in adipocyte apoptosis. These data further demonstrate that physiological 
doses of 1α, 25-(OH)2-D3 inhibit apoptosis and this effect is attributable to the inhibitory 
effect on mitochondrial uncoupling. In contrast, high doses of 1α, 25-(OH)2-D3 stimulate 
apoptosis via a calcium-dependent mechanism. 
 
6.2 Introduction 
A substantial body of recent evidence demonstrate that dietary calcium regulates 
adiposity (1-5). High dietary calcium, by suppressing 1α, 25-(OH)2-D3, decreases 
intracellular calcium and thereby inhibits lipogenesis and stimulates lipolysis (4-8), while 
low dietary calcium intakes increase 1α, 25-(OH)2-D3 and thereby causes an increase in 
adiposity (9). Although the anti-obesity effect of dietary calcium appears to be primarily 
attributable to the regulatory effect of 1α, 25-(OH)2-D3 on intracellular calcium on 
adipocyte lipid accumulation, regulation on adipocyte apoptosis may also involved. 
We have recently shown that 1α, 25-(OH)2-D3 has dual effects on adipocyte 
apoptosis, with low (within the physiological range) doses of 1α, 25-(OH)2-D3, which 
can be induced by low calcium diets in vivo, inhibiting apoptosis and pharmacologically 
high doses of 1α, 25-(OH)2-D3 stimulating apoptosis(10). The mechanism of these dual 
effects on adipocyte apoptosis induced by 1α, 25-(OH)2-D3 is yet to be determined. 
However, we have previously demonstrated that 1α, 25-(OH)2-D3 inhibits mitochondrial 
uncoupling protein 2 (UCP2) expression in cultured human adipocyte via a calcium 
independent mechanism(11). Because UCP2, which is highly expressed in white adipose 
tissue, has been founded to function as mitochondrial uncoupler of oxidative 
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phosphorylation and thus reduce efficiency of ATP synthesis (12), it is reasonable to 
propose that UCP2 may stimulate adipocyte apoptosis. Accordingly, the inhibition of 
UCP2 by low doses of 1α, 25-(OH)2-D3 may suppress apoptosis. This observation, 
coupled with the observation that intracellular calcium plays a key role in apoptosis (13), 
led us to test the hypothesis that low dose of 1α, 25-(OH)2-D3 inhibits apoptosis by 
suppressing UCP2 expression while high dose of 1α, 25-(OH)2-D3 stimulates apoptosis 
via a calcium dependent pathway. 
 
6.3 Materials and Methods 
6.3.1 Culture and Differentiation of 3T3-L1 Adipocytes 
3T3-L1 preadipocytes were incubated at a density of 8000 cells/cm2 (10 cm2 dish) 
and grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS and 
antibiotics at 37°C in 5% CO2. Confluent preadipocytes were induced to differentiate 
with a standard differentiation medium consisting of DMEM-F10 (1:1, vol/vol) medium 
supplemented with 1% FBS, 1µM dexamethasone, IBMX (0.5 mM) and antibiotics (1% 
penicillin/streptomycin). Preadipocytes were maintained in this differentiation medium 
for 3 days and subsequently cultured in adipocyte medium. Cultures were refed every 2–3 
days. Cell viability was measured via trypan blue exclusion. 
6.3.2 UCP2 Transfection 
UCP2 full-length cDNAs were amplified by RT-PCR using mRNAs isolated 
from mouse brown and white adipose tissues, respectively. The PCR primers for this 
 276
amplification are shown as follows: UCP2 forward, 5’-
GCTAGCATGGTTGGTTTCAAG-3’,reverse, 5’-GCTAGCTCAGAAAGGTGAATC-3’. 
The PCR products were then subcloned into pcDNA4/His expression vectors. The 
linearized constructs were transfected into 3T3-L1 preadipocytes using lipofectamine 
plus standard protocol (Invitrogen, Carlsbad, CA). After 48 hrs of transfection, cells were 
split and cultured in selective medium containing 400 ug/ml zeocin for the selection of 
resistant colonies. Cells were fed with selective medium every 3 days until resistant 
colonies were identified. These resistant foci were picked, expanded, tested for 
expression,and frozen for future experiments. 
6.3.3 siRNA Preparation and Transfections  
Duplex siRNA corresponding to UCP2 gene was designed and chemically 
synthesized by Invitrogen. The following gene-specific sequences were used successfully: 
Si-UCP2 sense 5'-GCCUCUACGACUCUGUCAA-3' and antisense 5'-
UUGACAGAGUCGAGGC-3'. Transfection of siRNA was performed with 
OligofectamineTM reagent (Invitrogen Life Technologies, CA) in 6-well plates. Briefly, 
Oligofectamine diluted in DMEM was applied to the duplex siRNA mixture, and the 
formulation was continued for 20min to allow the Oligofectamine-oligonucleotide 
complex to form. Per well, 800µl of plating medium and 10ul of 20µM duplex siRNA 
duplex siRNA formulated with 4µl of Oligofectamine were applied in a final volume of 
1ml. Cells were then incubated at 370C in a CO2 incubator for 4hrs. 500 ul of DMEM 
medium containing 3x serum was added to transfection mixture after transfection, and 
cells were incubated for 48 h~72h. 
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6.6.4 Western Blot Analysis  
Adipocytes  were  harvested and sonicated in a homogenization buffer containing 
50 mM Tris-HCl (PH 7.4), 250mM sucrose, 1mM EDTA, 1mM dithiothreitol, 1% (v/v) 
Triton X, 10% protease cocktail (Sigma). Cell homogenates were incubated on ice for 1h 
to solublize all proteins, and the insoluble protein was removed by centrifugation at 
12,500g at 40C for 15 min. Homogenate intrafranatant protein from equal numbers of 
cells (determined via protein quantitation using Bradford method as described previously) 
was boiled in Laemmli sample buffer and subject to 10% SDS-polyacrylamide gel 
electrophoresis (PAGE). Proteins on the gels were transferred to Hybond ECL 
nitrocellulose membrane (Amersham  Pharmacia Biotech, Piscataway,  NJ). The 
transferred membranes with proteins were blocked, washed, incubated with 1:1000 
dilution of anti-UCP2 polyclonal antibody or 1:500 dilution of anti-actin polyclonal 
antibody (Santa Cruz Biotechnology, CA) followed by peroxidase-conjugated secondary 
antibody (Santa Cruz Biotechnology, CA). Visualization was detected with 
chemiluminescence reagent, using the Western Blotting Luminal Reagent(Santa Cruz 
Biotechnology, CA ). 
6.3.5 Determination of Mitochondrial Membrane Potential 
Mitochondrial membrane potential were analyzed spectrophotometrically with a 
lipophilic cationic dye JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazol 




6.3.6 Measurement of Cytosolic Ca2+([Ca2+]c) and Mitochondrial Calcium([Ca2+]m) 
[Ca2+]c in adipocytes was measured using a fura-2 dual-wavelength fluorescence 
imaging system. Cells were plated in 35-mm dishes (P35G-0-14-C, MatTek). Prior to 
[Ca2+]c measurement, cells were put in serum-free medium overnight and rinsed with 
HEPES balanced salt solution (HBSS) containing the following components (in mM): 
138 NaCl, 1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, 4 NaHCO3, 5 glucose, 6 glutamine, 20 
HEPES, and 1% bovine serum albumin. Cells were loaded with fura-2 acetoxymethyl 
ester (fura-2 AM) (10 µM) in the same buffer for 2 h at 37°C in a dark incubator with 5% 
CO2. To remove extracellular dye, cells were rinsed with HBSS three times and then 
post-incubated at room temperature for an additional 1h for complete hydrolysis of 
cytoplasmic fura-2 AM. The dishes with dye-loaded cells were mounted on the stage of 
Nikon TMS-F fluorescence inverted microscope with a Cohu model 4915 charge-coupled 
device (CCD) camera. Fluorescent images were captured alternatively at excitation 
wavelengths of 340 and 380 nm with an emission wavelength of 520 nm. After 
establishment of a stable baseline, the responses to 1α, 25-(OH)2-D3 was determined. 
[Ca2+]c was calculated using a ratio equation as described previously. Each analysis 
evaluated responses of 5 representative whole cells. Images were analyzed with InCyt 
Im2 version 4.62 imaging software (Intracellular Imaging, Cincinnati, OH). Images were 
calibrated using a fura-2 calcium imaging calibration kit (Molecular Probes, Eugene, OR) 
to create a calibration curve in solution, and cellular calibration was accomplished using 
digitonin (25 µM) and pH 8.7 Tris-EGTA (100 mM) to measure maximal and minimal 
[Ca2+]c levels respectively.  
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Rhod-2/AM was used for qualitative measurement of [Ca2+]m(14). Cells were 
incubated with the Ca2+ sensitive fluorescent indicator rhod-2 AM (1-1·5 µM), for at least 
1 h at 370C in 5% CO2 in humidified air. Since rhod-2 AM consists of a cationic 
rhodamine molecule, it accumulates preferentially inside the mitochondria due to their 
negative membrane potential. After loading, the cells were kept in rhod-2 AM-free 
standard solution for at least 1 h to allow conversion of the dye to its Ca2+-sensitive, free 
acid form. Images of [Ca2+]m were acquired at the wavelength of 552nm excitation and 
590nm emission using the intracellular imaging system described above. Since rhod-2 is 
not a ratiometric dye, its fluorescence intensity was not calibrated to obtain absolute 
values of [Ca2+]m. Instead, only relative values were recorded as fluorescence signal (F) 
relative to the control value (F0). 
6.3.7 Total RNA Extraction 
A total cellular RNA isolation kit (Ambion, Austin, TX) was used to extract total 
RNA from 3T3-L1 cells according to manufacturer’s instruction.  
6.3.8 Quantitative Real-time PCR 
Adipocyte caspase-3 was quantitatively measured using a Smart Cycler Real 
Time PCR System (Cepheid, Sunnyvale, CA) with a TaqMan 1000 Core Reagent Kit 
(Applied Biosystems, Branchburg, NJ). The primers and probe sets were designed and 
synthesised by Applied Biosystems TaqMan® Assays-on-Demand™ Gene Expression 
primes and probe set collection according to manufacture’s instruction. Pooled 3T3-L1 
adipocyte total RNA was serial-diluted in the range of 1.5625-25 ng and used to establish 
a standard curve; total RNAs for unknown samples were also diluted in this range. 
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Reactions of quantitative RT-PCR for standards and unknown samples were also 
performed according to the instructions of Smart Cycler System (Cepheid, Sunnyvale, 
CA) and TaqMan Real Time PCR Core Kit (Applied Biosystems, Branchburg, NJ). The 
mRNA quantitation for each sample was further normalized using the corresponding 18s 
quantitation, with a forward primer: 5’-AGTCCCTGCCCTTTGTACACA-3’ and a 
reverse primer: 5’-GATCCGAGGGCCTCACTAAAC-3’. 
6.3.9 Statistical analysis  
All data are expressed as mean ± SE. Data were evaluated for statistical 
significance by one-way analysis of variance (ANOVA), and significantly different group 
means were then separated by the least significant difference test by using SPSS (SPSS 
Inc, Chicago, IL.). 
 
6.4 Results 
We have previously shown that the increase of mitochondrial uncoupling by 
either chemical uncouplers or UCP2 overexpression in 3T3-L1 cells stimulates apoptosis, 
with significant increases in caspase-1 and caspase-3 expression as well as decrease in 
Bcl-2/Bax expression ratio (10). Consistent with this observation, we found in this study 
that suppression of UCP2 by siRNA transfection in 3T3-L1 cells caused a 70% decrease 
in UCP2 expression and a 52% increase in mitochondrial potential (p<0.05) (Figures 6-1 
and 6-2), indicating that suppression of UCP2 increases adipocyte mitochondrial 























Control            dsRNA
Figure 6-1. Western blot with anti-mouse UCP2 antibody of cell lysates harvested 
48hrs after siRNA transfection for evaluation of UCP2 protein reduction (upper 
panel).The internal control actin is shown in the low panel. Blot shown is representative 










Figure 6-2. Mitochondrial potential in 3T3-L1 and siRNA transfected 3T3-L1 
adipocytes (UCP2 ko). Data are expressed as mean ± SE (n =6). Different letters above 
the bars indicate a significant difference at level of p<0.05. 
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in caspase 3 expression (p<0.01) (Figure 6-3). These data suggest that UCP2 plays a 
direct role in stimulation of adipocyte apoptosis. Accordingly, suppression of UCP2 
expression decreases apoptotic stress. 
Although we demonstrated that overexpression of UCP2 favors adipocyte 
apoptosis while suppression of UCP2 decreases apoptotic stress (10), it is not clear 
whether other UCP isoforms may also be regulated correspondingly during UCP2 
manipulation and thereby affect apoptosis. Accordingly, we further used GDP as a 
general mitochondrial uncoupling inhibitor to investigate the effect of mitochondrial 
uncoupling inhibition on apoptosis. GDP at 100µM and 500 µM increased mitochondrial 
potential by 27% and 48% (p<0.05) respectively (Figure 6-4), confirming an inhibitory 
effect of GDP on mitochondrial uncoupling. Figure 6-5 shows that GDP treatments 
inhibited apoptosis in 3T3-L1 cells, with 47%-81% decreases in caspase-3 expression 
(p<0.01), indicating that general inhibition of mitochondrial uncoupling suppresses 
adipocyte apoptosis.  
Bay K 8644 (BK 8644) is a Ca2+ ionophore which stimulated adipocyte Ca2+ 
influx in a dose-dependent manner (Figure 6-6). This stimulation of BK8644 (1nM-
100nM) on [Ca2+]i is of comparable magnitude to the effect of 1α, 25-(OH)2-D3. 
However, BK8644 exerted no effect on mitochondrial potential or UCP2 expression 
(Figure 6-7). This result is consistent with our previous observation that 1α, 25-(OH)2-D3 
regulates UCP2 expression via a calcium-independent mechanism(10). Notably, BK 8644 
stimulated caspase-3 expression dose-dependently (Figure 6-8), indicating that increases 

























Figure 6-3. Caspase-3 expression in 3T3-L1 and siRNA transfected 3T3-L1 
adipocytes (UCP2 ko). Data are expressed as mean ± SE (n =6). Different letters above 

































Figure 6-4. Effect of mitochondrial uncoupling inhibitor GDP on mitochondrial 
potential in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different 



























Figure 6-5. Effect of mitochondrial uncoupling inhibitor GDP on caspase-3 
expression in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different 











































Figure 6-6. Effect of calcium channel ionophore Bay K 8644 on intracellular calcium 
levels in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different letters 


































Figure 6-7. Effect of mitochondrial uncoupling inhibitor GDP and calcium channel 
ionophore Bay K 8644 on mitochondrial potential in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant 






































Figure 6-8. Effect of calcium channel ionophore Bay K 8644 on caspase-3 expression 
in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6). Different letters above 
the bars indicate a significant difference at level of p<0.05. 
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with our previous finding that mitochondrial uncoupling increases cytosolic calcium level 
(15), inhibition of mitochondrial uncoupling with GDP decreased [Ca2+]i level 
significantly (data not shown). Combining 1mM GDP with 1nM BK 8644 exerted no 
effect on [Ca2+]i but induced similar magnitude of increases in mitochondrial potential as 
observed in GDP alone (Figure 6-7), indicating that the regulation of mitochondrial 
potential is calcium independent. However, addition of Bay K 8644 caused a significant 
increase in caspase-3 expression (Figure 6-9), suggesting that [Ca2+]i stimulates 
apoptosis independent of mitochondrial potential. 
Stimulation of calcium influx by BK 8644 increased mitochondrial calcium 
(Figure 6-10) (p<0.05). Although 1α, 25-(OH)2-D3 induced similar effects on [Ca2+]i 
increase as BK8644, the opposite effect on mitochondrial calcium was observed with low 
dose of 1α, 25-(OH)2-D3 (0.1nM to 10nM) pretreated cells, with significant decreases in 
mitochondrial calcium. The high dose of 1α, 25-(OH)2-D3, however, caused similar 
increases in mitochondrial calcium as observed with BK 8644. 
 
6.5 Discussion 
We investigated the effects of the calcium channel ionophore BK 8644, a 
mitochondrial uncoupling inhibitor (GDP) and UCP2 silencing using siRNA transfection 
on apoptosis. BK 8644, which exerted no effect on mitochondrial uncoupling, caused a 
dose dependent increase in intracellular calcium as well as mitochondrial calcium storage, 
and stimulated caspase-3 expression, indicating that increases in intracellular calcium 




























Figure 6-9. Effect of mitochondrial uncoupling inhibitor GDP and calcium channel 
ionophore Bay K 8644 on caspase-3 expression in 3T3-L1 adipocytes. Data are 
expressed as mean ± SE (n =6). Different letters above the bars indicate a significant 
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Figure 6-10. Effect of calcium channel ionophore Bay K 8644 on mitochondrial 
calcium in 3T3-L1 adipocytes. Data are expressed as mean ± SE (n =6).  
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mitochondrial uncoupling with GDP decreased intracellular calcium and mitochondrial 
potential and thereby inhibited apoptosis. Consistent with our previous data that the 
mitochondrial uncoupler 2, 4-dinitrophenol (DNP) stimulates apoptosis (10), these results 
indicate a direct role of mitochondrial uncoupling in stimulating of apoptosis. Specific 
suppression of UCP2 also decreased apoptosis while UCP2 overexpression caused the 
opposite effect. Accordingly, the inhibitory effect of low dose of 1α, 25-(OH)2-D3 on 
apoptosis may be mediated by its suppression of UCP2 expression (11). Although 1α, 25-
(OH)2-D3 increases [Ca2+]i, and such increases are often associated with apoptosis, only 
the very high dose (>100nM) of 1, 25(OH)2D3 stimulated apoptosis. This result indicates 
that the pro-apoptotic effect of intracellular calcium with the treatment of 1α, 25-(OH)2-
D3 may be overwhelmed by its anti-apoptotic effect induced by suppression of UCP2. 
Early studies by Kaiser and Edelman demonstrated that glucocorticoid-stimulated 
apoptosis is associated with enhanced [Ca2+]i influx (16), providing the first evidence that 
increased [Ca2+]i might be involved in triggering apoptosis. This hypothesis was further 
supported by the observation that increased level of inositol 1,4,5-triphosphate(InsP3) 
receptor in lymphocytes stimulates apoptosis while IP3R-deficient cells are resistant to T-
cell receptor (TCR)-induced apoptosis(17-18). Calcium was also linked to the release of 
arachidonic acid from cells triggered to undergo apoptosis by various chemotherapeutic 
agents (19), suggesting that calcium is important to many cPLA2-dependent apoptotic 
responses. Consistent with this, the present study confirms that increases in intracellular 
calcium influx stimulate apoptosis by increasing caspase-3 expression. This result may 
explain the pro-apoptotic effect of high dose 1α, 25-(OH)2-D3. In addition, calcium 
increases precede the cytolysis of the targets of cytotoxic T cells, indicating rapid, 
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sustained intracellular calcium increase is required for the apoptotic process (20). 
Although 1α, 25-(OH)2-D3 induced dose-dependent increases in [Ca2+]i, our data indicate 
that the magnitude of this increases in [Ca2+]i may determine whether apoptosis results. 
Previous studies demonstrate that intracellular calcium storage sites also appear to be 
affected, as the cytosolic calcium undergo changes in response to apoptotic stimuli (21-
22). During apoptotic stress, the mitochondrial calcium pool may also be affected, since 
mitochondrial potential, which plays a key role in maintaining mitochondrial calcium 
homeostasis, drops very early during apoptotic death (23). Decreased mitochondrial 
potential reduces ATP production and causes cytochrome c leakage and mitochondrial 
swelling (24). Accordingly, mitochondrial uncoupling might stimulate apoptosis by 
decreasing mitochondrial potential. This hypothesis is further supported by our 
observations that the chemical uncoupler DNP decreases adipocyte mitochondrial 
potential and stimulates apoptosis (10) while in present study, the mitochondrial 
uncoupling inhibitor GDP causes the opposite effects. Consistent with this, 
overexpression of UCP2 stimulated apoptotic proteases while suppression of UCP2 
decreased expression of these genes, indicating that UCP2 plays a positive role in 
regulation of apoptosis. 1α, 25-(OH)2-D3, which has been found to inhibit UCP2 
expression via a calcium-independent pathway (11), suppressed apoptosis at 
physiological low doses from 0.1nM to 10nM, suggesting that the anti-apoptotic effect of 
low doses of 1α, 25-(OH)2-D3 might be mediated by suppression of UCP2 expression.  
In the present study, 1α, 25-(OH)2-D3 induced similar effect on [Ca2+]i increase 
as BK 8644 but the two compounds exerted different effects on mitochondrial calcium 
storage, as low doses 1α, 25-(OH)2-D3 (0.1nM to 10nM) decreased mitochondrial calcium 
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while BK 8644 increased mitochondrial calcium. However, the high dose of 1α, 25-
(OH)2-D3 (100nM) caused similar increases in mitochondrial calcium as observed in BK 
8644. Since mitochondrial calcium overload might trigger apoptosis by inducing 
mitochondrial potential collapse and cytochrome c release, the pro-apoptotic effect of the 
high dose of 1α, 25-(OH)2-D3 is most likely a result of the stimulation of mitochondrial 
calcium. In contrast, the decreases in mitochondrial calcium observed in response to 
treatment with lower dose of 1α, 25-(OH)2-D3 indicates that reduction of mitochondrial 
calcium load, along with the inhibitory effect on UCP2 contribute to the anti-apoptotic 
effect of low dose of 1α, 25-(OH)2-D3.  
Although low doses of 1α, 25-(OH)2-D3 may also induce apoptotic stress via a 
calcium dependent mechanism, this signal is counter-balanced by the suppression of 
UCP2, which may increase the capability to maintain intracellular homeostasis by 
regulating mitochondrial potential and ATP production. Indeed, many calcium channel 
and pumps located either on plasma membrane or intracellular organelles are ATP 
dependent. High dose of 1α, 25-(OH)2-D3, however, induced much greater increases in 
intracellular calcium, resulting in more rapid and stronger apoptotic signals, which could 
not be offset by suppression of UCP2.  
In summary, physiological low dose of 1, 25-(OH)2-D3 inhibits apoptosis by 
suppression of UCP2 expression. Since the low doses of 1, 25-(OH)2-D3 used in this 
study are within the range of physiological levels which response to dietary calcium, the 
anti-obesity effect of high dietary calcium may, in addition to the previously cited 
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Summary and Conclusion 
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Dietary calcium stimulates UCP2 expression in white adipose tissue and core 
temperature in aP2 transgenic mice during ad lib feeding, energy restriction and refeeding 
follwing energy restriction, resulting in an attenuation of fat accumulation, an 
acceleration of fat loss and an inhibition of weight and fat regain. In addition, UCP2 
appear toregulate lipid metabolism directly and mitochondrial uncoupling induced by 
chemical uncouplers modulates both lipogenesis and lipolysis.Uncoupling protein 2 also 
stimulates adipocyte apoptosis by decreasing mitochondrial potential and ATP 
production, and disturbing cytosolic and mitochondrial calcium homeostasis. In addition, 
inhibition of UCP2 expression with physiological low doses of 1α, 25(OH)2D3 inhibits 
adipocyte apoptosis. Accordingly, suppression of 1α, 25(OH)2D3 by increasing dietary 
calcium stimulates UCP2 expression and thus favors adipocyte apoptotic death. 
In conclusion, adipocyte UCP2 plays an important role in modulation of adiposity 
through regulating mitochondrial potential gradient, energy metabolism and cellular 
calcium homeostasis, thus results in modulation of both adipocyte lipid metabolism and 
adipocyte numbers, thereby regulating total adiposity. Thus, UCP2 appear to be a 
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